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Abstract
Usher syndrome type 1C is an autosomal recessive condition in which 
profound, congenital sensorineural deafness is found in association with 
vestibular hypofunction and childhood onset retinitis pigmentosa. The gene 
responsible for Usher type 1C, USH1C, codes for a PDZ domain-containing 
protein, harmonin, of unknown function. In addition, the locus for a form of non- 
syndromic autosomal recessive deafness, DFNB18, overlaps with the USH1C 
gene.
In this thesis the USH1C gene is studied in more detail, both at the molecular 
level and at the protein level. Two cohorts of patients, individuals diagnosed 
with Usher type 1, and a group of sibs with recessive non-syndromic deafness 
concordant for markers flanking the DFNB18 locus, were screened for 
mutations in USH1C. One Usher type 1 patient was homozygous for a 
recurrent mutation, and the possibility of a founder effect was investigated by 
analysing intragenic SNPs. Another Usher type 1 patient had two novel coding 
mutations that were studied in more detail to establish whether they were likely 
to be disease-causing or represent rare polymorphisms.
USH1C is an alternatively spliced gene with evidence for tissue-specific 
isoforms of the protein. The repertoire of alternative isoforms and their tissue 
distributions were studied in human foetal tissues using non-quantitative RT- 
PCR. Particular attention was paid to a putative isoform thought to utilize an 
alternative start site in the centre of the gene. This isoform may have
importance in other tissues when a mutation at the 5’ end of USH1C results in 
a non-functional protein from the usual start site............... ..............
The sub-cellular localization of harmonin was investigated in individual human 
epithelial cells using fluorescent immunocytochemistry, and fluorescent 
immunohistochemistry was used to study the localization in mouse inner ear 
sections. Finally, to understand more about the possible role of harmonin in the 
ear and the eye, an in vitro GST pull-down assay was set up to investigate the 
interaction of harmonin with another Usher type 1 protein, protocadherin 15.
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1. Introduction
1.1. Overview
Hearing loss is the most common sensory defect in humans. Approximately 1 
in 1000 individuals is affected by severe or profound deafness at birth and a 
further 1 in 1000 children is affected by less severe, progressive, hearing loss 
that leads to deafness before adulthood. The prevalence of hearing impairment 
further increases with age, with nearly half of the population experiencing a 
hearing loss of greater than 26 dB by the age of 80 (reviewed by Morton, 
1991). Although there are a number of environmental causes of hearing 
impairment, including ototoxic drugs and infections, approximately 50% of 
childhood deafness can be attributed to genetic causes. Of those with a genetic 
form of hearing loss, around 30% have a syndromic form of hearing loss that 
presents in addition to other clinical features. Over 400 syndromes, where 
deafness is found associated with a wide array of other pathologies, have been 
described (OMIM), a number of these syndromes also include eye defects. 
Usher syndrome is the most common cause of deaf-blindness, accounting for 
more than 50% of individuals who are both deaf and blind (Boughman, et al., 
1983).
Profound, congenital deafness has a dramatic effect on the acquisition of 
communication skills and on the mode of education. Profoundly deaf children, 
who do not have cochlear implants, will often use sign language to 
communicate, a language which relies on vision. In the case of Usher
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syndrome, individuals also lose their vision, a sense upon which their 
communication is based. Hence, the early diagnosis of Usher syndrome is 
vitally important so that a child does not become more socially isolated. 
Diagnosis of Usher syndrome will be greatly aided by the identification of the 
genes responsible.
1.1.2. Hearing loss
Hearing loss can be clinically classified in many different ways: according to the 
type (sensorineural, conductive or mixed), progression, frequency (low to high), 
severity (mild to profound), onset (congenital, early or late), vestibular 
involvement and whether the cause is genetic or non-genetic. As mentioned 
above, approximately 50% of the 1 in 1000 children that is affected by severe 
(70 to 89 dB) or profound (>90 dB) deafness at birth are considered to be due 
to genetic factors (Morton, 1991). The majority of the genetic causes 70% are 
considered to be non-syndromic, that is, the deafness occurs in isolation and is 
not associated with any other phenotype.
1.1.2.1. Non-syndromic deafness
The non-syndromic forms of prelingual deafness are almost exclusively 
sensorineural. Sensorineural hearing loss occurs when the transmission of the 
sound signal from the inner ear to the cortical auditory centres in the brain is 
affected; this is normally due to inner ear defects. Non-syndromic deafness is 
extremely genetically heterogeneous and is classified according to the mode of 
inheritance. Several studies have shown that 70-75% of non-syndromic hearing 
impairment is inherited recessively, 20-25% are autosomal dominant and the 
remainder are X-linked or mitochondrial (Table 4 in Morton, 1991). There are
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currently ninety loci reported on the Hereditary Hearing Loss homepage 
(http://dnalab-www.uia.ac.be/ dnalab/hhh/L of which forty-eight are autosomal 
dominant (DFNA), thirty-seven are autosomal recessive (DFNB) and five are X- 
linked loci (DFN). In addition, mutations in two mitochondrial genes (12S rRNA 
and tRNASer(UCN)) are also responsible for non-syndromic deafness.
This genetic heterogeneity, combined with the absence of a clinically distinct 
phenotype for the different gene defects and the tendency of deaf people to 
marry each other, at one time made the mapping of these forms of deafness 
and the identification of the causative genes very difficult. These problems were 
initially overcome largely by studying geographically isolated deaf families. The 
first locus for an autosomal recessive form of deafness, DFNB1, was identified 
by homozygosity mapping in a Tunisian family (Guilford, et al.t 1994). The gene 
responsible for DFNB1, GJB2 (connexin 26), a gap junction protein involved in 
recycling potassium ions back into the endolymph, now appears to account for 
50% or more of the recessive deafness in some populations. Furthermore, 
different populations appear to have common founder mutations and high 
heterozygote carrier rates. For example, 35delG accounts for a high proportion 
of the connexin 26 mutations in Caucasian populations and a recent pan- 
European study detected a carrier frequency for 35delG of between 1 in 35 and 
1 in 79 (Gasparini, et al., 2000).
Over the last ten years a variety of genes underlying non-syndromic forms of 
deafness have been identified. A wide range of protein types, including 
unconventional myosins, ion transporters and channels, gap junction proteins,
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transcription factors and extracellular matrix components, have been shown to 
cause hearing impairment when mutated.
1.1.2.2. Syndromic deafness
In contrast to non-syndromic deafness, syndromic deafness may be conductive 
(i.e. due to middle and/or external ear defects), sensorineural, or a mixture of 
the two. Syndromic deafness tends to be less genetically heterogeneous within 
a phenotype and it is easier to group families with similar phenotypes for 
linkage analysis. Hence, the genes mutated in many of the more common 
forms of syndromic deafness were identified before those for non-syndromic 
deafness (reviewed by Petit, et al.t 2001; Resendes, et al., 2001; Hereditary 
Hearing Loss homepage) (Table 1.1).
Usher syndrome is the association of sensorineural deafness with the 
progressive loss of vision in the form of retinitis pigmentosa and is the subject 
of this thesis.
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Table 1.1. Genes identified for common forms of syndromic hearing 
impairment (as detailed on HHH).
Disorder Locus Location Gene
Alport
Xq22
2q36-q37
COL4A5
COL4A3/COL4A4
BOR 8q13.3 EYA1
Jervell + Lange- JLNS1 11p15.5 KCNQ1
Nielsen JLNS2 21q22.1-q22.2 KCNE1 (IsK)
Norrie ND Xp11.3 NDP
Pendred PDS 7q21-34 SLC26A4
STL1 12q13.11-q13.2 COL2A1
Stickler STL2 1p21 COL11A1
STL3 6p21.3 COL11A2
Treacher Collins TCOF1 5q32-q33.1 TCOF1
Usher*
USH1B 11 q 13.5 MY07A
USH2A 1q41 USH2A
WS type I 2q35 PAX3
WS type II 3p14.1-p12.3 
8q11
MITF
SLUG
Waardenburg WS type III 2q35 PAX3
WS type IV 13q22
20q13.2-q13.3
22q13
EDNRB
EDN3
SOX10
* at the start of this work only two Usher genes had been identified.
1.2. Structure and Function of the Ear
1.2.1. The auditory pathway
The mammalian ear is made up of three parts: the outer, middle and inner ear 
(Fig. 1.1). The auricle of the outer ear is designed to gather high frequency 
vibrations (sound waves) travelling through the air and conduct them inwards, 
through the external auditory canal, to the tympanic membrane, or eardrum,
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which separates the outer and middle ears. The middle ear consists of a chain 
of three tiny bones: malleus, incus and stapes, which pick up the vibrations of 
the tympanic membrane, amplify them and transmit them to the oval window of 
the inner ear (Fig. 1.1). The inner ear is a bony cavity containing the snail­
shaped cochlear duct, which processes auditory signals, and the vestibular 
apparatus, responsible for balance. Both the cochlea and the vestibular 
apparatus are endolymph-filled membraneous structures bathed in the 
perilymph of the temporal bone.
The organ of Corti is the sensory epithelium of the cochlear duct and contains 
the hair cells. The function of the hair cells is to convert sound waves 
transmitted to the endolymph into electrical impulses, which are then carried by 
nerve fibres to the auditory cortex of the brain. Hair cells are so called because 
of the presence of distinct bundles of actin-filled stiff microvilli, called 
stereocilia, on their apical surface. A gelatinous membrane, known as the 
tectorial membrane, covers the organ of Corti and makes contact with the 
stereocilia (Fig. 1.2). Sound waves entering the cochlear duct cause 
displacement of the tectorial membrane relative to the organ of Corti and in the 
process deflect the stereocilia of the hair cells. Deflection of the stereocilia 
causes mechanotransduction channels located at their tips to open. The 
ensuing influx of potassium ions, from the potassium-rich endolymph, alters the 
membrane potential of the hair cell. Depolarization of the hair cell leads to 
activation of voltage-gated calcium channels, which leads to an influx of 
calcium into the hair cell that, in turn, triggers the release of neurotransmitters 
that activate the acoustic nerve. The hair cells are re-polarized when the 
potassium ions leave through potassium channels and enter the supporting
cells. The potassium ions then diffuse to the stria vascularis (Fig. 1.2), through 
gap junctions formed between the cells, and are recycled back into the 
endolymph, resetting the mechanoelectrical transduction system, (reviewed by 
Forge and Wright, 2002; Willems, 2000).
Figure 1.1. Diagram showing the 
outer, middle and inner ear.
(Willems, 2000).
The auricle and the external acoustic 
duct constitute the outer ear. The 
malleus, incus, stapes and the 
tympanic membrane form the middle 
ear and the cochlea and vestibular 
apparatus are the inner ear. The 
vestibular apparatus comprises the 
sacculus, utriculus and three semi­
circular canals set at 90° to each other.
Stria
vascularis
Scala media /  
with endolymph ' /  <*rr
Potassium
Inner hair 
cell
Spiral
limbus
Supporting
cells
Outer hair 
cellsCochlear Scala tympani 
with perilymph
Figure 1.2. Diagram of a cross-section through the cochlear duct (Willems, 2000). 
The organ of Corti comprises the tectorial membrane and the sensory inner and outer 
hair cells, located on supporting cells on the basilar membrane. Reissner’s membrane 
encloses the organ of Corti in the potassium rich endolymph, keeping it separate from 
the perilymph of the cochlea duct. Black arrows indicate the flow of potassium into the 
hair cells, in response to sound waves, and then recycling back into the endolymph.
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1.2.2. Cell-cell adhesion in the inner ear
A fundamental property of any epithelium is the ability to separate different 
compartments within an organism and to regulate the exchange of substances 
between them, such that fluids with different molecular compositions can be 
maintained. This is particularly important in the inner ear, where the perilymph 
and endolymph must be completely compartmentalized (Fig. 1.2.). Leakage of 
solutes through the paracellular pathway, between adjacent cells, must be 
prevented in order to maintain the electrochemical gradient in the inner ear, 
which is required for the process of hearing.
In general, three types of junctions mediate adhesion between adjacent 
epithelial cells: tight junctions, adherens junctions and desmosomes (Fig. 1.3). 
These complexes each contain transmembrane proteins, which mediate 
binding at the extracellular surface, and associated cytoplasmic proteins that 
structurally link the transmembrane proteins to the cytoskeleton.
T ig h t Junction
Junction
Desmosome
Figure 1.3. Three types of 
intercellular junctions bet­
ween adjacent epithelial cells
(Perez-Moreno, etal., 2003).
(A) A schematic illustrating the 
three major types of intercellular 
junctions in epithelial cells. In the 
most apical junction, tight junctions, 
transmembrane proteins link to the 
actin cytoskeleton. Adherens jun­
ctions and desmosomes are both cadherin-based junctions, also linked to the actin 
cytoskeleton. (B) Electron micrograph showing the ultrastructure of all three junctions 
between two epithelial cells.
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1 2.2.1. Cadherin-based junctions
The adherens junctions, located near the apical surface of polarized epithelial 
cells, are thought to form the initial cell-cell contacts between adjacent cells and 
act as a prerequisite for the formation of other junctions (reviewed by Perez- 
Moreno, et at., 2003). Adhesion at adherens junctions, as well as at the 
desmosomes, is mediated by a superfamily of adhesion molecules known as 
cadherins. Cadherins are single transmembrane-spanning glycoproteins. The 
extracellular N-terminal portion of a cadherin molecule consists of a varying 
number of ectodomains (designated EC) that are highly homologous to each 
other. These ectodomains confer specific calcium-dependent homophilic 
binding between parallel dimers of cadherin molecules on adjacent cells 
(reviewed by Patel, et a/., 2003). The adhesive binding activity of the cadherin 
ectodomain is then strengthened by the interactions of the cytoplasmic 
C-terminal domain, usually via other ‘linker’ proteins, with the actin cytoskeleton 
of the cell (reviewed by Ivanov, etal., 2001; Yap, etal., 1997).
1.2.2.2. Tight junctions
Tight junctions are the most apical of the cell-cell contacts and the only one of 
the intercellular junctions that forms an actual barrier to the passage of ions 
and molecules through the paracellular pathway between the cells. Tight 
junctions also prevent the movement of lipids and proteins between the apical 
and basolateral domains of the plasma membrane, thereby maintaining cell 
polarity.
Integral proteins, such as the claudin family, constitute the backbone of tight 
junction strands. Each claudin possesses four transmembrane domains and
cytoplasmic N- and C-termini. The two extracellular loops of each claudin show 
enormous variability in both distribution and number of charged amino acid 
residues. Thus, it is now generally accepted that the heterogeneous interaction 
of different claudins between the tight junction strands of neighbouring cells is 
responsible for the enormous variety in electrical resistance and paracellular 
ionic selectivity displayed by various epithelia (reviewed by Tsukita, et a i , 
2001). Recently, expression of claudins 1-3, 8-10, 12, 14 and 18 in the cells 
lining the scala media of the mouse cochlea (organ of Corti, stria vascularis, 
Reissner’s membrane and spiral limbus) was demonstrated (Kitajiri, et al., 
2004). This indicates that the compartmentalization, required in the inner ear 
for normal hearing, is regulated through tight junctions in a very complex 
manner.
Besides the integral proteins that form the backbone of the tight junction 
strands, there are also a number of cortical proteins associated with the tight 
junctions. Several of these are PDZ domain-containing proteins that function as 
scaffolds, bringing together cytoskeletal components and signalling proteins 
with the integral proteins of the tight junctions (reviewed by Gonzalez-Mariscal, 
etal., 2003).
1.2.3. Structure of the hair ceil stereocilia
The hair bundle that projects from the apical surface of the sensory hair cells in 
the inner ear is formed from a cluster of stereocilia. Each stereocilium is a 
highly specialized, plasma membrane-bound process that contains a parallel 
bundle of actin filaments at its core (Tilney, et al., 1980). Rows of stereocilia on 
the apical surface of outer hair cells are arranged in a V-shape and they
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increase in height in one direction across the surface of the hair cell in a 
‘staircase-like’ fashion (Fig. 1.4A).
The stereocilia are not true cilia, though, as they do not contain the ‘9+2’ 
structure of microtubules. However, each hair cell does possess one true 
cilium, known as the kinocilium, which is present to one side of the stereocilia 
bundle during development, but it recedes as the cochlea matures. The 
function of the kinocilium is unknown, but it is thought that its position on the 
apical surface of the hair cell defines the polarity of the asymmetric hair bundle.
Figure 1.4. Stereocilia and their links
(A) Scanning electron microscopy showing the hair bundle of an outer hair cell 
(adapted from Petit, et al., 2001). (B) Diagrammatic representation of the various 
cross-links between adjacent stereocilia within a hair bundle (adapted from Forge and 
Wright, 2002).
Within the shaft of a stereocilium, adjacent actin filaments are extensively 
cross-linked by fimbrin (Shepherd, et al., 1989) and espin (Zheng, etal., 2000). 
Cross-linking has the effect of making the stereocilium much more rigid than 
would be expected if the actin filaments were free to move with respect to one
top connectors
s h a ft co n n ecto rs
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another. A frameshift mutation identified recently in espin in the deaf Jerker 
mouse mutant reveals just how important maintenance of stereocilia rigidity is 
for normal hearing (Zheng, et al., 2000).
The stereocilia are supported on the cuticular plate, which is a network of actin 
filaments within the apical cytoplasm of the hair cell that forms a rigid platform. 
The shaft of a stereocilium tapers at its proximal end, where the actin filaments 
insert into the cuticular plate like a rootlet (Tilney, et al., 1980). This anchoring 
of the rigid stereocilia allows them to pivot at the taper like a stiff rod in 
response to deflections applied to the tips of the stereocilia by movements 
against the tectorial membrane.
In a further level of rigidity, the stereocilia in an individual bundle are also 
connected to one another by a variety of filamentous extracellular cross-links 
(Fig. 1.4B). Lateral links connect the shaft of one stereocilium to its neighbour 
(Tsuprun and Santi, 2002) and tip-links run from the top of a stereocilium to the 
shaft of an adjacent, longer stereocilium (Kachar, et al., 2000). Therefore, the 
stereocilia do not move individually, but as a bundle. The tip-link is believed to 
be the gating element that controls mechanotransduction in the hair cells. It is 
thought that tension in the tip-link is increased when the stereocilia bundle is 
deflected and that this tension leads to the opening of mechanotransduction 
channels, present in the tips of the stereocilia, and an influx of K+ ions 
(reviewed by Pickles and Corey, 1992). At least three types of lateral links 
between the stereocilia have been observed: ankle links, shaft connectors and 
top links (Fig. 1.4B) (Tsuprun and Santi, 2002). The proteins that comprise 
these links are currently unknown, but the compositions of the lateral links are
distinct from each other as well as from the tip-links (Tsuprun and Santi, 2002). 
A number of unconventional myosin motor proteins also localize to the cuticular 
plate and the stereocilia, and are believed to have a role in maintaining the 
structure and function of the hair bundle (Hasson, et al., 1997).
1.2.4. Mouse models for studying the inner ear
As illustrated in the preceeding section, animal models are becoming 
increasingly valuable tools for the study of human diseases and disorders, 
particularly in a disorder such as deafness, in which studies on the human ear 
can only be performed post-mortem (reviewed by Avraham, 2003; Probst and 
Camper, 1999). The mouse is an excellent model for studying hearing 
impairment for several reasons; being a mammal the mouse cochlea is similar 
to that of humans, mice have a relatively short gestation period of three weeks 
and the availability of inbred strains facilitates comparisons of mutants on the 
same genetic background. Furthermore, the mouse genome sequence was 
completed recently (Waterston, et al., 2002) and approximately 99% of mouse 
genes have a homologue in the human genome. There are also now excellent 
web resources available that deal with mouse models for deafness 
(Appendix D).
Mouse mutants for deafness are easily recognizable since they often have 
associated vestibular defects that lead to a ‘head bobbing’ or ‘circling’ 
phenotype. In addition, the absence of a Preyer reflex (ear flick) in response to 
an intense auditory stimulus, produced by a click-box, is a good indication that 
a mouse has severe or profound hearing impairment.
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1.2.4.1. Generation of mouse mutants
Mouse mutants for deafness can aid in the identification of new deafness 
genes in phenotype-driven screens, but they also have an important role to 
play in the cloning of genes at known human deafness loci and in functional 
studies. There are three main types of mouse mutants: spontaneous, radiation 
or chemically induced, and engineered.
The shaker-1 mouse mutant is an example of a mutation that arose 
spontaneously in 1929, but it wasn’t until 1995 that the gene responsible, 
Myo7a, was identified via positional cloning (Gibson, etal., 1995). The shaker-2 
mouse arose around the same time as the shaker-1, however, this mutant 
arose in the progeny of an X-ray irradiated mouse. The gene mutated in 
shaker-2 mice, Myo15a, was identified when a large BAC (bacterial artificial 
chromosome) transgene was used to rescue the shaker-2 circling and deaf 
phenotype (Probst, et al., 1998). Mouse spermatogenic cells are also 
particularly susceptible to mutagenesis by chemicals such as N-ethyl-N- 
nitrosourea (ENU) and recent large ENU-mutagenesis screens have increased 
the number of mouse models for many human diseases, including deafness 
mutants (Hardisty, etal., 1999; Justice, etal., 1999; Nolan, etal., 2000).
Finally, mouse mutants may be engineered by performing gene-targeted 
mutagenesis or deletion of a gene in embryonic stem cells, which are then 
selected for and injected into blastocysts that are implanted into mice. A 
number of mouse mutants with inner ear defects have been produced in this 
way (reviewed by Anagnostopoulos, 2002).
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Sometimes simple knockout experiments are not very helpful. If the knockout 
gene is vital to early development, the transgenic mouse will be embryonic 
lethal. In this situation a conditional knockout mouse may be designed in which 
expression of the target gene is inactivated in only selected, predetermined 
cells of the animal. This approach was used to study the role of connexin 26 in 
the inner ear (Cohen-Salmon, et al., 2002), since the connexin 26 knockout 
mouse is embryonic lethal due to placental failure.
1.2.4.2. Study of mutant mice inner ears
Once a particular gene for deafness has been cloned in the mouse, there are a 
number of ways in which it can be studied in order to gain more information 
about its function. Inner ear material can be obtained from mice at all stages of 
development, from embryo through to adult, which is difficult to achieve with 
human tissue. Gene expression may be detected by extracting RNA from inner 
ear tissue and performing reverse-transcription PCR (RT-PCR). Real-time PCR 
allows a quantitative evaluation of mRNA levels in specific tissues at specific 
time points in development. For example, an increase in expression levels of 
the transmembrane cochlear-expressed gene 1 (Kurima, et al., 2002) in the 
ears of postnatal mice, shown by real-time quantitative RT-PCR, was found to 
correlate with the degeneration of inner and outer hair cells of the deafness 
mouse mutant, Tmc1dn/dn (Kurima, et al., 2002). Specific areas of gene 
expression, at the RNA level, may be revealed by in situ hybridization, where a 
labelled DNA probe is hybridized to a whole embryo, cochlea or tissue section.
However, it is important to study expression at the protein level as well as at 
the RNA level, since RNA experiments may give limited information. For
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example, if the protein is exported from the cell, studying the RNA will not give 
a real impression about the expression of the protein and, hence, its function. 
Protein expression/localization may be studied using immunofluorescence. An 
antibody, specific to the protein of interest, is applied to a dissected cochlea or 
tissue section and then may be detected using a secondary antibody with a 
fluorescent label. Another tool available in the mouse is transgenesis, utilized to 
study endogenous gene expression. A gene of interest may be substituted with 
a reporter gene, such as green fluorescent protein (Riesen, et al., 2002) or the 
p-galactosidase gene. This approach was used to detect subtle expression 
patterns of M athl, a transcription factor required for the genesis of inner ear 
hair cells (Bermingham, et al., 1999). Transgenesis is a much more sensitive 
technique than RNA in situ-hybridization or protein detection by 
immunofluorescence.
1.3. Structure and Function of the Eye
Like the ear, the tissues of the eye are also highly adapted to the processing of 
sensory information. The human eye functions much like a camera; a single 
lens focuses light images on a sheet of light receptors (equivalent to the film), 
and the image is then “developed” by neuron processing in the visual cortex of 
the brain. The cornea is the transparent portion of the sphere at the front of the 
eye through which light enters. The light then passes through the pupil, the 
dark central opening of the iris, to the lens, which focuses the rays on the rear 
surface of the eye, a light-sensing epithelial layer known as the neural retina.
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1.3.1. The retina
The retina is an out-pouching of the central nervous system that is composed 
of three layers of cells (Fig. 1.5A) (reviewed by Rattner, et al., 1999). The outer 
layer contains the photoreceptor cells, the rods and cones, which mediate dim 
light and bright light (colour vision), respectively. The rods (and subsequently 
the cones) are the site of the primary pathology in Usher syndrome. An 
enlarged, modified cilium, known as the outer segment, protrudes from the 
apical surface of the photoreceptor cells. The outer segments contain the visual 
pigment (rhodopsin) assembled in flattened membranous discs, which are 
constantly renewed by synthesis and assembly at their base, and shedding of 
older material from the tip (Fig. 1.5B). The second layer of cells contains bipolar 
cells, the second order neurones onto which the photoreceptors synapse. The 
third cell layer, the innermost layer through which light rays must first pass in 
order to reach the photoreceptor cells, contains ganglion cells, the output cells 
of the retina, whose axons come together to form the optic nerve.
Adjacent to the neural retina is the retinal pigment epithelium (RPE), in which 
each RPE cell makes contact with approximately forty-five outer segments 
(Fig. 1.5B). The RPE has two important functions; firstly, to recycle the 
photoreceptor outer segment, the RPE engulfs and digests the distal 10% of 
each outer segment on a daily basis, and secondly, the RPE also recycles the 
visual pigment.
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Figure 1.5. Schematic representation of the different cell types within the 
neural retina
(A) The three layers of the retina are depicted, with the retinal pigment epithelia 
adjacent to the outer layer of photoreceptor cells. The photoreceptors synapse onto 
bipolar neuronal cells, which in turn synapse onto the ganglion cells, which form the 
inner layer of the retina (adapted from Rattner, et al., 1999). (B) The disks stacked in 
the rod outer-segment contain the visual pigment, rhodopsin. The molecular 
components of the outer segment are synthesized in the inner segment and 
transported to the outer segment via the connecting cilium. An equal amount of the 
distal outer segment is phagocytosed by the retinal pigment epithelium (Dryja, 2001).
Each visual pigment is composed of a lipoprotein, opsin, covalently linked to 
the light-receptor molecule itself, 11-c/s retinal (a derivative of vitamin A). When 
light enters the eye it activates the visual pigment by inducing a conformational 
change of the 11-c/s retinal to all-trans retinal. The all-trans retinal then 
dissociates from opsin, to be replaced by a new molecule of 11-c/s retinal, and 
is transported to the RPE. In the RPE, all-trans retinal is changed back to the 
11 -cis retinal conformation and then it is returned to the photoreceptor cell to 
associate with another opsin molecule, (reviewed by Rattner, et al., 1999).
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1.3.2. Retinitis pigmentosa
Retinitis pigmentosa (RP) is a descriptive name applied to conditions in which 
the retina degenerates. The rods are the predominantly affected photoreceptor 
cell in RP and the disease manifests in the patient at a young age, as night 
blindness. As the disease progresses the cone photoreceptor cells also 
degenerate (Fig. 1.6) affecting day vision and central visual acuity. A blind-spot 
develops in the mid-peripheral visual field, an area in normal retinas with a high 
rod/cone ratio. This blind spot gradually enlarges, as more cone photoreceptors 
die, and the visual field is reduced to an island of central vision (tunnel vision) 
and scattered patches of far peripheral vision. Vision is usually lost altogether 
during middle age.
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Figure 1.6. Light micrographs comparing a retina with RP (centre) and a 
retina with end-stage RP (right) with a normal retina (left) (Dryja, 2001). 
Light rays enter from the top of the Figure and must pass through all the nerve fibre 
layers (ganglion cells and bipolar cells) and the photoreceptor nuclear layer before 
reaching the photoreceptor outer segment to interact with rod or cone opsin and 
initiate vision. The centre panel shows histologic changes observed in eyes with early 
to moderately advanced RP. The photoreceptor outer segments are absent and the 
number of photoreceptor nuclei is reduced. In end-stage RP (right panel), there are no 
recognizable cell layers. The retina is reduced in thickness and cell number.
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Retinitis pigmentosa is a hereditary disorder that, like deafness, is also very 
genetically heterogeneous. To date, thirty genes have been cloned for isolated 
retinitis pigmentosa as well as numerous other genes that can lead to RP as 
part of a syndrome when mutated http://www.sph.uth.tmc.edu/retnet/. 
(reviewed by Dryja, 2001).
The genes identified in patients with non-syndromic retinitis pigmentosa may be 
classified into several functional groups (reviewed by Phelan and Bok, 2000). 
The most commonly mutated genes in retinitis pigmentosa are those encoding 
proteins of the visual cascade of the photoreceptor cell outer segment. 
Mutations in the genes concerned with the series of biochemical steps involved 
in the visual cycle, which both provides and recycles the chromophore of 
rhodopsin, may also cause retinitis pigmentosa. Furthermore, genes encoding 
the structural components of the photoreceptor cell, and certain photoreceptor 
cell transcription factors, have also been found to cause non-syndromic retinitis 
pigmentosa (Table 1.2).
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Table 1.2. Summary of genes commonly mutated in non-syndromic
retinitis pigmentosa.
Gene Function Reference
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RHO Visual pigment, rhodopsin (Dryja, efa/., 1990)
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PDE Phosphodiesterase (McLaughlin etal., 1993)
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CNGA1
Cation channel in photoreceptor 
membrane
(Dryja, etal., 1995)
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SAG
Binds rhodopsin and terminates 
visual cycle
(Nakazawa, etal., 1998)
U) c
RPE65
Isomerization of all-fra/7S-retinol to 
11-c/s-retinol
(Morimura, etal., 1998)
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The eye and the ear share certain features that may start to provide a 
hypothesis as to how both can be affected by mutations in a single gene. 
Firstly, both are ciliated: in photoreceptors, a connecting cilium connects the 
inner segment to the outer segment (Fig. 1.5B); embryonic hair cells of the ear 
have an apical cilium, the kinocilium. Secondly, both cell types possess 
microvillus structures: the outer segments of photoreceptors contain 
membraneous discs, where the phototransduction occurs; the stereocilia on the 
apical surface of hair cells are microvillous projections. Finally, both the
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photoreceptors and the sensory cells of the inner ear form specialized 
synapses, known as ribbon synapses. Ribbon synapses are capable of 
transmitting rapid and sustained action potentials, unlike conventional 
synapses, which convey information as transient action potentials.
Therefore, the study of genes important for the functioning of both the eye and 
the ear may lead to the identification of biological processes shared by both of 
these organs. This, in turn, may lead to possible treatments for patients with 
dual pathology.
1.4. Usher Syndrome
As mentioned previously, Usher syndrome, the association of sensorineural 
deafness with retinitis pigmentosa, is the most common form of deaf blindness. 
It is, however, both clinically and genetically heterogeneous, with different 
genetic subtypes being more prevalent among certain ethnic groups.
1.4.1. Prevalence and classification
1.4.1.1. Prevalence
The prevalence of Usher syndrome has been estimated in several populations: 
3.2/100,000 in Colombia (Tamayo, et al., 1991), 3.6/100,000 in Norway 
(Grondahl, 1987), a conservative estimate of 4.4/100,000 in the United States 
(Boughman, et al., 1983), 5/100,000 in the Danish population (Rosenberg, et 
al., 1997) and 6.2/100,000 in the UK (Hope, et al., 1997). These figures may 
not represent real differences between populations, but rather differences in 
ascertainment.
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Despite the fact that Usher syndrome is relatively rare, it is estimated to 
account for more than 50% of the deaf-blind population (Boughman, et al., 
1983), approximately 3%-6% of all congential deafness cases (in a literature 
survery by Vernon, 1969) and 5%-15% of patients with retinitis pigmentosa 
(reviewed by Dryja, 2001).
1.4.1.2. Classification
Usher syndrome is an autosomal recessive disorder that is typically classified 
into three clinical subtypes according to the degree of hearing loss and 
vestibular function (Smith, et al., 1994). In Usher syndrome type 1, the most 
severe form, an affected child is born profoundly deaf and with absent 
vestibular function, which manifests itself in early childhood as a delay in motor 
development. Usher syndrome type 2 is distinguished from Usher syndrome 
type 1 by less severe hearing loss and the absence of any vestibular problems. 
The hearing loss is moderate-to-severe, with patients often benefitting from 
hearing aids, unlike Usher type 1 patients, who are seldom helped by hearing 
aids. In type 3, the least severe form of Usher syndrome, the hearing loss is 
post-lingual and progressive, with a varied age of onset, and there is a varying 
degree of vestibular involvement.
Visual dysfunction is generally not used to classify Usher syndrome, since 
there is considerable overlap between the subtypes in the age of onset of 
retinitis pigmentosa. Perceived night blindness and the diagnosis of retinitis 
pigmentosa tend to occur at an earlier age in Usher type 1 than in Usher type 
2, although the difference between the two types is less dramatic than
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previously thought. Furthermore, there is no significant difference in the 
severity of retinitis pigmentosa and the associated ophthalmoscopic findings 
between Usher types 1 and 2 (Tsilou, etal., 2002).
The most common form of Usher syndrome is type 2, accounting for 50% or 
more of all Usher subjects in some populations (Hope, et al., 1997; Rosenberg, 
et al., 1997). Usher syndrome type 3 was originally thought to be the most rare 
form of Usher and was estimated to comprise 3% of all Usher syndrome cases 
(Rosenberg, et al., 1997). However, a nationwide study in Finland suggested 
that around 40% of Usher patients have Usher syndrome type 3 (Pakarinen, et 
al., 1995) and this was confirmed by the finding of a founder mutation in the 
Finnish population (Joensuu, etal., 2001).
It appears, though, that not all Usher patients are easily classified into one of 
the three defined clinical subtypes, a mixed population, with atypical forms of 
Usher phenotype, is also emerging. Patients with milder retinal phenotypes and 
no obvious vestibular dysfunction have been reported with USH1D mutations 
(Bolz, et al., 2001; Bork, et al., 2001) and patients with progressive hearing 
loss, similar to that of Usher type 3, have been reported with USH1B mutations 
(Liu, etal., 1998b) and USH2A mutations (Liu, etal., 1999). Furthermore, it has 
also been suggested that Usher syndrome type 1 should be sub-divided into 
those with profound hearing loss and absent vestibular function, and those with 
profound hearing loss and normal vestibular function (Otterstedde, etal., 2001).
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1.4.2. Genes involved in Usher syndrome
To date eleven loci for Usher syndrome have been mapped, seven for type 1 
(1A-1G), three for type 2 (2A-2C) and one for type 3. Eight out of the eleven 
genes have now been identified (Table 1.3 and Hereditary Hearing Loss 
homepage).
Table 1.3. The Usher syndrome loci and genes identified to date.
Locus
Genomic
location
Gene Protein
USH1A 14q32 Unknown Unknown
USH1B 11 q13.5 MY07A Myosin VIIA
USH1C 11 p15.1 USH1C Harmonin
USH1D 10q CDH23 Cadherin 23
USH1E 21q Unknown Unknown
USH1F 10q21-22 PCDH15 Protocadherin 15
USH1G 17q24-25 SANS Sans
USH2A 1q41 USH2A Usherin
USH2B 3p23-24.2 Unknown Unknown
USH2C 5q14.3-q21.3 VLGR1 VLGR1
USH3 3q21-q25 USH3 Clarin-1
1.4.2.1. Usher genes identified previously
At the beginning of this study only two of the Usher syndrome genes had been 
identified: MY07A, the gene responsible for Usher syndrome type 1B, and 
USH2A, the gene encoding the protein defective in Usher syndrome type 2A, 
Usherin.
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1.4.2.1.1. MY07A
MY07A, encoding the motor protein myosin VIIA, was the first Usher syndrome 
gene identified (Weil, et al., 1995). It accounts for approximately 50% of Usher 
syndrome type 1 cases in a population of European extraction (Astuto, et al., 
2000).
Myosins are actin-based motor proteins that bind actin and hydrolyse 
adenosine triphosphate (ATP) to produce force and movement. The highly 
conserved N-terminal motor head domain possesses the actin- and ATP- 
binding sites and is followed by an a-helical sequence and one or more IQ 
(isoleucine-glutamine) motifs that may bind calmodulin. The unique C-terminal 
tail may contain various putative protein-protein interacting domains that are 
thought to confer specific properties on a class of myosin.
There are currently twelve classes in the myosin superfamily in humans, based 
on the degree of sequence divergence of the motor domain and the tail domain 
structure (reviewed by Berg, et al., 2001). The conventional myosins are those 
in class II, familiar from studies of muscle contraction, whose tails contain an 
extensive stretch of coiled-coil a-helix-forming sequences that allow the 
molecules to dimerize and form a tail that can self-associate to form filaments. 
All other classes of myosins are known as unconventional myosins and are not 
known to have filament-forming abilities.
Myosin VIIA is one such unconventional myosin. It is a 254 kDa protein with the 
typical motor head domain containing the ATP- and actin-binding motifs, a neck
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region composed of five IQ motifs and a long tail that begins with a short coiled- 
coil domain, followed by two large repeats each containing a MyTH4 (myosin 
tail homology 4) domain of unknown function, and a domain homologous to the 
membrane-binding domain of the proteins of the FERM (4.1, exrin, radixin, 
moesin) superfamily, a family of proteins that mediate linkage of the 
cytoskeleton to the plasma membrane. A poorly conserved SH3 domain, a type 
of domain known to interact with proline-rich regions, separates the two repeats 
(Chen, etal., 1996) (Fig. 1.7).
repeat I repeat I!
coiled |------------  1 |-------- ------------1
motor 
head
Figure 1.7. Schematic illustrating the domains of myosin VIIA (Kussel- 
Andermann, et al., 2000).
The conserved motor head domain is followed by five IQ calmodulin binding motifs, a 
short coiled-coil and two MyTH4 -  FERM repeats separated by a poorly conserved 
SH3 domain.
Myosin VIIA is a common component of cilia and microvilli in mouse tissues 
(Wolfrum, et al., 1998). In addition, myosin VIIA expression has also been 
observed in the cochlear and vestibular neuroepithela of human embryos as 
well as in the retinal pigment epithelium and photoreceptor cells (Weil, et al., 
1996).
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1.4.2.1.2. Shaker-1, the Usher type 1B mouse model
As mentioned previously, Shaker-1, the mouse model for Usher type 1B, arose 
spontaneously in 1929, but the gene responsible, Myo7a, was not identified 
until 1995 (Gibson, et al., 1995). Shaker-1 homozygotes exhibit hyperactivity, 
head-tossing and circling due to vestibular dysfunction, as well as deafness 
caused by progressive disorganization of the stereocilia found on the hair cells 
of the organ of Corti in the cochlea (Self, et al., 1998) (Fig. 1.8). Expression of 
myosin Vila, the protein defective in Usher syndrome type 1B, has been 
localized to the inner and outer hair cells of the mouse cochlea and vestibular 
system and to the retinal pigment epithelial cell layer of the eye (El-Amraoui, et 
al., 1996; Hasson, etal., 1995; Sahly, etal., 1997).
Figure 1.8. Scanning electron 
micrographs of the surface of the 
organ of Corti of shaker-1 homo­
zygotes and littermate controls
(adapted from Self, et al., 1998)) 
Micrographs of littermate control (A) 
and shaker-1 homozygote (B) three 
days after birth. Higher magnification 
micrographs of littermate (C) control 
and shaker-1 homozygote (D) twenty 
days after birth. Mutants are showing 
widespread disorganization of the 
stereocilia bundles.
Of interest, the shaker-1 mouse mutant does not display any signs of retinal 
degeneration. This was originally hypothesized to be due to the expression of 
myosin Vila in both the pigment epithelium and the photoreceptor cells of 
human eyes, compared with expression only in the pigment epithelium of
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mouse eyes (El-Amraoui, et al., 1996). However, myosin Vila expression has 
since been localized to the connecting cilium of the mouse photoreceptor cells 
too (Liu, et al., 1997a). Therefore, the difference between the mouse and 
human phenotypes could simply represent inherent differences between the 
two species, or it could indicate that genetic background is an important 
determinant in the extent of the pathology. Hence, although shaker-1 is a good 
model for studying the function of the myosin Vila in the inner ear and why 
mutations lead to deafness, it may not be a very good model for the retinal 
pathology.
1.4.2.1.3. USH2A
The second Usher gene to be identified, USH2A, encodes a novel basement 
membrane protein, usherin (Eudy, et al., 1998). Usherin is a 180 kDa protein 
with an amino terminus domain with homology to the thromobospondin family 
of extracellular matrix proteins, followed by an LN module and ten laminin-EGF- 
like (LE) motifs and four fibronectin type III repeats at the C-terminus. The 
globular LN domain is a common feature of laminins, which, along with the LE 
motifs, are required for polymerization of laminins into the networks found in 
basement membranes. Usherin localizes to all basement membranes in both 
the eye and inner ear, as well as being widely expressed in the basement 
membranes of the small intestine, colon and most of the reproductive organs 
(Bhattacharya, etal., 2002).
1.4.3. Usher syndrome type 1C
Early epidemiological studies showed that the prevalence of Usher syndrome 
was high in the French Acadian population of Louisiana. Acadians are
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descendants of the French settlers of Nova Scotia in the early 17th century. 
Upon being forced out by the British in 1755 they scattered around America 
and Canada with a large number ending up in Louisiana. Presumably this was 
a relatively small population with a few founder members and therefore a 
certain degree of inbreeding. The Acadian subtype of Usher syndrome was 
mapped in 1992 to 11 p15-p13 (Smith, et a/., 1992) and termed Usher type 1C. 
Until identification of the gene in 2000 (Bitner-Glindzicz, et al., 2000; Verpy, et 
ai, 2000), Usher type 1C was thought to be exclusive to the Acadians.
The gene underlying type 1C Usher syndrome was originally isolated, through 
its protein product, in two groups of patients with gastro-intestinal pathology. In 
a group of patients suffering from colon cancer, an antigen, designated 
PDZ-73, was among forty-eight distinct antigens isolated in the patients’ sera, 
which was used to screen cDNA expression libraries derived from the tumours 
by a method known as SEREX (SERological Expression cloning) (Scanlan, et 
al., 1999). Briefly, a cDNA library was constructed from RNA extracted from 
colon cancer tumour samples and transferred to a nitrocellulose membrane. 
The library was then screened using autologous sera, and positive clones were 
detected using an alkaline phosphatase-conjugated goat anti-human IgG 
antibody. In contrast, when sera from patients suffering from X-linked 
autoimmune enteropathy (AIE) associated with tubulonephropathy was used to 
screen a human duodenal cDNA expression library; the same protein was 
identified and designated AIE-75 (Kobayashi, et al., 1999). Both of these 
proteins, AIE-75 and PDZ-73, are encoded by the same gene, now termed 
USH1C, whose protein product has been re-named harmonin.
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1.4.3.1. Cloning USH1C
The role of this gene, encoding PDZ-73/AIE-75, in the pathogenesis of Usher 
syndrome in humans came to light by two different approaches used to identify 
the Usher type 1C gene. In one approach, USH1C was identified in a 
subtracted mouse cDNA library derived from inner ear sensory areas (Verpy, et 
al., 2000). cDNA generated from the five vestibular sensory patches was 
subjected to three rounds of hybridization/subtraction against a mixture of 
cDNA generated from mouse liver, dorsal root ganglia and the membraneous 
and cartilaginous parts of the semicircular canals. cDNA specific to the inner 
ear sensory areas would not hybridize to cDNA from the other tissues and 
could then be identified by amplification. One of the ear-specific cDNA clones 
mapped to the same region of chromosome 11 (11 p15) to which the gene
i
responsible for USH1C had been originally mapped (Smith, et al., 1992) and 
was a good candidate, on the basis of the potential function of the protein.
In our group, a contiguous gene deletion found in patients suffering from severe 
hyperinsulinism, profound congenital sensorineural deafness, enteropathy and 
renal tubular dysfunction, which overlapped the USH1C locus, led to the 
identification of the USH1C gene (Bitner-Glindzicz, et al., 2000). The deletion 
identified in our family included all but the first two exons of USH1C and most 
of the 5’ exons of the adjacent gene, ABCC8, a gene encoding a component of 
ATP-sensitive K+ (KAtp) channels (Fig. 1.9), mutated in some patients with 
hyperinsulinism (Thomas, etal., 1995).
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USHfC (AIE- 75/PDZ-73) ABCC8 (SDR!)
Exon ^
t6kb
Figure 1.9. Genomic structure of USH1C and ABCC8 (Bitner-Glindzicz, et 
al., 2000).
Rectangles represent exons and the lines connecting them represent introns. As 
indicated, 16 kb separate the last exon of USH1C from the first exon of ABCC8. The 
unfilled exons are located within the 122 kb contiguous gene deletion.
1.4.3.2. Expression of US FI 1C
USH1C is located at 11 p15.1 and comprises twenty-eight exons, which span 
approximately 51 kb of genomic DNA. Twenty of the exons are constitutive 
(exons 1-14 and 16-21), whilst the remaining eight are alternatively spliced 
(exons 15, A-F and G/G’) and account for the observation of various different 
transcripts (Scanlan, et al., 1999; Verpy, et al., 2000) (Fig. 1.10).
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Figure 1.10. Alternative isoforms of USH1C identified to date.
This figure is adapted from Verpy, et al., (2000) to include additional isoforms of 
USH1C identified by Scanlan, et al., (1999). Boxes represent exons, with the 
constitutive exons numbered in black and the alternatively spliced exons numbered in 
pink. Asterisks denote in-frame stop codons. Further explanation on the alternative 
isoforms is given in Chapter 4, Figure 4.1.
Although USH1C is fairly widely expressed in many tissues of the human body, 
including the small intestine, colon, kidney, pancreas, testis, lung, liver, heart 
and brain (Kobayashi, et al., 1999; Scanlan, et al., 1999), expression in the 
mouse inner ear (Verpy, et al., 2000) and developing human eye (Bitner- 
Glindzicz, et al., 2000) is restricted to the sensory areas. Initially, expression of 
transcripts containing the alternative exons A-F and G/G’ (the harmonin b 
isoforms) was detected in the mouse inner ear, but not in the eye (Verpy, et al., 
2000). Hence, it was hypothesized that mutations in the ‘ear-specific’ exons of 
USH1C could cause deafness in the absence of retinal phenotype.
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1.4.3.3. Mutations in USH1C
Upon identification of the USH1C gene, a 216G>A change was identified in the 
cDNA extracted from cell lines from an Acadian family with Usher type 1C. This
• t,
change does not change an amino acid, but was shown to create a new splice 
site in exon 3 that lead to deletion of thirty-nine base pairs and a shortened 
transcript postulated to be unstable (Bitner-Glindzicz, etal., 2000). However, an 
expansion of a variable number of tandem repeats (VNTR) of a 45 bp 
sequence in intron 5 to nine repeats (9VNTR), proposed to affect transcriptional 
and/or post-transcriptional processes, was also found in the Acadian population 
(Verpy, et al., 2000). This expansion has since been shown to be in complete 
linkage disequilibrium with the 216G>A mutation (Savas, et al., 2002). It is 
thought that the two events occurred at about the same time since neither 
change has been found independent of the other. However, it has not yet been 
confirmed that the 9VNTR allele contributes to the USH1C phenotype in the 
Acadian patients.
Surprisingly, since it was thought that Usher type 1C was confined to the 
Acadian population (Astuto, et al., 2000), further mutations have also been 
identified in families from a variety of ethnic backgrounds. IVS5-2delA, a 
mutation that affects the invariant A in the AG of the intron 5 acceptor splice 
site, expected to lead to aberrant splicing, was found in two unrelated 
Lebanese families (Verpy, et al., 2000). The insertion of a cytosine in a run of 
six cytosines in exon 3, 238-239insC, predicted to cause a frame-shift in the 
protein and a premature stop signal at codon 148 was identified in a Pakistani 
family (Bitner-Glindzicz, et al., 2000; Verpy, et al., 2000) and four families of 
European descent (Verpy, et al., 2000).
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A number of single nucleotide polymorphisms (SNPs) have also been identified 
in USH1C (Zwaenepoel, etal., 2001).
1.4.3.4. USH1C codes for the protein harmonin
The USH1C gene encodes a PDZ domain-containing protein (see section 1.6.), 
known as harmonin (from the Greek harmonia, meaning “assembling”), of 
which the main isoform has a molecular mass of approximately 73 kDa and 
contains 3 PDZ domains and a coiled-coil domain. In the longer harmonin b 
isoforms, the additional exons code for an extra coiled-coil domain and a 
putative protein degradation motif (PEST) (Fig. 1.11). PDZ domains and coiled- 
coils are both protein interaction motifs, whilst the PEST motif is a polypeptide 
sequence enriched in proline (P), glutamic acid (E), serine (S) and 
threonine (T) residues, which has been shown to target the protein containing it 
for rapid degradation (Rogers, et al., 1986).
COOH
Figure 1.11. Schematic representation of the protein domains of harmonin 
isoforms a and b.
The shorter harmonin a isoform has three PDZ domains and one coiled-coil, while the 
longer harmonin b isoform has an extra coiled-coil and a PEST protein degradation 
motif, both indicated in pink.
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1.5. Allelism
The study of both syndromic and non-syndromic deafness has given rise to a 
number of examples of allelism, that is, different mutations in the same gene, 
which give rise to both types of deafness (Table 1.4). In addition, mutations in 
USH2A have been shown to cause non-syndromic retinitis pigmentosa (Rivolta, 
et al., 2000), as well as Usher syndrome type 2A (Eudy, et al., 1998).
Table 1.4. Genes allelic for syndromic and non-syndromic deafness.
Gene
Syndromic
Deafness
Non-syndromic
Deafness*
SLC26A4 (pendrin) Pendred
syndrome(Everette' a/' 1997)
DFNB4(F*rasad| a^ 1
GJB2 (connexin 26) Vohwinkel
syndrome(Maestriniefa/’ 1999)
DFNB1(KeIseI1, 
DFNA3(Kelsel1, a^ 1 9^97^
MY07A Usher type iB (we,lera/- iyaj5) DFNB2(LIU’ e^ a^ * ^^ 7b) 
DFNA11 ^ Liu’et al" 1997c)
CDH23 Usher type 1D,BOIzera' ^ uul) DFNB12(BorK’ a^ ’
PCDH15 Usher type DFNB23(Arimed’ a^ ’
* DFNB is autosomal recessive deafness, DFNA is autosomal dominant deafness.
The locus for non-syndromic, autosomal, recessive deafness, DFNB18, 
overlaps with that for USH1C (Jain, et al., 1998). If USH1C mutations could be 
identified in patients with autosomal non-syndromic recessive deafness (i.e. in 
patients who are deaf in the absence of an eye phenotype), then this may aid 
the understanding of the function of harmonin in both organs.
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1.5.1. Alternative splicing
USH1C is an alternatively spliced gene and it has already been demonstrated 
that harmonin exists as several alternatively spliced isoforms, some of which 
are thought to be ear-specific (Scanlan, et al., 1999; Verpy, et al., 2000). 
Therefore, it is possible that mutations in exons found only in the ear-specific 
isoforms could lead to non-syndromic autosomal recessive deafness, DFNB18, 
in the absence of an eye phenotype.
Alternative splicing is a means of producing multiple protein products from a 
single gene. The splicing pattern of a typical multi-exon mRNA can be altered 
in many ways (Fig. 1.12). The use of alternative exons or the lengthening or 
shortening of exons by the use of alternative 5’ or 3’ splice sites can lead to the 
introduction or removal of protein domains with novel functions. The use of 
alternative 5’ untranslated regions (5’ UTR) allows alternative regulation of 
gene expression in different tissues.
Figure 1.12. Patterns of 
alternative splicing
(Black, 2003).
Grey boxes represent con­
stitutive sequences present 
in all final mRNAs. Hatched 
boxes represent alternative 
RNA segments that may or 
may not be used. (A) Cassette exons maintain the reading-frame, whether or not they 
are included. (B) Exons may be mutually exclusive. (C, D) Alternative 5’ and 3’ splice 
sites allow the lengthening or shortening of a particular exon. (E, F) Alternative 
promoters and alternative poly(A) sites alter the beginning or end of a transcript. (G) 
Introns may be retained in the translated mRNA. (H) A single pre-mRNA can exhibit 
multiple sites of alternative splicing that are often used in different combinations to 
produce many different final mRNAs.
Poly (A)
“  • Poly(A) Poly (A)
R v v w v ,
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It is postulated that alternative splicing has a major role in the production of 
complexity in the human genome. Subsequent to completion of the human 
genome sequencing project, the number of human genes is estimated to be 
approximately 30,000-35,000 (Lander, et al., 2001; Venter, et al., 2001). This 
figure is surprisingly low when compared to the genomes of much simpler 
organisms, such as the fruit fly Drosophila melanogaster and the nematode 
C. elegans, which contain around 14,000 and 19,000 genes, respectively (The 
C. elegans sequencing consortium, 1998; Adams, et al., 2000).
Early estimates of the frequency of alternative splicing reported that between 
35% and 59% of human genes show evidence of at least one alternative splice 
form (Modrek and Lee, 2001). However, a more recent genome-wide survey of 
alternative splicing, using exon-junction microarrays to monitor the exon-exon 
connections of 10,000 multi-exon genes, estimates that as many as 74% of 
human multi-exon genes may be alternatively spliced (Johnson, et al., 2003a). 
Furthermore, it appears that alternative splicing tends to insert or delete 
complete protein domains more frequently than expected by chance 
(Kriventseva, et al., 2003), thus indicating that alternative splicing has a role in 
increasing the functional diversity of the proteome.
Alternative USH1C transcripts involve the inclusion of additional exons between 
exons 14 and 16 and between exon 20 and 21 that may or may not alter the 
open reading frame (Fig. 1.10) (Scanlan, et al., 1999; Verpy, et al., 2000). 
Furthermore, a putative short isoform of harmonin, PDZ-37, has also been 
reported (Fig. 1.10) (Scanlan, et al., 1999). This isoform lacks the first two PDZ
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domains and is thought to utilize an alternative transcription initiation site in 
exon 12.
The physiological significance of these alternative isoforms is not yet known. 
However, the additional exons, A to F, encode an extra coiled-coil domain and 
the a putative protein degradation motif (PEST). Furthermore, a change in the 
open reading frame can result in the loss of the third PDZ domain and/or the 
presence of a novel C-terminus that may or may not possess a PDZ-binding 
motif. Therefore, it can be hypothesized that not all of the isoforms of harmonin 
will have the ability to form the same interactions. In addition, some isoforms do 
appear to have tissue specific expression patterns (Scanlan, et al., 1999; 
Verpy, et al., 2000). Therefore, the USH1C gene appears to have the ability to 
produce several protein products, each with slightly different binding abilities.
1.6. PDZ Domains
Harmonin is a PDZ domain-containing protein. PDZ domains are one of the 
most common modular protein interaction domains and are able to mediate 
specific interactions that underlie the assembly of large protein complexes 
involved in signalling or subcellular transport. Therefore, it is not surprising that 
disruption of these interactions could play a role in disease. However, harmonin 
was the first PDZ domain-containing protein to be linked to a human disease 
(Bitner-Glindzicz, etal., 2000; Verpy, etal., 2000).
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1.6.1. Structure and function
1.6.1.1. Structure of PDZ domains
PDZ domains are named after the first three proteins in which the 90 amino 
acid repeat sequence was first recognized: the post-synaptic protein density 
protein, PSD-95/SAP90, the Drosophila septate junction protein, Discs-large 
(Dig), and the epithelial tight junction protein ZO-1 (zonula occludens-1). PDZ 
domains are also sometimes known as Discs-large homology repeats, or GLGF 
repeats after the highly conserved Gly-Leu-Gly-Phe amino acid sequence 
found within the domains. The role of PDZ domains in protein-protein 
interactions was established when it was discovered that the first and second 
PDZ domains of PSD-95 could bind to the C-termini of either the Shaker K+ 
channel (Kim, et al., 1995) or the NMDA (N-methyl-D-aspartate) receptor 
(Kornau, et al., 1995). Subsequently, the structure of various PDZ domains 
have been determined crystallographically, PDZ3 of PSD-95 being the first 
(Doyle, et al., 1996), allowing the mechanism of their protein interaction to be 
deduced.
The basic structure of a PDZ domain is a compact globular fold in which six p- 
strands (pA-pF) sandwich two a-helices (aA and aB). A peptide-binding groove 
is located between the pB-strand and the aB-helix in which C-terminal peptides 
bind as an antiparallel p-strand. The N- and C-termini of the domain are located 
near each other on the opposite side of the domain from this peptide-binding 
site (Fig. 1.13).
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Figure 1.13. Diagram illustrasting the 
structure of a typical PDZ domain (Hung 
and Sheng, 2002).
A ribbon diagram of PDZ3 of PSD-95 
illustrating the six (3-strands (turquoise) and 
two a-helices (red), with a peptide (yellow) 
binding as a |3-strand between the aB helix 
and (3B strand. The N- and C-termini are 
located near each other on the opposite side 
of the domain from the peptide-binding groove.
1.6.1.2. Function o f PDZ domain-containing proteins
An increasing number of roles have been identified for PDZ domain-containing 
proteins in different cell types. PDZ-based scaffolds organize signal 
transduction pathways such as phototransduction in Drosophila (reviewed by 
Pawson and Scott, 1997) and the signalling machinery at synapses (reviewed 
by Gomperts, 1996). PDZ proteins have also been implicated in the 
establishment of cell polarity and the trafficking of proteins to particular 
subcellular localizations (Bilder, 2001; and reviewed by Bredt, 1998). More 
recently, studies on the cystic fibrosis transmembrane conductance regulator 
channel (Pagani, et al., 2003) indicate that PDZ domains may be able to 
modulate the function of their associated proteins, as well as the localization, 
by having a direct effect on channel gating, possibly by linking monomeric 
subunits of the channel (Raghuram, etal., 2001).
1.6.2. Ligand specificity
PDZ domains recognize specific C-terminal peptides, usually 4-5 amino acids 
in length, in their protein ligands. This specificity is determined by the amino
60
acids present at the ligand-binding surface. The conserved GLGF motif, within 
the PDZ domain, is important for hydrogen bond co-ordination of the C-terminal 
carboxylate group of the ligand.
The carboxylated amino acid at the end of a peptide ligand, termed PO, is a 
major determinant in the interaction of a PDZ domain with its ligand. In general, 
PDZ domains require a hydrophobic residue at the end of its ligand, as the side 
chain has to project into a hydrophobic pocket. However, PDZ-interacting 
peptides ending with a negatively charged acidic amino acid residue 
(asparagine or glutamine) (Vaccaro, et al., 2001), or with a polar cysteine 
residue (Maximov, etal., 1999) have also been described. The next residue, P- 
1, is thought to have a minor role in the specificity as its side-chain has been 
observed to point away from the interaction surface (Doyle, et al., 1996). 
However, the next residue along, P-2, determines the binding specificity of the 
domain through its interaction with the first residue of aB helix (position aB1). 
Hence, the nature of the side-chain of the amino acid residue at the -2  position 
is believed to be a major determinant in PDZ-binding specificity. Nevertheless, 
residues that are further away from the C-terminus of the ligand protein may 
also be involved in the specification of peptide/PDZ binding (Songyang, et al., 
1997).
PDZ domains are, however, also able to bind to internal peptide sequences, as 
long as they form a specific tertiary structure that conformationally mimics the 
chain terminus. This has been observed for the interaction between the PDZ 
domain of neuronal nitric oxide synthase (nNOS) and the syntrophin PDZ 
domain (Hillier, et al., 1999). Therefore, it can be seen that PDZ domain-
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containing proteins have the ability to form homo- and hetero-oligomers that 
would be useful in assembling protein networks.
1.6.3. Classification of PDZ domains
Initial attempts to classify PDZ domains based on their ligand specificity lead to 
the observation of two main classes of PDZ domains: class I -X-S/T-X-<|) and 
class II -X-(j)-X-<|) (where <j> is hydrophobic and X is any amino acid) (Songyang 
et al., 1997). However, a growing number of C-terminal ‘exceptions’ have been 
identified (Maximov, et al., 1999; Vaccaro, et al., 2001) and a novel system to 
classify PDZ domains was devised (Bezprozvanny and Maximov, 2001). 
Essentially, the nature of the amino acid residues at two critical positions within 
the binding cleft of the PDZ domain is examined. The first (Pos1) immediately 
follows the (3B strand, while the second (Pos2) corresponds to the first position 
in the second a-heilx (aB1). This classification allows all known PDZ domains 
to be arranged into twenty-five groups and hence the ligand specificity of 
‘orphan’ PDZ domains, with no known binding partners, may, to a certain 
extent, be predicted. Nevertheless, the only way to be sure of the binding 
specificity of a given PDZ domain is to investigate candidate peptide ligands in 
functional assays (Songyang, etal., 1997; Vaccaro, etal., 2001).
1.7. Gene Characterisation and Elucidation of 
Function
Once a gene has been cloned, there are a number of approaches that can be 
used to characterise it further and determine the possible function(s) of the
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protein that it encodes. Molecular methods can be used to identify mutations in 
patient cohorts and to study alternative splicing and gene expression patterns. 
In addition, antibodies may be raised to the protein and used to study its 
subcellular and/or tissue localization. Furthermore, the function of a protein 
may be infered through knowledge of the proteins with which it interacts, and 
there are various methods available to identify and confirm protein-protein 
interactions.
1.7.1. Mutation detection
There is a variety of methods for screening a gene for mutations. Sequencing 
and hetero-duplex analysis methods are among those most frequently used. 
Only sequencing will characterize fully a change in the DNA, but it is expensive, 
can be labour intensive and it will miss medium/large deletions. Hence, 
mutations are normally detected through other, higher throughput methods and 
then confirmed by sequencing. Many of these methods exploit the formation of 
hetero-duplexes to detect differences between two sequences. Many mutations 
occur in the heterozygous form and naturally form hetero-duplexes. If a 
mutation is homozygous, some wild type DNA may be added to the PCR 
product and hetero-duplex formation can be forced by denaturing the DNA mix 
and then allowing it to cool slowly.
In single-strand conformation polymorphism (SSCP) analysis, the fact that 
hetero-duplexes often have abnormal mobility in non-denaturing 
polyacrylamide gels is exploited. However, hetero-duplexes also have 
abnormal denaturing profiles and will normally denature more easily than their 
corresponding homoduplex. This feature is taken advantage of in denaturing
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gradient gel electrophoresis (DGGE) and denaturing high performance liquid 
chromatography (DHPLC). DHPLC requires more optimization for an individual 
DNA fragment than does SSCP, but it appears to be a more sensitive method 
of mutation detection, with detection rates of 92-100% reported (Dobson-Stone, 
etal., 2000; Gross, etal., 1999; Liu, etal., 1998a; Prasad, etal., 2004; Rickard, 
etal., 2001).
The majority of point mutations and small deletions and insertions can be 
picked up using hetero-duplex analysis methods and sequencing. However, it 
is not possible to identify larger deletions and duplications using these 
methods. Southern blotting, fluorescent in situ hybridization (FISH) or 
quantitative PCR are better methods to use for the detection of large deletions 
or duplications.
1.7.2. Assignment of pathogenicity
Once changes in the DNA sequence have been detected, the next step is to 
determine whether they are disease-causing or represent silent polymorphic 
changes. An insertion or deletion, that causes a frame-shift in the open-reading 
frame, or a nonsense mutation that changes a codon to a stop codon, can be 
predicted to lead to a truncated protein product. However, it is more difficult to 
predict the outcome of missense mutations.
Missense mutations may or may not lead to a change in amino acid residue 
and, in most cases experimental verification that a change is disease-causing 
is required. Regardless of whether or not a missense mutation affects the 
protein sequence, it may have an unpredicted effect on splicing by creation of a
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cryptic splice site or by disruption of an exon splicing enhancer (ESE) (Ars, et 
al., 2000; Liu, et al., 2001; Teraoka, et al., 1999). Such effects are less easy to 
predict and may be investigated by analysis of RNA, either from patients with 
the mutation, or by exon-trapping experiments. Briefly, the DNA of interest is 
sub-cloned into a plasmid expression vector that contains an artificial minigene, 
which can be expressed in a suitable host cell. The minigene is transcribed and 
the RNA spliced under control of the host cells RNA splicing machinery. 
Splicing of the inserted DNA can then be analysed by isolating RNA from the 
cells and making cDNA, which is then amplified and sequenced.
In addition, some nonsense mutations have been shown to induce exon- 
skipping, resulting in the production of a functional, albeit smaller, protein 
(Dietz, etal., 1993; Ginjaar, etal., 2000).
1.7.2.1. Missense changes
Upon identification of a novel missense nucleotide change, several factors 
need to be considered to determine whether the change is likely to be disease- 
causing. Firstly, does it segregate with the disease phenotype, i.e. is it carried 
by all the affected individuals and not carried by the unaffected members of the 
family? Secondly, does it occur commonly in an ethnically matched control 
population? To address this, at least fifty control individuals (i.e. 100 
chromosomes) must be screened for the change to confirm that it is carried by 
less than 1% of the population. However, for this, the prevalence of the disease 
must also be taken into consideration. For example, the 35delG mutation in 
connexin 26 has a carrier rate as high as 1 in 35 in some populations 
(Gasparini, et al., 2000), but it is still pathogenic. In addition, it is also possible
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that the change could represent a very rare polymorphism.
The next step is then to look at the effect this nucleotide change would have on 
the protein that it encodes. Is the change in amino acid a significant one such 
that it could affect the tertiary structure of the folded protein? For example, the 
conformation of the protein could be affected by a change in the size, charge or 
bond-forming capabilities (e.g. disulphide bridges) of the amino acid side chain. 
Then, is the amino acid found in a highly conserved region? Conservation of an 
amnio acid through the species is normally an indication that it plays an 
important role in the function of the protein. This can be determined by aligning 
the protein sequence with its orthologous sequences from other species.
If an amino acid change is not found in a control population and it is predicted 
to be significant enough to alter the protein function then this hypothesis needs 
to be tested further. If, however, the change is not found in a control population 
and it would not be predicted to have a significant effect on protein function, it is 
still possible that the nucleotide change could affect splicing of the mRNA. 
Furthermore, even if an alteration in the DNA sequence is not predicted to be 
disease-causing, it could still prove useful in future studies.
1.7.2.2. Polymorphisms
SNPs represent two allele single nucleotide variations, distributed throughout 
the human genome. SNPs are reported to have an average density of one SNP 
every 1-2 kb of DNA (Sachidanandam, et al., 2001) and have a low rate of 
recurrent mutation. This makes SNPs ideal for association studies. In contrast, 
microsatellites, another type of sequence variation found within the human
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genome, are more highly mutable than SNPs, but occur less frequently within 
the genome. Microsatellites are di-, tri- and tetranucleotide repeats with allele 
sizes of 200-400 bp in length, which, because they are more informative than 
SNPs, are better suited to linkage studies.
Furthermore, the alleles of individual polymorphisms may be considered 
together in haplotypes, and the non-random association of alleles within a 
haplotype is known as linkage disequilibrium. As the distance between two 
polymorphisms increases, linkage disequilibrium decreases since greater 
distances provide more opportunity for recombination events to occur. 
Therefore, SNPs are valuable tools for studying human evolution as well as the 
gene variants that are associated with common diseases. Because of their 
relatively low rate of mutation, SNPs can be very useful for determining the 
origin of certain common mutations, i.e. whether they are likely to be recurrent 
or due to a founder effect, according to the haplotypes on which they are found. 
An excellent example is the 35delG mutation in connexin 26, commonly found 
in Caucasian populations. 35delG, deletion of a single guanine in a run of six 
guanines, was generally hypothesized to be a recurrent mutation, based on 
studies using microsatellite markers over a 2 cM interval. However, a study of 
the SNPs in a much smaller interval of 70 kb showed that the high frequency of 
the 35delG mutation was the result of an ancient founder effect (Van Laer, et 
al., 2001).
1.7.3. Protein function
Information about gene function may be gained by studying the protein it 
encodes. The domains of a protein may be analysed using bioinformatics to
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compare with similar domains found in other proteins, and expression of the 
protein within cells and tissues may be studied.
1.7.3.1. Subcellular localization
Determination of sub-cellular localization of a protein can provide important 
clues to its potential function. For example, it is only since sub-cellular 
localization studies were performed that it has emerged that Bardet-Biedl might 
be a disease of the cilia (Ansley, et al., 2003). Relevant cultured cells can be 
fixed, permeabilized and then stained with an antibody raised against the 
protein. Co-localization of a protein with a specific intracellular compartment 
may be visualized by double-staining using antibodies raised against the 
markers of various sub-cellular compartments.
1.7.3.2. Protein-protein interactions
Even after studying the structure and expression pattern of a novel gene, its 
function may not be obvious. However, most proteins function by interacting 
with other proteins in complex networks.
The most powerful way to screen for protein-protein associations is the yeast 
two-hybrid system. This is a library-based method in which the bait gene (i.e. 
the protein of interest) is coupled to the DNA-binding domain of a transcription 
factor and a library of cDNA sequences are coupled to the transcription factor 
activation domain. Yeast cells are then co-transfected with the bait gene 
construct and the cDNA library constructs. The yeast cells are engineered to 
carry a reporter gene, which is activated when the domains of the transcription 
factor are brought together through the interaction of the proteins to which they
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are bound. The clones in the positive cells must then be isolated and 
sequenced to determine the identity of the interacting protein. Once a positive 
protein-protein interaction has been identified, the yeast two-hybrid system may 
also be used to determine specifically which domain of the protein is involved in 
the interaction. Phage display is another library-based method, which can be 
used to identify proteins that interact with a candidate protein.
Other approaches to study potential protein-protein interactions are co- 
immunoprecipitation and GST pull-down assay. Both of these techniques 
require an antibody to the protein of interest. Co-immunoprecipitation studies 
protein interactions in vivo and employes an antibody to precipitate the protein, 
with any bound proteins, from a cell lysate. Candidate binding proteins may 
then be specifically sought. In the in vitro GST pull-down assay the protein of 
interest is incubated with a candidate interacting protein fused to a GST moiety. 
The GST-fusion protein is then recovered on glutathione Sepharose beads and 
any bound protein is detected on immunoblot (western blot). Both of these 
methods may be used to confirm results obtained from yeast two-hybrid 
studies.
Hence, it can be seen that a combination of methods, at both the molecular and 
protein level, are required to fully characterize a novel gene. This is 
demonstrated in this thesis with the characterization of the recently identified 
USH1C gene.
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1.8. Aims of Thesis
When the gene for Usher syndrome type 1C, USH1C, was identified in 2000 it 
encoded a PDZ domain-containing protein of unknown function. The aim of this 
thesis is to characterize the USH1C gene further by mutation analysis and 
gene expression studies, in an attempt to elucidate its role within the ear. Study 
into the role of this gene within the eye is the subject of another PhD thesis.
The approaches used were:
1) To screen patients to find novel mutations in USH1C, which might yield 
information about important functional domains. To do this, patients with 
type 1 Usher syndrome were screened, as well as patients with non- 
syndromic hearing loss, to establish whether mutations of USH1C also 
cause autosomal, recessive, non-syndromic deafness, DFNB18.
2) To investigate alternative isoforms of USH1C using RACE and RT-PCR. 
Tissue-specific expression patterns were studied in human foetal tissues 
and novel isoforms were sought to explain the observation of 
gastrointestinal symptoms in patients with deletion of the USH1C gene.
3) To gain insight into the function of harmonin by studying protein expression 
in mouse cochlear sections and to establish the sub-cellular localization of 
harmonin in a human epithelial cell line.
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4) To further elucidate a role for harmonin by testing a candidate protein (the 
product of another gene mutated in type 1 Usher) for interaction with 
harmonin in an in vitro GST pull-down assay.
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2. Materials and Methods
2.1. Materials
Company
AB gene
Amersham Pharmacia 
Biotech
Amresco
Bioline
Bio-Rad
Citifluor Ltd 
Fermentas 
Invitrogen™
Product
PCR film 
96-well plates
Hybond ECL nitrocellulose membrane
Glutathione Sepharose® 4B
GST vector pGEX-4T-1
19:1 Acrylamide/Bis-acrylamide
5x TBE
Urea
dNTPs,
Taq polymerase with 10x buffer and 50 mM 
MgCh.
10xTGS buffer
Coomassie Brilliant Blue R-250 powder
Gel Doc™ 2000 imaging system
Precision plus protein™ standards
Protein assay dye
Glycerol/PBS mounting solution
Eel 13611 restriction endonuclease enzyme
100bp ladder
5’ RACE kit
Agarose
DMEM with L-Glutamate 
Dnase I
Hind III DNA fragments 
LB broth
Low-mass DNA ladder
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Lab-Tek®
L.I.P equiptment and 
services
Molecular Probes 
MWG
National Diagnostics
New England Biolabs (NEB)
Novagen
Perkin Elmer (PE) Applied 
Biosystems
Promega
Qiagen
One Shot® TOP10 competent cells 
RPMI medium 
S.O.C. medium
Superscript™ II Reverse transcriptase
T4 DNA Ligase
Trizol™
Vector pZErO™-2
Zero Background/Kan cloning kit
4-well glass Chamber Slide™
5-ml capacity plastic moulds
Rhodamine conjugated Phalloidin 
Oligonucleotides
37.5:1 Acrylamide/Bis-acrylamide (Sequagel) 
30% Acrylamide mix
Diluent, acrylamide gel concentrate and buffer 
for genotyping gels
Restriction endonuclease enzymes (except Eel 
13611)
DNA polymerase I, the large (Klenow) fragment 
Calf intestinal alkaline phosphatase (CIP) 
BugBuster® protein extration reagent 
IPTG
ABI 377 DNA sequencer 
BigDye™ cycle-sequencing kit 
GS500 Tamra size standard 
Loading dye
Streptavidin-AP conjugate
TNTr Quick Coupled Transcription/Translation
system
Transcend™ Biotin-Lysyl-tRNA
Western Blue™ stabilized substrate for alkaline
phosphatase
HotStarTaq™ DNA polymerase
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QIAprep spin miniprep kit 
QIAquick PCR purification kit 
QIAquick gel extraction kit 
Raymond A. Lamb Optimal Cutting Temperature compound (OCT)
Roche Expand™ long template PCR system
Santa Cruz Biotechnology, Anti-rabbit-FITC IgG conjugate
Inc.
Stratagene
Transgenomic
VWR™ International 
Sigma
Biotinylated anti-mouse IgG 
Biotinylated anti-rabbit IgG 
Goat serum
Mouse monoclonal anti-GST antibody 
Rabbit serum
BL21 competent E. coli cells
WAVE DNA analysis system
TEAA
Acetonitrile
All other chemicals
2.1.1. Software 
Application
Primer design
Gel image capture 
Determine of conditions for 
hetero-duplex analysis 
DNA sequence analysis 
Genotype analysis
Capture of fluorescent 
microscopy images 
Capture of confocal 
microscopy images
Product
Primer 3
Quantity One 4.4.0. 
WaveMaker™
Sequence Navigator 
Genescan version 2.0 
and Genotyper 
Openlab 3.1.1.
Leica confocal software
Company
MIT website (see 
Appendix D)
Bio-Rad
Transgenomic™
PE Applied Biosystems 
PE Applied Biosystems
Improvision
Leica microsystems
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2.1.2. Solutions
Coomassie blue solution
11.1 mM EDTA, pH 7.3 
DNA loading buffer 
4% Paraformaldehyde
Phosphate buffered 
saline (PBS)
Protease inhibitor mix 
(Sigma)
10% Methanol 
25% Acetic acid
0.05% (w/v) Coomassie Brilliant blue R-250 powder
4.13 g/100 ml EDTA 
0.44 g/100 ml NaOH pellets
50% Glycerol
Orange G dye powder to desired colour
4 g paraformaldehyde per 100ml PBS
~4-5 drops concentrated NaOH to aid solubilization
137 mM NaCI
2.7 mM KCI
10 mM Na2HP04
1.8 mM KH2 PO4
pH adjusted to 7.4 with HCI
2 mM AEBSF 
1 mM EDTA 
130 jllM  Bestatin 
14 jaM E-64 
1 pM Leupeptin 
0.3 |aM Aprotinin
75
1x RACE PCR buffer 
(Invitrogen)
RIPA buffer
6x SDS loading buffer
5x TBE buffer
20 mM Tris-HCI, pH 8.4 
50 mM KCI
2.5 mM MgCh 
10 mM DTT
400 pM each dATP, dCTP, dGTP, dTTP
150 mM NaCI 
1% NP-40
0.5% sodium deoxycholate 
0.1% SDS 
50 mM Tris, pH 8.0
0.35 M Tris-HCI, pH 6.8 
10.28% SDS 
36% glycerol 
5% p-mercaptoethanol 
0.012% bromophenol blue
0.089 M Tris 
0.089 M Boric acid 
2 mM EDTA, pH 8.0
TE buffer 10 mM Tris
1 mM EDTA, pH adjusted to 8.0 with HCI
1x TGS buffer 25 mM Tris 
192 mM Glycine 
0.1% (w/v) SDS 
pH 8.3
Western transfer buffer 48 mM Tris
39 mM Glycine 
20% (v/v) methanol 
pH 9.2
2.1.2.1. Qiagen DNA preparation buffers 
Buffer P1 50 mM Tris-HCI
10 mM EDTA 
100 pg/ml RnaseA
Buffer P2 0.2 M NaOH 
1% SDS
Buffer EB 10 mM Tris-HCI, pH 8.5
2.1.2.2. Media
LB (Luria-Bertani) broth 10 g/l Bactotryptone
5 g/l Bacto-yeast extract 
0.17 M NaCI
LB agar 15 g/l bacto-agar added to LB broth
SOC medium
2.1.3. Gels
0.5% Agarose gel
2% Agarose gel 
Sequencing gel
Genotyping gel
20 g/l Bactotryptone
5 g/l Bacto-yeast extract 
10 mM NaCI
2.5 mM KCI 
20 mM Glucose
0.5 g agarose/100 ml TBE buffer 
0.5 |ag/ml ethidium bromide
2 g agarose/100 ml TBE buffer 
0.5 pg/ml ethidium bromide
6 M urea
10.4% acrylamide/bisacrylamide [19:1] 
0.05% APS 
0.07% TEMED 
in 1x TBE buffer
74% diluent
16% acrylamide gel concentrate 
10% buffer 
0.08% APS 
0.04% TEMED
12%SDS-PAGE 12% acrylamide mix
resolving gel 375 mM Tris-HCI, pH 8.8
0.1% SDS
0.1% ammonium persulphate (APS)
0.04% TEMED
SDS-PAGE stacking gel 4.95% acrylamide mix
125 mM Tris-HCI, pH 6.8 
0.1% SDS 
0.1% APS 
0.1% TEMED
2.1.4. Oligonucleotide primers
All primers were designed using the Primer 3 programme on the 
Massachusetts Institute of Technology website (http://www- 
qenome.wi.mit.edu/cqi-bin/primer/primer3 www.cgi) and synthesised by MWG, 
unless otherwise stated. All primer sequences and the corresponding PCR 
conditions used are listed in Appendix A. PCR reactions were carried out using 
either a touchdown protocol (see section 2.2.1.1.) or at the annealing 
temperature indicated, with 1.5 mM MgCh, unless otherwise stated.
2.1.5. Patient cohorts
Two cohorts of patients were screened for mutations in USH1C.
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2.1.5.1. Usher syndrome type 1 patients
To ascertain whether mutations in USH1C make a large contribution to the 
incidence of Usher syndrome type 1 in the UK, fourteen British individuals of 
mixed ethnic origins, diagnosed with Usher syndrome type 1, were obtained 
from Prof. Shomi Bhattacharya at the Institute of Opthalmology in London.
2.1.5.2. Sib pairs with non-syndromic deafness
The locus for Usher syndrome type 1C overlaps with the locus for autosomal 
recessive deafness DFNB18 (Jain, et al., 1998) and it was hypothesized that 
these two forms of deafness could be allelic.
As part of a larger study funded by the National Lottery Charities Board, sib 
pairs with non-syndromic recessive deafness, referred by audiologists and 
geneticists, were collected throughout the UK by Bob Mueller, Tim Hutchin and 
colleagues at the University of Leeds. Haplotype analysis of microsatellite 
markers flanking all of the known DFNB loci, was performed on a total of 133 
Caucasian sib pairs and fifty-five sib pairs of Pakistani and Middle Eastern 
origin (Navarro-Coy, et al., 2001). The sib pairs had previously been screened 
for mutations in GJB2. Mutations were found in 32% and these were removed 
from further analysis.
From the original cohort of 133, sixteen Caucasian sib pairs and two small 
consanguineous families showed concordance for polymorphic markers 
flanking the DFNB18 locus and were donated to us for screening the USH1C 
gene.
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2.1.6. Control DNA
A number of phenotypically normal DNA samples from different ethnic groups 
were made available to us.
A panel of ninety-six pan-ethnic DNA samples, that had been selected at 
random and anonymized, were obtained from the Diagnostic Clinical Genetics 
Unit at the Institute of Child Health.
Dr. Tim Hutchin and Prof. Bob Mueller at the University of Leeds donated a 
panel of eighty anonymous Pakistani DNA samples to use as ethnically 
matched control samples for screening for novel changes found in the USH1C 
gene and for analysis of intragenic USH1C SNPs.
Dr. Mary Petrou in the Department of Haematology at UCL donated a panel of 
fifty anonymous Greek Cypriot DNA samples to use for analysis of intragenic 
USH1C SNPs.
2.1.7. Human foetal tissues
Human foetal tissues, ranging from fifty-four days to thirteen weeks of 
development, were obtained from the MRC Human Embryo Resource at the 
Institute of Child Health. This was approved by the local Ethical committee.
2.1.8. Mice
Cochleae were extracted from CD1 mice ranging in age from two days to 
twelve days post-natal.
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2.1.9. Plasmid vectors and constructs
The pZErO™-2 vector (see Appendix B) was used for cloning PCR products for 
sequencing and for in w'fro-translation of cDNA sequences. The pGEX-4T-1 
vector (see Appendix B) was used for the production of GST-fusion proteins for 
analysis in GST pull-down assays.
Dr Matthew Scanlan (Scanlan, et al., 1999), at the Ludwig Institute for Cancer 
Research in New York, donated a full-length copy of USH1C isoform a1 cDNA 
cloned in the pBK-CMV vector.
The IMAGE clone 0363071 comprises the pT7T3D vector with an insert of 
human cDNA sequence from the 3’ end of the MCC2 gene. A fragment of 3’ 
MCC2 sequence was subcloned into the pGEX-4T-1 vector for expression of a 
GST-MCC2 fusion protein for use as a positive control in GST pull-down 
assays.
2.1.10. Competent E. co//cells
One Shot® TOP10 competent cells were used for general propagation and 
maintenance of plasmids and clones.
BL21 competent E. coli cells were used for the expression of GST-fusion 
proteins. These cells are deficient in the Lon and OmpT proteases and hence, 
provide high protein expression levels.
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2.1.11. Human epithelial cell lines
The human gut cell lines Caco-2 and HT29 were used to study the expression 
of alternative USH1C isoforms and for USH1C localization studies.
Caco-2 cells are human colon adenocarcinoma cells established from the 
primary colon tumor of a 72-year-old Caucasian man in 1974.
HT29 cells are human colon adenocarcinoma cells established from the 
primary tumor of a 44-year-old Caucasian woman with colon adenocarcinoma 
in 1964.
HEK293 cells are human embryonal kidney cells established from a human 
primary embryonal kidney transformed by adenovirus type 5.
2.1.12. Antibodies
Dr Ichiro Kobayashi at the Hokkaido University School of Medicine in Japan 
donated a polyclonal rabbit anti-harmonin antibody (Kobayashi, et al., 1999) 
and Dr Matthew Scanlan at the Ludwig Institute for Cancer Research in New 
York donated a monoclonal mouse anti-harmonin antibody (Scanlan, et al., 
1999). Both antibodies were raised to the major harmonin isoform a1, which 
lacks the alternative exons A-F and exon G/G’. However, no epitope mapping 
has been carried out with either antibody, so it is not known which parts of the 
protein they are able to recognise.
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2.2. Methods
2.2.1. Polymerase chain reaction (PCR)
The polymerase chain reaction (PCR) mix consisted of 25-250 ng DNA, 
25 pmol of each primer, 1x reaction buffer, containing Tris CI, KCI, (NH4)2S 0 4 
and 1.5 mM MgCI2; pH 8.7, 200 dGTP, dCTP, dTTP, dATP and 
1 unit HotStarTaq™ polymerase in a typical reaction volume of 25 jal. Reactions 
were either carried out in 96-well plates sealed with PCR film, or in 0.5 ml tubes 
using an Eppendorf Mastercycler thermal cycler with a hot-lid at 105°C and 
applying a pressure of 150 N.
Conditions for thermal cycling started with an initial denaturing step of 15 min. 
at 96°C to activate the HotStarTaq™ DNA polymerase, followed by 35 cycles of 
96°C for 30 s, 15 s at an appropriate annealing temperature (Appendix A), 
72°C for 30 s and a final extension step of 10 min. at 72°C.
2.2.1.1. Touchdown PCR
To amplify all fragments at the same time and obtain clean, specific products 
(important for hetero-duplex analysis, see section 2.2.3.), a touchdown cycling 
method was employed. The first annealing temperature was 70°C and this was 
decreased by 1°C each cycle for the first fifteen cycles, then the annealing 
temperature was held at 55°C for the remaining twenty cycles.
2.2.12. Amplification of large DNA fragments
Amplification of 26.5 kb of genomic DNA, for analysis of two novel missense 
coding variants, was achieved using the Expand™ Long Template PCR
84
System. Two separate master mixes were prepared on ice. Master mix 1 
contained 2.5 pi of each dNTP at a concentration of 10 mM (500 pM final 
concentration), 300 nM of each primer, up to 500 ng of genomic DNA and 
sterile dhhO to a total volume of 25 pi. Master mix 2 contained 5 pi 10x buffer 3, 
with 22.5 mM MgC^ and detergents, between 0.5 pi and 1 pi of the supplied 
enzyme mix (the thermostable Taq DNA polymerase and the proofreading Pwo 
DNA polymerase) and sterile dh^O to a final volume of 25 pi. A 25 pi aliquot of 
master mix 1 was pipetted into 25 pi of master mix 2 in a 0.2 ml thin-walled 
tube on ice and mixed well by vortexing. The reaction mixture was overlayed 
with 30 pi mineral oil and cycling on the Eppendorf Mastercycler thermal cycler 
was started immediately.
The DNA was first denatured at 92°C for 2 min., followed by ten cycles of 92°C 
for 10 s, an annealing temperature of 65°C for 30 s and 68°C for 19 min. This 
cycling was repeated for a further twenty rounds with the elongation step 
extended by 20 s each cycle for greater yield.
Products were visualized on a 0.5% agarose gel (see section 2.1.3.). A 10 pi 
volume of PCR product was diluted with 10 pi loading buffer and 
electrophoresed at ~30 V for 1-2 h. Products were sized by comparison to 
Hind III DNA fragments.
2.2.1.3. Allele-specific PCR
Allele-specific PCR was used to determine if two coding variants in USH1C 
occurred on the same allele or different alleles. Two forward oligonucleotide
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and two reverse oligonucleotide primers were designed (Appendix A, Table 
A.4), with the forward primers complimentary to the nucleotide changes found 
at one variant and the reverse primers complimentary to the nucleotides found 
at the other variant. The pairs of primers differed only in their 3’ nucleotide 
depending on whether they were specific for the wild type or the variant 
sequence. The primers were designed to have melting temperatures (Tm) as 
close to each other as possible by adjusting the primer length. Allele-specific 
oligonucleotides (ASO) were used in all possible combinations (four reactions) 
to perform nested PCRs on the original 26.5 kb PCR product, as described in 
section 2.2.1.2. At an annealing temperature of 59°C, the oligonucleotides with 
3’ ends complimentary to the template amplified, while those with the mismatch 
3’ ends did not.
2.2.1.4. Nested PCR
Nested PCRs were carried out with oligonucleotides, designed using the Primer 
3 programme (Appendix D) and situated 10-20 base pairs inside the 
oligonucleotides used in the primary PCR (Appendix A). The secondary PCR 
was cycled in the same way as the primary PCR, using either 1 pi of the 
primary PCR product or 1 pi of a 1 in 10 dilution of the primary product, and an 
annealing temperature adjusted for the melting temperature (Tm) of the new 
oligonucleotides.
All PCR products were diluted with an equal volume of loading buffer, 
separated by 2% agarose gel electrophoresis (~120 V, for ~45 min. in 
1x TBE buffer), stained with ethidium bromide and visualised under UV. The 
gel image was captured on a Bio-Rad Gel Doc™ 2000 imaging system, using
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Quantity One 4.4.0 software. Products were sized by comparison to 100 bp 
ladder.
2.2.2. RT-PCR analysis
2.2.2.1. Isolation of RNA from cell lines, urine and foetal tissues 
RNA was extracted from human foetal tissues, human cell lines and ceil pellets, 
obtained from urine samples, using TRIZOL. Tissue samples were 
homogenized in 1 ml TRIZOL reagent per 50-100 mg tissue using plastic 
homogenizers that fit 1.5 ml tubes. Adherent cells were removed directly from 
the flask bottom by the addition of 1-2 ml TRIZOL and gently mixed by 
repeated aspirations with the pipette. Homogenized samples were incubated at 
room temperature for 5 min. to permit complete dissociation of nucleoprotein 
complexes. Chloroform was added at a ratio of 0.2 ml per 1 ml TRIZOL 
reagent, the tubes sealed, shaken vigorously by hand for 15 s and incubated at 
room temperature for 2-3 min. Next, samples were centrifuged at 12,000 g for 
15 min. at 4°C.
Following centrifugation, the colourless upper aqueous phase containing the 
RNA was transferred to a fresh 1.5 ml tube, the lower red, organic phase was 
saved for DNA isolation. RNA was precipitated from the aqueous phase by 
mixing with 0.5 ml isopropyl alcohol per 1 ml TRIZOL reagent used initially. 
Samples were incubated at room temperature for 10 min. and centrifuged at
12,000 g for 10 min. at 4°C. The supernatant was removed and the RNA pellet 
washed once with 75% ethanol, adding at least 1 ml ethanol per 1 ml TRIZOL 
reagent. The sample was mixed by vortexing and centrifuged at 7,500 g for 
5 min. at 4°C. The RNA pellet was briefly air-dried and re-suspended in
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RNase-free water (DEPC-treated) by repeated aspirations and incubating for
10 min. at 55°C. RNA was stored at -80°C until required.
2.2.2.2. First-strand synthesis (RT-PCR)
Reverse transcription (RT) was carried out using Superscript™ II Reverse 
Transcriptase with both oligo dT and random nonamer primers.
The RNA was first treated with DNase to ensure no genomic DNA 
contamination, 12 pi RNA was mixed with 2 pi DNAse I enzyme, 2 pi 10x 
buffer, made up to 20 pi with RNase-free water and incubated at room 
temperature for 15 min. The DNase I was de-activated by adding 5 pi 25 mM 
EDTA, pH 8 and incubating at 65°C for 10 min. Next, 1 pi oligo dT primer and 
1 pi random nonamer primer were added to the Dnase treated RNA and 
incubated at 70°C for 10 min. The mixture was then quick-chilled on ice and the 
remaining components of the RT-PCR were added: 9 pi 5x first strand buffer, 
4.5 pi 0.1 M DTT, 2 pi 10 mM dNTPs and 2.5 pi RNAse inhibitor. The mixture 
was centrifuged and heated to 42°C for 2 min. before adding 1 pi Superscript™
11 Reverse Transcriptase enzyme and incubating for a further 50 min. at 42°C. 
The enzyme was heat-inactivated at 70°C for 15 min.
The quality of the cDNA and the presence of any contaminating genomic DNA 
were checked by amplification of the house-keeping gene HPRT using 1 pi of 
each sample and oligonucleotide primers located in exons 7 and 9 of the HPRT 
gene.
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Primers around the alternatively spliced exons in the USH1C cDNA were 
designed for gene-specific amplification in a variety of human foetal tissues, 
cell lines and urine (Apendix A, Table A.3).
2.2.2.3. 5 ’ Rapid amplification of cDNA ends (5’ RACE)
Rapid amplification of cDNA ends (RACE) was performed on USH1C to identify 
isoforms with novel 5’ ends.
A 14.5 pi aliquot of RNA isolated from the human foetal tissue of interest 
(section 2.2.2.1.) was combined with 2.5 pmoles of gene-specific primer, GSP1 
(Appendix A, Table A.2), in a 0.5 ml tube and incubated at 70°C for 10 min. The 
tube was transferred immediately to ice and 8.5 pi 5’ RACE PCR buffer (section
2.1.1.) was added to give a final reaction volume of 24 pi. As for RT-PCR, the 
reaction was incubated at 42°C for 1 min. before 1 pi Superscript™ II Reverse 
Transcriptase was added and the reaction incubated for a further 50 min. at 
42°C. The reaction was terminated by a 15 min. incubation at 70°C and any 
remaining RNA was removed by incubating with 1 pi RNase mix at 37°C for 30 
min. The cDNA product was purified using QIAquick PCR purification columns 
(section 2.2.4.1.).
A homopolymeric tail was added to the 3’-end of the purified cDNA using 
dCTP. Ten microlitres of purified cDNA was mixed with 6.5 pi dhfeO, 5 pi 5X 
tailing buffer and 2.5 pi 2 mM dCTP in a 0.5 ml tube and incubated at 94°C for 
3 min. The tube was chilled on ice for 1 min., then 1 pi TdT enzyme was added 
and the reaction incubated at 37°C for 10 min. TdT was heat-inactivated at
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65°C for 10 min. and the tube placed on ice. The tailed cDNA was amplified 
using an abridged anchor primer, that anneals to the cytosine tail, and a nested 
gene-specific primer, GSP2 (Appendix A, Table A.2), with extension steps of 2 
min., to amplify cDNA >1 kb. To generate enough product to detect by ethidium 
bromide staining, the PCR product was diluted 1 in 100 and re-amplified using 
the abridged universal amplification primer and a second, nested, gene-specific 
primer, GSP3 (Appendix A, Table A.2). The final amplified sample was 
analysed using agarose gel electrophoresis, ethidium bromide staining and the 
appropriate molecular size standard.
2.2.3. Hetero-duplex analysis by denaturing high performance liquid 
chromatography (DHPLC).
DHPLC is a system for the automated detection of single base-pair 
substitutions and small insertions or deletions. It relies on the fact that under 
partial denaturing conditions, hetero-duplexes (fragments of double stranded 
DNA containing a mismatch) are less stable than their corresponding 
homoduplex and will be eluted earlier from a column containing a DNA 
separation matrix. A double-stranded DNA molecule is retained on the matrix 
via electrostatic interactions between the positive surface potential generated 
by triethylammonium (TEAA) ions absorbed at the stationary phase and the 
negative surface potential generated by the phosphodiester groups of the 
sugar-phosphate backbone of DNA. The DNA separation matrix is held at a 
temperature specific to the fragment being analysed, such that the DNA is 75% 
double-stranded (ds). The interaction between the TEAA ions and the DNA 
fragment is weakened by the addition of a hydrophilic counter-ion (acetonitrile)
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in a gradient of increasing concentration until the DNA is eluted from the 
column.
2.2.3.1. Preparation of DNA fragments for DHPLC analysis
All twenty-eight exons of USH1C were amplified using the primers listed in 
Appendix A, Table A.1, and touchdown PCR with HotStar Taq Polymerase, as 
described in section 2.2.1.1. Reactions were carried out on Eppendorf 
Mastercycler thermal cyclers, in 25pl volumes in 96-well plates sealed with 
PCR film and a hot-lid applying a pressure of 150 N. Equal volumes of patient 
and wild type PCR products were then combined and hetero-duplexes were 
forced to form (necessary for identification of homozygous changes) by heating 
to 95°C for 5 min. and allowing the mixture to cool slowly, in 5°C increments for 
2 min. at each temperature, until 25°C. Samples were injected onto the column 
of the Transgenomic™ WAVE DNA analysis system, in both ‘spiked’ (i.e. 
forced hetero-duplexes) and ‘unspiked’ (i.e. wild type patient DNA) forms, and 
analysed according to the manufacturers’ instructions, using optimum 
conditions pre-determined for each exon of the USH1C gene (Table 2.1).
2.2.3.2. Optimisation of DHPLC running conditions
WaveMaker™ software supplied by Transgenomic™ was used to estimate the 
column temperature and acetonitrile buffer gradient required to observe the 
separation of homo- and hetero-duplexes for a given fragment. WaveMaker™ 
uses the DNA sequence of the fragment of interest to predict an appropriate 
acetonitrile buffer gradient to use. A wild type DNA fragment was then used for 
seven or eight 12-minute runs at a range of appropriate temperatures. A 
melting-curve was then constructed, by plotting the time at which the DNA was
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eluted from the column against the temperature of the column for that run. The 
time at which 75% double-stranded DNA would be eluted is calculated as 
follows:
Time at 100%ds - time at 0%ds x 75 + time at 0%ds (1)
100
Hence, the temperature at which the DNA is 75% double-stranded was read 
from the melting-curve. This temperature was used with the specified 
acetonitrile buffer gradient for 7-minute mutation detection runs of that 
particular DNA fragment (Table 2.1) on the WAVE DNA analysis system. A wild 
type of each DNA fragment was then run to confirm that the fragment is eluted 
at approximately 3-4 min. during the mutation detection run, such that hetero­
duplexes may be easily identified.
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Table 2.1. Conditions used for performing DHPLC analysis on USH1C
exons
Exon
Column
Temp.
(°C)
0.0
min.
(%A)
0.1
min.
(%A)
4.1
min.
(%A)
4.2
min.
(%A)
4.7
min.
(%A)
4.8
min.
(%A)
6.8
min.
(%A)
1 66 45 40 32 0 0 45 45
2 61 46 41 33 0 0 46 46
3 66 49 44 36 0 0 49 49
4 65 45 40 32 0 0 45 45
5 63 54 49 41 0 0 54 54
6 65 52 47 39 0 0 52 52
7 62 51 46 38 0 0 51 51
8 64 46 41 33 0 0 46 46
9 63 45 40 32 0 0 45 45
10 62 49 44 36 0 0 49 49
11 65 53 48 40 0 0 53 53
12 65 45 40 32 0 0 45 45
13 60 45 40 32 0 0 45 45
14 61 52 47 39 0 0 52 52
15 63 49 44 36 0 0 49 49
A 60 45 40 32 0 0 45 45
B 59 44 39 31 0 0 44 44
C 60 45 40 32 0 0 45 45
D 63 41 36 28 0 0 41 41
E 62 44 39 31 0 0 44 44
F 61 46 41 33 0 0 46 46
16 61 48 43 35 0 0 48 48
17 63 50 45 37 0 0 50 50
18 63 51 46 38 0 0 51 51
19 63 45 40 32 0 0 45 45
20 63 54 49 41 0 0 54 54
G/G’ 62 47 42 34 0 0 47 47
21 62 49 44 36 0 0 49 49
The column temperature corresponds to the temperature that the column was held at 
for the entire run, while the times correspond to the different steps in the hetero-duplex 
analysis run and the percentage of the buffer A that was in the buffer A and buffer B 
mix being run over the column at that stage. 0.0 min. is the loading step, 0.1 min. is 
the start of the acetonitrile gradient, 4.1 min. is the end of the acetonitrile gradient, 4.2 
min. is the start of the column clean, 4.7 min. is the end of the column clean, 4.8 mins 
is the start of the column equilibration and 6.8 min. is the end of the column 
equilibration. Buffer A is 5% TEAA and Buffer B is 5% TEAA and 25% Acetonitrile.
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2.2.4. Automated DNA sequencing
2.2.4.1. Purification of PCR products
PCR products were purified using a QIAquick PCR purification kit and a 
Haraeus Biofuge. PCR products were mixed with 5 volumes buffer PB and the 
whole sample was applied to a QIAquick spin column. Spin columns were 
placed in 2-ml collection tubes and centrifuged for 60 s at 10,000 g to bind the 
DNA to the column. The flow-through was discarded, the column washed with 
0.75 ml buffer PE and centrifuged again for 60 s at 10,000 g. The flow-through 
was again discarded and the column centrifuged for an additional 60 s at
10,000 g to remove residual ethanol from the PE buffer. The spin column was 
placed in a clean 1.5 ml tube and 15 pi EB buffer (10 mM Tris-CI, pH8.5) was 
applied to the centre of the membrane. After standing for 60 s, DNA was eluted 
from the column by centrifuging at 10,000 g for 60 s.
2.2.4.2. Cycle sequencing
Direct sequencing was performed on both strands of the DNA template using 
ABI Prism BigDye Terminator cycle sequencing ready reaction kits. The 
reaction consisted of 10-20 ng purified PCR product, 3.2 pmol primer, 4 pi 
BigDye Terminator ready reaction mix, made up to a total volume of 10 pi with 
sterile milliQ water. Cycle sequencing was performed on an Eppendorf 
Mastercycler thermal cycler using a hot-lid. The cycling programme was 25 
cycles of 96°C for 30 s, 50°C for 15 s and 60°C for 4 min.
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2.2A .3. Ethanol precipitation of sequenced products
To precipitate products of sequencing reactions, 10 pi sterile milliQ water 50 pi 
95% ethanol and 2 pi 3M sodium acetate were added to a 10 pi sequencing 
reaction. Samples were mixed and incubated at room temperature for 30 min. 
Samples were then centrifuged at 10,000 g for 20 min., the supernatant 
removed and the DNA pellet washed with 250 pi 70% ethanol. Samples were 
centrifuged again at 10,000 g for 5 min., supernatant removed and the pellet 
allowed to air-dry.
2.2.4.4. Polyacrylamide gel electrophoresis of sequencing products 
Direct automated sequencing analysis was performed on an ABI 377 DNA 
sequencer. The gel mix was prepared according to section 2.1.3. Gels were 
poured between two clean 36-cm Perkin Elmer plates clamped into a cassette 
and separated by 0.2-mm spacers. Gels were allowed to set for a minimum of 
2 h.
Prior to loading, pelleted sequencing products (see section 2.2.4.3.) were re­
suspended in 4 pi loading dye (5:1; formamide:blue dextran), denatured at 
96°C for 2 min. and immediately placed on ice. A 2-pl volume of each sample 
was electrophoresed for 7 h at 50°C and 1.2 kV in 1x TBE buffer, using the 
following parameters: mobility file - DT BDset-Any; Run module - Seq run 36E- 
1200 and the appropriate gel matrix file. Sequencing runs were analysed using 
Sequence Analysis and Sequence Navigator software.
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2.2.5. Genotyping
2.2.5.1. Microsatellite markers flanking major USH1 loci
Microsatellite markers flanking the major Usher type 1 loci, USH1B, USH1C, 
USH1D and USH1F, were identified using the ensembl genome browser 
(http://www.ensembl.org/) and amplified, using fluorescently labelled 
oligonucleotides (Appendix A, Table A.7.), in 25-pl reaction volumes as 
described in section 2.2.1.
2.2.5.2. Polyacrylamide gel electrophoresis of PCR products for genotyping 
Polyacrylamide gel electrophoresis of amplified microsatellite markers was 
carried out on the ABI 377. Gels were made according to section 2.1.3 and 
poured between clean gel plates clamped in a cassette with 0.2-pm spacers 
and left to set for 1 h prior to running.
Markers were pooled, with FAM and TET labelled PCR products diluted 
between 1 in 10 and 1 in 20 and with HEX-labelled products always present at 
double the concentration of the other two. A 2-pl volume of each DNA pool was 
added to 2 pi of size standard (ABI GS500 Tamra). Samples were denatured at 
96°C for 3 min. and placed on ice prior to loading all 4 pi of each sample. The 
gel was electrophoresed for 2 h and the data was collected and analysed using 
Genescan version 2.0 and Genotyper software.
2.2.6. Haplotype analysis
To determine what genetic background the recurrent 238-239insC mutation is 
found on, intragenic USH1C SNPs were analysed
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2.2.6.1. Restriction endonuclease digest tests
Nine intragenic SNPs across the USH1C gene were genotyped using 
restriction enzyme digests tests The appropriate exon fragment was amplified, 
as described in section 2.2.1., and the PCR product digested with the relevant 
restriction enzyme (Table 2.2.). One microlitre of the appropriate restriction 
enzyme buffer (at 10x concentration), 10-20 units of restriction enzyme and 1 pi 
10x BSA, if required, were added to the PCR product to give a total volume of 
10 pi. Digests were incubated at the appropriate temperature for a minimum of 
1 h (at 65°C) or overnight (at 37°C).
Digests were run out on either a 2.5% agarose or a 3% agarose/1 % nusieve 
gel, depending on the degree of separation required, and the products were 
visualised under a UV light with ethidium bromide.
Table 2.2. Restriction digests used for genotyping USH1C intragenic
SNPs
Polymorphism
Restriction
Enzyme
used*
Products if 
wild type (bp)
Products if 
variant (bp)
PCR
Primers
IVS1-45C>G -Mwol 122+42+172 122+214 Exon 2
IVS2-16C>T -Neil 110+147+120 257+120 Exon 3
381G>T +Bsal 345 248+97 Exon 4
IVS7+61G>A -Sau96l 118+56+27 118+83 Exon 7
IVS7-27G>A +Nlalll 84+148+104 84+13+135+104 Exon 8
IVS13+21C>G +BsaJI 73+190+103 73+190+8+95 Exon 13
1188A>G -Bsrl 15+71+59+131 15+71+190 Exon 14
1557G>C +Hgal 347 179+168 Exon 19
1737T>C -Mbol 123+178+9+139 301+9+139 Exon 21
* Plus (+) or minus (-) sign indicates whether enzyme site is gained or lost, 
respectively, in the variant.
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2.2.7. Cloning
USH1C cDNA was sub-cloned into the pZErO™-2 vector from the Zero 
Background/Kan cloning kit to allow in v/Yro-translation of harmonin from the 
Sp6 promoter. The 3’ ends of PCDH15 and MCC2 cDNA were cloned into the 
GST vector pGEX-4T-1 for the expression of GST-fusion proteins in E. coli. 
See Table 2.3 for details of the cloning procedure used in each case.
Table 2.3. Summary of cloning approaches used
Insert for 
cloning
Vector
Cloning
method
Method used to obtain 
insert
Linearizing
vector
Full length 
USH1CcDNA
LLLlNQ. Blunt-
ended
Digested from pBK-CMV 
vector using Spel and 
Xbal
Ecl136II 
Digest
3’ end of 
M CC2cDNA
pGEX-
4T-1
Blunt-
ended
Digested from IMAGE 
clone 0363071 using 
Notl and Sacl
Smal
Digest
3’ end of 
PCDH15cDNA
pGEX-
4T-1
Blunt-
ended
Amplified from human 
foetal kidney cDNA
Smal
Digest
2.2.7.1. Preparation of blunt-ended linear plasmid vectors 
Circular DNA vectors were linearized using blunt cutting restriction digest 
enzymes, i.e. Ecl136II for pZErO™-2 and Smal for pGEX-4T-1. Restriction 
enzyme digests were performed as described in section 2.2.6.1. using 
200-500 ng plasmid DNA in a total reaction volume of 10 pi. To prevent them 
self-ligating, linearized vectors were treated with calf intestinal alkaline 
phosphatase (CIP), to remove the free 5’ phosphate groups. Ten units of CIP 
enzyme were added to the digested vector and the total volume made up to 
20 pi, using the appropriate buffer and dH20. The reaction was incubated at 
37°C for 60 min., and the digested vector DNA purified by 
phenol/chloroform/isoamyl alcohol extraction (section 2.2.7.2.).
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2.2.7.2. Phenol/chloroform/isoamyl alcohol extraction of DNA
To remove enzymes, DNA was purified by adding an equal volume of 
phenol:chloroform:isoamyl alcohol mix, in the ratio 25:24:1, and vortexing. The 
mixture was then centrifuged at 10,000 g for 5 min. after which the top aqueous 
layer was removed to a fresh tube. The DNA was ethanol precipitated from the 
aqueous layer as described in section 2.2.4.3. by adding a one-tenth volume of 
3 M sodium acetate and two and a half volumes of cold 100% ethanol and 
incubating at -80°C for 1 h. The DNA pellet was re-suspended in an appropriate 
volume of TE buffer.
2.2.7.3. Preparation of blunt-endedDNA inserts
Full-length USH1C cDNA was obtained by digesting it out of the pBKCMV 
vector using Spel and Xbal restriction digest enzymes. A fragment 
corresponding to the 3’ end of MCC2 cDNA was digested from IMAGE clone 
0363071, using enzymes Notl and Sacl (Table 2.3.). Double digests were 
performed as described in section 2.2.6.1., except the total reaction volume 
was increased to 20 pi, so the amount of glycerol present from the two 
enzymes did not inhibit the reaction. After digestion, the DNA product was 
obtained by gel purification (see section 2.2.7.4.).
A fragment corresponding to the 3’ end of PCDH15 cDNA was obtained by 
amplifying from human foetal kidney cDNA using gene-specific primers 
(Appendix A, Table A.5).
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DNA inserts were blunt-ended using DNA polymerase I, the large (Klenow) 
fragment which has 3 -5 ’ exonuclease activity and 5 -3 ’ polymerase activity. To 
allow the exonuclease activity of the enzyme to remove 3’ extensions, 5 units of 
Klenow DNA polymerase I, in the appropriate buffer, was added to the DNA 
fragment and incubated at 37°C for 5 min. Then, to fill in 5’ extensions, 2 pi of a 
2 mM dNTP mix was added and incubated at room temperature for 20 min. The 
enzyme was heat-inactivated by incubating at 75°C for 20 min.
2.2.1 A. Gel purification of DNA fragments
DNA fragments were gel purified using a QIAquick gel extraction kit and a 
Haraeus Biofuge. The DNA fragment was excised from an agarose gel using a 
clean, sharp scalpel. The gel slice was weighed and three volumes of buffer 
QG were added to one volume of gel (i.e. 100 mg = 100 pi) and incubated at 
50°C for 10 min. or until the gel slice had completely dissolved. Then, one gel 
volume of isopropanol was added to the sample and mixed. The sample was 
applied to a QIAquick column in a 2-ml collection tube and centrifuged for 1 
min. at 10,000 g to bind the DNA to the column. The flow-through was 
discarded and 0.5 ml buffer QG was added to the QIAquick column and 
washed through by centrifuging for 1 min. at 10,000 g. To wash the DNA,
0.75 ml buffer PE was added to the QIAquick column and centrifuged again for 
1 min at 10,000 g. The flow-through was discarded and the QIAquick column 
was centrifuged for an additional 1 min. at 10,000 g to remove residual PE 
buffer. The QIAquick column was then placed in a clean 1.5-ml tube, 30 pi 
buffer EB (10 mM Tris CI, pH 8.5) was added to the centre of the QIAquick 
membrane and the column was left to stand for 1 min. before centrifuging at
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10,000 gfor 1 min. to elute the DNA.
2.2.7.5. Blunt-end ligation reactions
The insert DNA fragment and the linearized vector, were electrophoresed on a 
2% agarose gel with a low mass DNA ladder to estimate the concentration of 
both. For blunt-end ligation reactions the molar ratio of insertvector needs to 
be 10:1.
i.e. 10 x size of insert(bp) x no of linear vector = ng of insert (2)
size of vector (bp)
Ligations reactions consisted of 10-15 ng linearized vector, enough blunt- 
ended insert so that the molar ratio of insertvector was 10:1 (see equation 2), 
1 (j.l 10x ligation buffer and 1 |il concentrated T4 DNA ligase made up to a final 
volume of 10 plI with sterile dHaO. Ligation reactions were incubated at 25°C for
1 h or 16°C overnight and then the reactions were placed at -20°C until ready 
to be used in transformations. In addition, a negative control reaction containing 
10 ng vector only, in the absence of insert DNA, was set up for determination of 
the background number of non-recombinants.
2.2.7.6. Transformation of competent E. coli
For each ligation reaction a 50- t^l aliquot of One Shot® TOP10 competent 
E. coli cells was thawed on ice. Four microlitres of ligation product (see section
2.2.7.5.) were added directly to the competent cells on ice and mixed gently. 
Transformations were left on ice for 20 min. and the cells were then heat- 
shocked by incubating at 42°C for 45 s and returned immediately to ice for
2 min. A 250-jlx I volume of pre-warmed SOC medium was added and the cells
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were incubated at 37°C for 1 h with shaking. A 200-jil aliquot of each 
transformation was then spread on separate LB-agar plates containing 
30 pg/ml kanamycin (pZErO-2) or 50 pg/ml ampicillin (pGEX-4T-1), depending 
on the antibiotic resistance gene carried by the vector. Plates were inverted 
and incubated at 37°C overnight.
2.2.7.7. Identification of clones containing insert
Approximately twenty colonies were picked from the LB-agar plate using an 
inoculating loop and dipped first into a PCR mix containing the appropriate 
vector primers (Appendix A, Table A.6.1.) and then into 5 ml LB broth, 
containing the appropriate antibiotic. The 5 ml culture was incubated at 37°C, 
with shaking at 225 rpm, overnight. The PCR was cycled using touchdown, as 
described in section 2.2.1.1., and the products analysed on agarose gel, as 
described in section 2.2.1.5. Only the plasmid DNA from the 5 ml overnight 
cultures, whose corresponding PCR product indicated the presence of an insert 
of the expected size, were prepared using the Qiagen miniprep kit, as 
described in section 2.2.7.8. The orientation of inserts was confirmed by 
sequencing using vector primers (Appendix A, Table A.6.1.). The sequence of 
the inserts in the clones used in subsequent experiments were confirmed using 
additional insert primers where required (Appendix A, Table A.6.2.).
2.2.7.8. Preparation of plasmid DNA
Plasmid DNA was extracted from E. coli cells using the Qiagen miniprep kit.
A single bacterial colony grown on LB plates, with the appropriate antibiotic, 
was used to inoculate 5 ml LB medium containing the appropriate antibiotic at 
the correct final concentration (kanamycin, 30 pg/ml; ampicillin, 50 pg/ml).
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Cultures were incubated at 37°C, with shaking, overnight. The following day, 
glycerol stocks were prepared by adding 600-pl culture to 400 pi 30% glycerol 
and stored at -80°C.
The plasmid DNA from the remainder of the 5-ml culture was extracted using 
QIAprep miniprep kit and a Haraeus Biofuge. E. coli cells from the 5-ml 
overnight culture were pelleted by centrifugation at 10,000 g for 1 min. The 
pelleted cells were then re-suspended in 250 pi buffer P1 by vortexing. A 
250-pl volume of buffer P2 was added and the tube inverted gently 4-6 times to 
mix until the solution became viscous and slightly clear. Next, 350 pi buffer N3 
was added and the tube inverted, another 4-6 times. The sample was 
centrifuged at 10,000 g for 10 min., and the supernatant was placed in a 
QIAprep spin column, which in turn was placed in a 2-ml collection tube. The 
QIAprep spin column was centrifuged at 10,000 g for 60 s and the flow-through 
discarded. The column was washed to remove trace nuclease activity by 
adding 0.5 ml buffer PB and centrifuging at 10,000 g for 60 s The flow-through 
was discarded and the column was washed again by adding 0.75 ml buffer PE 
and centrifuging at 10,000 g for 60 s The flow-through was discarded and the 
column centrifuged for an additional 1 min. at 10,000 g to remove residual 
wash buffer. The QIAprep column was then placed in a clean 1.5-ml tube and 
50 pi buffer EB (10 mM Tris-CI, pH 8.5) was added to the centre of the 
membrane, left to stand for 1 min. and centrifuged at 10,000 g for 1 min. to 
elute the DNA.
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2.2.8. Immunohistochemistry
For localization of harmonin expression within the mouse cochlea, frozen 
mouse cochleae sections were prepared and stained with fluorescently labelled 
antibodies.
2.2.8.1. Dissecting mice cochleae
Mice were terminated by cervical dislocation; the heads were then removed 
and dissected to access the inner ear. The cochlea was removed from the 
bulla, the bony structure encasing it. Then, using a hyperdermic needle, a small 
hole was pierced in the apex of the cochlea to aid the fixation process and the 
cochlea was placed in fixing solution as quickly as possible, usually within 
10 min. of culling.
2.2.8.2. Fixing cochleae
Cochleae were fixed in a solution of 4% paraformaldehyde in phosphate 
buffered saline (PBS) for 24 h at 4°C. To de-calcifiy the cochleae, they were 
washed once in PBS for 5 min. and placed in a 4.13% (11.1 mM) EDTA, pH 7.3 
solution at 4°C for 3-4 days. Finally, the cochleae were washed once more in 
PBS for 5 min. and left to equilibrate in 20% sucrose in PBS, a cryoprotection 
solution, at 4°C overnight prior to embedding.
2.2.8.3. Embedding cochleae
Cochleae were frozen in an Optimal Cutting Temperature compound (OCT) on 
dry ice. A 5-ml capacity plastic mould was half-filled with OCT and placed on 
dry-ice and allowed to start solidifying before a single cochlea was placed in the 
centre. The cochleae were orientated on their side with the apex of the cochlea
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directed towards the side of the mould such that, upon sectioning, slices would 
be cut through all turns of the cochlea at once. More OCT was then poured on 
top and allowed to freeze completely before the embedded cochleae were 
placed at -80°C for long-term storage.
2.2.8.4. Sectioning cochleae
Frozen cochleae were sectioned on the cryostat. The temperature of the 
cryostat chamber was set at approximately -22°C, while the specimen platform 
temperature was set around -1 8  to -20°C for optimal sectioning conditions. 
Cochleae embedded in OCT were removed from the moulds and fixed onto the 
sectioning platform using fresh OCT. Embedded cochleae were cut in ~10-pm 
thick sections and three sections were collected on each TESPA- (3- 
aminopropyltriethoxysilane) coated microscope slide (see section 2.2.8.5.).
2.2.8.5. TESPA coating microscope slides
Glass microscope slides were coated with TESPA to help the tissue sections 
adhere to them. The glass microscope slides were immersed for a minimum of 
30 s in a 10% Hydrochloric acid/70% ethanol solution, followed by DEPC- 
treated water and then 95% ethanol. Slides were then placed in an oven at 
65°C overnight to dry. The dried slides were immersed in a 2% TESPA-in- 
acetone solution for only 30 s then in 100% acetone twice and once in DEPC- 
treated water, before finally drying in an oven at 45°C overnight. Prepared 
slides were stored at room temperature until required.
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2.2.8.6. Staining cochleae sections
Slides containing cochlear sections for staining were removed from the -80°C  
freezer and defrosted at room temperature for 20 min. Excess OCT-embedding 
medium was carefully scraped from around the sections using a scapel and a 
PAP pen was used to draw a wax border around each section to isolate it from 
the others on the slide. Then, each section was blocked with 4% goat serum in 
PBS with 0.1% Tween 20 (PBS-T) at room temperature for 2 h. Sections were 
washed twice with PBS for 4 min. each and incubated overnight at 4°C with a 1 
in 50 dilution of rabbit polyclonal anti-harmonin antibody (Kobayashi, et a/., 
1999) in PBS, or, for controls, with either PBS alone or a 1 in 50 dilution of 
rabbit serum in PBS. The following day the sections were washed in PBS for 4 
min., incubated with a 1 in 100 dilution of an anti-rabbit-FITC conjugate for 4 h 
at room temperature and washed twice more with PBS for 4 min. each. For 
actin and cell nuclei localization, sections were incubated in a combination of a 
1 in 100 dilution of Phalloidin-Rhodamine conjugate and a 1 in 200 dilution of 
Hoechst in PBS for 20 min. at room temperature. Finally, sections were washed 
twice more with PBS for 4 min. each, left to air-dry and mounted with a cover 
slip using a Glycerol/PBS mounting solution.
2.2.8.7. Fluorescent microscopy
Stained cochleae sections were visualised using a 40x oil objective lense on a 
Zeiss Axiophot fluorescent microscope. Images were captured using Openlab
3.1.1 software.
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2.2.9. Immunocytochemistry
To study harmonin localization at the cellular level, cell lines expressing 
harmonin were cultured, fixed and stained with fluorescently labelled 
antibodies.
2.2.9.1. Tissue culture
Caco-2 cells were grown in DMEM with L-Glutamine, supplemented with 10% 
foetal calf serum (FCS) and 1% penicillin-streptomycin antibiotics at 37°C with 
5% CO2 and were split approximately 1 in 4 every 3-4 days. HT-29 cells were 
grown in RPMI medium supplemented with 2 mM L-Glutamate, 10% FCS and 
1% penicillin-streptomycin antibiotic mix at 37°C with 5% CO2 and were split 
approximately 1 in 6 every 2-3 days.
2.2.9.1.1. Splitting cells
Tryspin-EDTA solution, sterile PBS and fresh medium were pre-warmed to 
37°C. Old medium was removed from confluent cells in a 75-cm2/250-ml tissue- 
culture flask and ~5 ml sterile PBS was added to the flask to gently wash off 
excess medium from the cells. The PBS was removed and ~2 ml trypsin-EDTA 
was added to the flask and left to incubate with the cells at 37°C for ~5 min. or 
until the cells detached from the bottom of the flask. The action of the trypsin 
was blocked by the addition of ~10 ml fresh medium and cells were aspirated 
with a pipette a few times to separate any clumps. Approximately 2-3 ml of 
trypsinized cells were added to a new flask with ~10 ml of fresh medium and 
placed back in the incubator at 37°C.
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2.2.9.1.2. Freezing cells
Cells were trypsinized, as described in section 2.2.9.1.1. and the cells from one 
flask were transferred to a 15-ml tube and pelleted by centrifuging at 
~300-400 g for 5 min. The pellet was re-suspended in 2 ml fresh medium and 
repeatedly aspirated with a pipette to remove any clumps. Next, 2 ml medium, 
with 20% DMSO, was added to the re-suspended cells to give a final volume of 
4 ml with 10% DMSO. Cells were quickly aliquoted into 1-ml screw top vials 
and immediately placed at -80°C  in a chamber bathed in isopropanol to ensure 
slow freezing. After 24 h the vials of cells were placed in liquid nitrogen for 
long-term storage.
2.2.9.1.3. Thawing cells
Vials of frozen cells were removed from liquid nitrogen, quickly thawed at 37°C 
and immediately added to ~12 ml of the appropriate pre-warmed medium. Cells 
were aspirated with a pipette a few times to avoid clumps forming.
2.2.9.2. Fluorescent staining of human epithelial cell lines 
Cells for staining were trypsinized, pelleted and re-suspended in 3-4 ml fresh 
medium. To ascertain the concentration of the re-suspended cells, 15 jil of cells 
were placed on a disposable counting slide and the number of cells in the grid 
were counted under the microscope. Cells were diluted to 1x105/ml, and 0.5 ml 
(i.e. 50,000 cells) of cells were placed in each well of a 4-well glass chamber 
slide. Cells were left to incubated at 37°C in the chamber slide for 
approximately 48 h until they reached around 50% confluency.
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To aid the adherence of the cells, the chamber slides were pre-treated with 
200 pi collagen solution per well and incubated at 37°C for a minimum 2 h. The 
collagen solution was then removed and the wells were washed once with 
sterile PBS and left to dry.
Medium was removed from the cells and they were washed for 5 min. with PBS 
and fixed by incubating in 200 pi 4% paraformaldehyde solution per chamber at 
room temperature for 20 min. Fixing solution was removed and the cells were 
washed again with PBS for 5 min. To permeabilize the cells, 200 pi 1% Triton in 
PBS was added to each chamber and left to incubate at room temperature for 
5 min. The Triton solution was removed and cells were washed once more with 
PBS for 5 min., then blocked in 5% goat serum in PBS for 2 h at room 
temperature and washed again in PBS for 5 min.
The fixed, permeabilized and blocked cells were incubated overnight at 4°C in 
a 1 in 50 dilution of rabbit polyclonal anti-harmonin antibody (Kobayashi. et al., 
1999), or a 1 in 50 dilution of rabbit serum, or PBS alone. The following day, 
cells were washed three times in PBS for 5 min. and incubated in a 1 in 50 
dilution of anti-rabbit-FITC IgG conjugate for 4 h at room temperature. Cells 
were washed again three times in PBS for 5 min., air dried, the chambers 
removed from the glass slide and the cells mounted with a glycerol/PBS 
solution.
2.2.9.3. Confocal microscopy
Fluorescently immunolabelled cells were viewed under a Leica confocal 
microscope using a 40x oil objective lense.
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2.2.10. Protein analysis
2.2.10.1. Protein extraction from human cell lines
Medium was removed from a 75-cm2/250-ml tissue-culture flask of cells and the 
cells washed once with 5-10 ml ice-cold PBS. Cells were scraped from the 
bottom of the flask and collected using more ice-cold PBS to wash out the 
flask. The cells were pelleted by centrifuging at ~250 g for 10 min. at 4°C. The 
PBS was removed and the cell pellet was re-suspended in 100-200 pi RIPA 
buffer with 2 -4  pi 50x solution of protease inhibitors. The cells were aspirated 
with a pipette and then with a 21-gauge needle to break them open. The 
solution of disrupted cells was left to incubate on a rotor at 4°C for 30 min. 
followed by centrifugation at 4°C at ~18 000 g for 20 min. The supernatant, 
containing the solublized protein extract of the cells, was transferred to a fresh 
tube and stored at -80°C.
2.2.10.2. Protein assay
All cell protein extracts were assayed using the Bio-Rad Protein Assay dye, a 
procedure based on the Bradford method, a dye-binding assay in which a 
differential colour change of the dye occurs in response to various 
concentrations of protein.
The dye reagent was first prepared by diluting one part dye reagent 
concentrate with four parts distilled, dH20 . The diluted reagent was filtered 
through Whatman #1 paper to remove particulates. Four dilutions (62.5, 125, 
250 and 500 pg/ml) of bovine serum albumin (BSA) were prepared as a protein
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standard as well as 2 -3  dilutions of the protein solution to be tested. A 50-pl 
volume of each standard and diluted sample was mixed with 1 ml of diluted dye 
reagent and incubated at room temperature for a minimum of 5 min. 
Absorbance at 595 nm was measured using an Eppendorf BioPhotometer and 
the concentration of the cell protein extracts was extrapolated from a standard 
curve of BSA concentration vs A595nm.
2.2.10.3. SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) of proteins 
Proteins were separated by 12% SDS-PAGE (see section 2.1.3.). Gels were 
assembled in a mini-PROTEAN 3 cell. Approximately 50 fig protein extract was 
combined with 6x SDS loading buffer (section 2.1.1.), denatured at 96°C for 
5 min. and electrophoresed at 200 V for approximately 1 h (or until the loading 
dye reached the bottom of the gel) in 1x TGS buffer (section 2.1.1.). For size 
comparison, 10 pi pre-stained Precision Plus Protein™ Standards were also 
loaded.
2.2.10.4. Coomassie staining SDS-PAGE gels
After SDS-PAGE, the gel was removed and incubated in a solution of 25% 
acetic acid and 10% methanol with 0.05% Coomassie brilliant blue dye powder 
for 1 h at room temperature, with gentle shaking. The gel was then destained in 
a fresh solution of 25% acetic acid and 10% methanol for 1 h at room 
temperature, with gentle shaking. The gel was dried on filter paper on a gel 
dryer at ~60°C for 1 h.
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2.2.10.5. Western transfer (Immunoblotting)
The SDS-PAGE gel was placed on filter paper, which was sandwiched next to 
a piece of nitrocellulose membrane. The proteins were transferred at 100 V for 
1 h in transfer buffer cooled to 4°C.
2.2.10.6. Colourimetric protein detection
The nitrocellulose membrane was blocked overnight in 5% non-fat dried milk, 
0.1% (v/v) Tween 20 in PBS at 4°C, with gentle rocking. The following day, the 
membrane was washed in PBS with 0.1% Tween 20 (PBS-T) twice for 2 min. 
and incubated with the appropriate primary antibody for 1 h at room 
temperature, with gentle shaking. A mouse monoclonal anti-harmonin antibody 
(Scanlan, et al., 1999) was used for harmonin detection, and a mouse 
monoclonal anti-GST antibody was used for detection of GST-fusion proteins.
The membrane was rinsed briefly with two changes of PBS-T and washed with 
fresh PBS-T for 15 min. on the shaker, followed by three washes of 5 min. 
Next, the membrane was incubated with a biotinylated IgG, raised against the 
relevant species (i.e. that which the primary antibody was raised), at room 
temperature for 1 h, with gentle shaking (the required dilution factor of each 
antibody was determined by titration). The membrane was washed again as 
before, then incubated in Streptavidin-AP conjugate (diluted 1 in 2 500 in fresh 
PBS-T) for 1 h at room temperature, with gentle shaking. The Streptavidin-AP 
solution was removed and the membrane washed twice for 1 min. each in 
PBS-T and then twice more for 1 min. with dh^O. The membrane was 
developed using Western Blue™ stabilized substrate for alkaline phosphatase 
for about 5-10 min., with gentle shaking, until the bands reached the desired
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intensity. Washing the membrane in water for several minutes halted the 
reaction and the membrane was air-dried.
2.2.10.7. Treatment of protein with calf intestinal alkaline phosphatase (CIP)
A 2-pl volume of in wfro-translated harmonin was added to 6 pi dh^O, 1 pi 
10x buffer 3 and 1 pi CIP enzyme and incubated at 37°C for 1 h. The digest 
was denatured at 96°C for 5 min. in 2 pi 6x SDS loading buffer, run on a 12% 
SDS-PAGE gel and analysed on immunoblot.
2.2.11. GST pull-down assay
To identify proteins with which harmonin interacts, a candidate protein was 
analysed in an in vitro GST pull-down system. Harmonin isoform a1 was 
in vitro-translated from USH1C cDNA and the 3’ portion of a candidate 
interacting protein was cloned in a GST vector (pGEX-4T-1) and expressed in 
E. coli as a GST-fusion protein.
2.2.11.1. In vitro transcription/translation ofcDNA
The human USH1C cDNA of the main isoform, a1, was sub-cloned into the 
pZErO™-2 vector. USH1C was translated in vitro using the TNTR Quick 
Coupled Transcription/Translation system.
The Transcend™ Non-radioactive Translation Detection System was used to 
confirm the presence of a protein product on immunoblot. An aliquot of the TNT 
Quick master mix was removed from the -80°C freezer, rapidly thawed by
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hand-warming and placed on ice. One microgramme of plasmid DNA template 
was added to 40 pi TNT Quick master mix, 1 pi 1 mM methionine, 1 pi 
Transcend™ Biotin-Lysyl-tRNA and made up to 50 pi final reaction volume with 
nuclease-free water. The components were mixed gently by pipetting and the 
reaction was incubated at 30°C for 90 min. and then stored at -20°C until 
required.
Following confirmation of translation of a protein of the expected size, further 
protein was translated in the absence of the Transcend™ Biotin-Lysyl-tRNA 
and detected on immunoblot with harmonin-specific antibodies.
2.2.11.2. Transcend™ non-radioactive translation detection system
To confirm that the in wYro-translation system was working, 1 pi in vitro- 
translated harmonin was run on a 12% SDS-PAGE gel, as described in section
2.2.10.3. The gel was blotted onto nitrocellulose membrane, as described in 
section 2.2.10.5., and the membrane was blocked by incubating in PBS-T for 
1 h at room temperature, with gentle shaking. The membrane was incubated 
with a 1 in 2 500 dilution of Streptavidin-AP conjugate in fresh PBS-T for 1 h at 
room temperature; with gentle shaking and then developed using Western 
Blue™ stabilized substrate for alkaline phosphatase, as described in section
2.2.10.6.
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2.2.11.3. Expression of GST-fusion protein
Competent BL21 E. coli cells transformed with pGEX-4T-1 constructs 
containing the cDNA fragment of the protein of interest cloned downstream of a 
GST tag, as described in section 2.2.7.6., were plated onto LB-amplicillin plates 
and incubated overnight at 37°C.
Single colonies were picked from the LB-ampicillin plates, used to inoculate 
5 ml of LB-ampicillin medium and incubated overnight at 37°C. The following 
day, 600 pi of 5-ml overnight culture was used to inoculate 12 ml of pre­
warmed, fresh LB-ampicillin medium in a 50-ml tube and the culture was 
incubated at a pre-determined temperature for optimal protein expression (28, 
30 or 37°C). The optical density (OD) of the 12-ml culture was measured at 600 
nm every 15-30 min. until the OD6oo reading was between 0.5 and 0.7. A 1-ml 
“pre-induction” sample was then removed from the 12-ml culture and 100 mM 
IPTG (Isopropyl-thiogalactosidase) was added to the remaining 11 ml to a final 
concentration of 0.1 mM (11 pi) and incubation at the appropriate temperature 
was continued for 2 -3  h. Cells were then pelleted in 1.5-ml aliquots by 
centrifuging at ~18 000 g for 3 min. and cell pellets were frozen at -80°C prior 
to protein extraction.
2.2.11.4. Protein extraction from E. coli
GST-fusion proteins were extracted from E. coli cell pellets using Bug Buster® 
Protein Extraction Reagent with Benzonase. The cell pellet from a 1.5-ml 
aliquot of cultured cells was re-suspended in 300 pi BugBuster® with 6 pi 50x
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protease inhibitors. The cell suspension was incubated at room temperature for 
20 min., with rotation. Insoluble cell debris was removed by centrifugation at 
4°C at 16 000 g for 20 min. The supernatant was transferred to a fresh 1.5-ml 
tube and either used directly or stored at -80°C until required.
2.2.11.5. Preparation of glutathione Sepharose beads
Glutathione Sepharose™ 4B is supplied as a 75% slurry. The beads were re- 
suspended by gently shaking the bottle and 133 pi of the 75% slurry was 
removed and transferred to a 1.5-ml tube. The beads were pelleted by 
centrifugation at 500 g for 5 min. and the supernatant was removed. 
Glutathione Sepharose™ 4B beads were washed by mixing with 1 ml cold 
(4°C) 1x PBS, to remove the 20% ethanol storage solution. The beads were 
pelleted again by centrifuging at 500 g for 5 min. and the wash solution 
removed. The beads were pre-blocked by adding 1 ml 1% BSA in PBS and 
incubating at room temperature for 15 min., with rotation. The beads were 
pelleted as before, the supernatant removed and the beads washed four more 
times with 1 ml cold PBS, as described above. Finally, the bead pellet was re­
suspended in 100 pi PBS to give a 50% slurry.
2.2.11.6. Purification of GST-fusion protein
The proteins extracted from a 1.5-ml aliquot of E. coli cells, as described in 
section 2.2.11.4., were incubated with 20 pi pre-blocked 50% Glutathione 
Sepharose slurry (i.e. a 10-pl gel bed volume) at room temperature for 30 min., 
with rotation. Beads were pelleted by centrifugation at 500 g for 5 min. and the
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supernatant removed. The beads were washed three times with 100 jj.I 0.1% 
Triton and 0.5 mM NaCI in PBS, followed by three washes with 100 pi 0.1% 
Triton in PBS and a final wash with 100 pi PBS. The bead pellet was then re­
suspended in 10 pi PBS and 2 pi 6x SDS loading buffer and denatured at 96°C 
for 5 min. before running on a 15% SDS-PAGE gel, as described in section
2.2.10.3.
Purified GST-fusion proteins were visualised on Coomassie-stained SDS- 
PAGE gels (see section 2.2.10.4.), or on immunoblots (see section 2.2.10.5.), 
and compared with unpurified cell lysates.
2.2.11.7. Protein-protein interaction assay
The cell lysate extract from a 1.5-ml aliquot of E. coli cells containing the GST- 
fusion protein of interest was incubated with 20 pi of a 50% slurry of 
Glutathione Sepharose™ 4B for 30 min. at room temperature, with rotation. 
The beads were washed three times with 100 pi 0.1% Triton in PBS and then 
incubated with 3 pi in wfro-translated harmonin, diluted in 100 pi PBS, for 1 h at 
room temperature, with rotation. Beads were washed three times with 100 pi 
0.1% Triton and 0.5 mM NaCI in PBS, followed by three washes with 100 pi 
0.1% Triton in PBS and a final wash with 100 pi PBS.
As a negative control, the above procedure was repeated with the GST protein 
tag alone and a GST-MCC2 fusion protein, shown previously to interact with 
harmonin (Ishikawa, et al., 2001), was used as a positive control. After the final
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wash, 10 |al PBS and 2 pi 6x SDS loading buffer were added to the Glutathione 
Sepharose™ 4B, incubated at 96°C for 5 min. and the supernatant was 
electrophoresed on a 12% SDS-PAGE gel, as described in section 2.2.10.3. 
Proteins were transferred from the SDS-PAGE gel onto nitrocellulose 
membrane, which was then developed using the mouse monoclonal anti- 
harmonin antibody, as described in section 2.2.10.6.
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3. USH1C Mutation Screen
3.1. Introduction
Prior to gene identification, Usher type 1C was thought to be rare outside the 
Acadian population of Louisiana. However, during the early part of this work, 
other groups identified mutations in patients from Pakistan, India, Lebanon and 
Europe (Table 3.1).
Table 3.1. Ethnic origins of Usher type 1C patients
Mutation Ethnic Origin Reference
238-239insC Pakistani
European
(Bitner-Glindzicz, etal., 2000; 
Verpy, etal., 2000) 
(Verpy, etal., 2000)
216G>A Acadian (Bitner-Glindzicz, etal., 2000)
IVS5-2delA Lebanese (Verpy, etal., 2000)
IVS1+1G>T European (Zwaenepoel, etal., 2001)
R31X European (Zwaenepoel, etal., 2001)
IVS5+1G>A European (Zwaenepoel, etal., 2001)
IVS8+2T>G Pakistani (Ahmed, etal., 2002)
769-770ins36 Indian (Ahmed, etal., 2002)
At the start of this work it was not known whether allelic mutations in USH1C 
might also be responsible for DFNB18, a recessive, non-syndromic form of 
deafness, for which the locus was shown, by linkage, to overlap with the 
USH1C region (Jain, et al., 1998). As transcripts containing the alternative 
exons A-F and G/G’ did not appear to be expressed in the eye (Verpy, et al.,
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2000), we and others hypothesized that mutations in these exons could lead to 
hearing defects without retinal degeneration and that DFNB18 and USH1C 
could be allelic variants of the same gene.
Given the recent findings of USH1C mutations in individuals of diverse ethnic 
backgrounds it was essential to know whether mutations in USH1C are a 
common cause of Usher syndrome type 1 in the UK and whether mutations in 
this gene contribute significantly to non-syndromic deafness in our population. 
It was also hoped that the identification of novel mutations in USH1C might 
yield information about important functional domains in the protein, harmonin.
To address this question, two cohorts of patients were screened for mutations 
in the USH1C gene; 1) fourteen British individuals, of mixed ethnic origins, that 
had been diagnosed with Usher type 1 by clinicians at Moorfields Eye Hospital, 
and 2) sixteen Caucasian sib pairs and two small consanguineous families, 
from the UK, with congenital/childhood onset non-syndromic deafness, who 
showed concordance for polymorphic markers flanking the DFNB18 locus (see 
section 2.1.5.2.).
3.2. Methods in Brief
All twenty-eight coding exons of the USH1C gene were amplified in each 
patient of both cohorts using touchdown PCR, as described in section 2.2.1.1. 
Hetero-duplex analysis was carried out on each exon fragment by DHLPC 
using the Transgenomic™ WAVE DNA analysis system, as detailed in
2.2.3. Exons, in which hetero-duplexes were identified, were then sequenced
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section
using the fluorescent dideoxy terminator method (section 2.2.4.) and analysed 
on the automated ABI 377 gel electrophoresis system.
Intragenic SNPs associated with a recurring USH1C mutation were 
investigated using restriction enzyme digests tests, as detailed in section 2.2.6. 
The phase of two novel coding changes in another Usher type 1 patient was 
determined by employing a strategy of long-range, nested, allele-specific PCR 
(section 2.2.1.2.).
The genotypes of sibs affected with Usher type 1 were ascertained by 
analysing markers flanking the four major USH1 loci (USH1B, USH1C, USH1D 
and USH1F), as described in section 2.2.5.1.
3.3. Results
3.3.1. Type 1 Usher patients
In the cohort of fourteen British individuals, of mixed ethnic origins, who had 
been diagnosed with Usher syndrome type 1, two of the patients were found to 
have the 238-239insC mutation (Fig. 3.1) reported previously (Bitner-Glindzicz, 
et al., 2000; Verpy, et al., 2000; Zwaenepoel, et al., 2001). A patient of Greek 
Cypriot origin was homozygous for 238-239insC, while the other patient, a 
British Caucasian, was found to be heterozygous for the mutation, but a second 
mutation could not be identified.
A third patient, of mixed Zulu and Ghanaian parentage, was found to be 
heterozygous for two, novel, coding changes. The first change was a G>A
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transition at nucleotide 388 (numbered according to Kobayashi, et al., 1999) 
(Fig. 3.2), resulting in a valine to isoleucine substitution at codon 130 (V130I) 
within the first PDZ domain of the protein. The second change was a G>T 
transition at nucleotide 1447 of the major isoform (Fig. 3.3), leading to an 
alanine to serine substitution at codon 483 (A483S) within the third PDZ 
domain. This patient was also heterozygous for two novel intronic changes, 
IVS12-42C>T and IVS13-12G>A, which have not been reported previously. At 
the time, ethnically matched controls could not be obtained to screen for these 
changes, however, none of them were observed in any of the other pan-ethnic 
patients (fourteen with Usher type 1 and eighteen with non-syndromic 
deafness), or the ninety-six control DNA samples that were analysed.
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Figure 3.1. DHPLC and
sequencing data for
USH1C exon 3 changes.
Electropherograms from 
DHPLC analysis are shown 
on the left and the 
corresponding homozygous 
sequence data is shown on 
the right.
A) Elution curve for wild 
type exon 3 fragments.
B) The heteroduplex formed 
when a fragment containing 
the 238-239insC mutation is 
spiked with a wild type 
fragment is eluted earlier 
than the wild type.
C) The heteroduplex formed 
when the same fragment of 
DNA contains the SNP 
IVS2-16C>T and is spiked 
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eluted slightly later then the 
238-239insC heteroduplex. 
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Figure 3.2. DHPLC and 
sequencing data for 
USH1C exon 5 changes.
Electropherograms from 
DHPLC analysis are shown 
on the left. The corre­
sponding sequence data 
shown on the right is for the 
reverse strand.
A) Elution curve for wild 
type exon 5 fragments.
B) The heteroduplex formed 
by the 388G>A mutation is 
eluted slightly earlier than 
the wild type. The corres­
ponding nucleotide sub­
stitution is underlined on the 
sequence chromatogram.
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Electropherograms from 
DHPLC analysis are shown 
on the left and the 
corresponding sequence data 
is shown on the right.
A) Elution curve for wild type 
exon 18 fragments.
B) The heteroduplex formed 
by the 1447G>T mutation is 
eluted earlier than the wild 
type.
C) The heteroduplex formed 
by the SNP 1440O T is 
eluted just after the 1447G>T 
heteroduplex. The corre­
sponding nucleotide sub­
stitutions are underlined on 
the sequence chromato­
grams.
A) Wild type
B) 1447G>T Mutation
Figure 3.3. DHPLC and 
sequencing data for USH1C 
exon 18 changes.
C) 1440O T Polymorphism
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3.3.1.1. Haplotype analysis
Subsequent to identification of two novel coding missense changes in the 
Usher type 1 patient of Zulu and Ghanaian parentage (SM), DNA from her 
affected sib (YM) became available and it was confirmed that she was also 
heterozygous for the V130I and A483S coding sequence changes. To ascertain 
whether the sibs only show linkage to USH1C and to exclude linkage to the 
other three major USH1 loci (USH1B, USH1D and USH1F), haplotype analysis 
was carried out by genotyping the sibs for markers flanking each locus. Linkage 
to USH1D and USH1F was excluded, but there was co-segregation of markers 
flanking both USH1B and USH1C (Fig. 3.4). Therefore, these sequence 
changes were investigated further to establish whether they might represent 
disease-causing mutations or rare polymorphisms.
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D11S1321 
D11S4179* 
D11S4186* 
D11S4166
D11S4160
D11S1981
D11S921
D11S902*
D11S4138*
D11S1888
D10S1685 
D1 OS 1650* 
D1 OS 1694*
D1 OS 1790 
D1 OS 1643* 
D1OS1124* 
D1OS1788
Distance
cM/kb
1.65/734
0.55/572
1.28/1479
0.0/41
0.0/198
0.0/204
0.0/267
0 .0/22
1.68/814
0.56/134
0 .0/66
1.07/1817
0.0/913
SM
203 211
236 236
163 163
116 120
268 252
157 153
247 247
147 147
199 195
217 213
269 267
139 135
147 147
187 183
147 125
201 201
260 246
YM
203 211
236 236
163 163
116 120
268 252
157 153
247 247
147 147
199 195
217 213
269 277
139 147
147 139
187 185
147 145
201 201
260 250
Figure 3.4. Data from genotyping sibs SM and YM for markers flanking the 
major Usher type 1 loci.
Markers flanking each of the USH1 loci indicated on the left were genotyped in both 
sisters. The alleles identified in each sib for each marker are given in base pairs 
underneath the corresponding sister. Bars of the same colour indicate alleles shared 
by the sisters. Asterisks denote the markers closest to the gene in question 
(D10S1650 and D10S1694 both lie within the USH1D gene, CDH23). Genetic 
distance, in cM, (data obtained from htto://research. marshfieldclinic.org/qenetics/) and 
physical distance, in kb, (data obtained from http://www.ensembl.org/) between the 
markers at each locus, are also given.
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3.3.1.2. Allele-specific PCR
To establish if the two novel missense coding changes, 388G>A and 1447G>T, 
could be sufficient to cause Usher sydrome, a recessive disorder, it was first 
necessary to determine whether or not these changes were inherited in trans or 
cis. In the absence of parental DNA, or any material for RNA extraction, a 
strategy of long-range PCR was employed, to amplify the 26.5 kb of genomic 
DNA that encompasses both changes. This was followed by a series of nested, 
allele-specific PCRs to determine whether these changes occur in cis or trans 
in these sibs (Fig. 3.5).
Ex5 Variant (A) 
Ex5 Wild type (C
26.5 kb of genomic DNA Ex 18 WHd type (C)
Ex18 Variant (A)
Nested, allele-specific PCRs
G' T
OR
Indicates that variants are in
C/S
Indicates that variants are in
TRANS
1st round
PCR
product
Possible 2nd 
round PCR  
products
Figure 3.5. Schematic outlining the procedure used to determine the 
inheritance pattern of the missense changes, 388G>A and 1447G>T, in 
the sisters SM and YM.
The first round of PCR amplifies the 26.5 kb of genomic DNA between exons 5 and 18, 
indicated as black lines. In a second round of nested, allele-specific PCRs only two out 
of the four sets of reactions will amplify a product, depending on whether the changes 
occur in cis or trans. The four PCRs are: 1) wild type forward + wild type reverse, 
2) wild type forward + variant reverse, 3) variant forward + wild type reverse and 
4) variant forward + variant reverse. If the changes are in cis PCRs 1 and 4 amplify, 
while if the changes are in trans then PCRs 2 and 3 amplify. Wild type alleles are 
indicated in green, while the variant alleles are indicated in red.
128
Amplification occurred when the variant exon 5 forward primer was used in 
combination with the variant exon 18 reverse primer, and conversely when both 
wild type primers were used (Fig. 3.6, lanes 1 and 4). Although there appears 
to be a small amount of non-specific product amplified when the variant exon 5 
primer and the wild type exon 18 primer were used (Fig. 3.6, lane 3), no 
product was observed when the wild type exon 5 primer was used in 
combination with the variant exon 18 primer (Fig. 3.6, lane 2). This, therefore, is 
a strong indication that the missense changes, 388G>A and 1447G>T, occur in 
cis in these sisters and thus reduces the likelihood that they are disease- 
causing mutations. Hence, no functional analysis was performed on these 
variants.
H2Q 1 2 3 4
23130
9416
6557
4361
2322
2027
Figure 3.6. Products amplified from nested, allele-specific PCRs on 
patient SM.
Each reaction was carried out using a different combination of forward (for the 388G>A 
change) and reverse (for the 1447G>T change) oligonucleotide primers: 1) wild type 
forward (G allele) + wild type reverse (G allele), 2) wild type forward + variant reverse 
(T allele), 3) variant forward (A allele) + wild type reverse, and 4) variant forward + 
variant reverse.
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3.3.1.3. Analysis of 238-239insC mutation
The 238-239insC mutation, found here in a Greek-Cypriot patient and a 
Caucasian, has been described on a number of occasions. As it occurs in a run 
of six cytosines, it could represent a mutational hotspot in the USH1C gene. 
However, using haplotype analysis with intragenic SNPs, Zwaenepoel, et al. 
showed that this mutation occurred on the same 39 kb haplotype in a Muslim 
family and individuals from Europe, and suggested that it was a founder 
mutation (Zwaenepoel, etal., 2001).
To determine if the 238-239insC mutation in our Greek Cypriot patient, and in a 
Pakistani patient reported previously (Bitner-Glindzicz, et al., 2000), also both 
lie on the same haplotype, the same intragenic SNPs were analysed and 
compared with the reported haplotype (Table 3.2).
The haplotype analysis carried out on our Greek Cypriot patient carrying the 
238-239insC mutation (Table 3.2) revealed a different haplotype over the 39 kb 
compared to that reported previously to be associated with the 238-239insC 
mutation (Zwaenepoel, et al., 2001). However, the haplotpye was conserved in 
the 7 kb of DNA immediately surrounding the 238-239insC mutation in our 
patient. It is, therefore, possible that the mutation is due to an ancient founder 
effect, and a cross-over event has since occurred in this Greek Cypriot patient 
between the mutation and the first change in the haplotype observed at 
IVS13+21C>G (Table 3.2).
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Table 3.2. Summary of haplotype analysis of patients homozygous for 238-239insC mutation.
 * -----------------------------------------------------------------------------------------
IVS1 IVS1 IVS2 381 IVS7 IVS7 IVS13 1188 IVS16 1440 1557 IVS19 1737 1877 1902
-45 -47 -16 G>T +61 -27 +21 A>G +12 C>T G>C +12 T>C C>T A>G
C>G G>T C>T G>A G>A C>G C>T G>C
Muslim family
and 4 
Europeans
(Zwaenepoel et al, 2001)
GG GG TT GG GG AA CC AA CC TT CC GG CC TT GG
Pakistani(Bitner
Glindzicz et al, 2000) GG GG TT GG GG AA cc AA CC TT cc GG CC TT GG
Greek Cypriot
(this study) GG GG TT GG GG AA GG GG cc CC GG GG TT CC AA
The fifteen intragenic SNPs that were genotyped are shown across the top of the table and the genotype of each SNP in the Greek 
Cypriot patient and a Pakistani family reported before (Bitner-Glindzicz et al, 2000), are compared with the genotypes reported 
previously (shown in red) (Zwaenepoel et al, 2001). Differences between the haplotypes are highlighted in yellow. A blue asterik 
denotes the position of the 238-239insC mutation between SNPs IVS2-16C>T and 381G>T in the haplotype.
Another possibility is that 238-239insC is a recurring mutation that has arisen 
on a common haplotypic background. To investigate this, the haplotype in the 
7 kb of DNA associated with the mutation (GTGGA) was examined in two 
control populations, fifty-three Pakistani and forty-four Greek-Cypriot DNA 
samples (Tables 3.3 and 3.4).
The 238-239insC mutation was, in general, found to be associated with the 
more common of the two alleles for each SNP studied (Table 3.5). Five out of 
forty-four Greek Cypriot samples and One out of fifty-three Pakistani samples 
were found to be homozygous for the GTGGA haplotype (Tables 3.3 and 3.4). 
Using the Hardy-Weinberg distribution, p2 + 2pq + q2 = 1, where p is the 
haplotype GTGGA and q is any other haplotype, then 34% of the Greek Cypriot 
control population (V5/44) and 14% of the Pakistani control population (Vi/53) 
would be expected to carry the GTGGA haplotype. The genetic background 
reported to be associated with the 238-239insC mutation is not particularly rare 
in these two populations and it is therefore possible that this mutation could 
have arisen on more than one occasion on the same background.
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Table 3.3. A 7 kb sub-section of the USH1C haplotype surrounding the 
238-239insC mutation found in forty-four Greek Cypriot control DNA 
samples.
Polymorphism
IVS145 IVS2-16 381 IVS7+61 IVS7 -27 
C>G C>T G>T G>A G>A
10
11
V  12 
Q.___
Ens
C/)
13
14
Q  15
16
17
18
19
20
21
22
23
24
Q.
Ea
</)
Polymorphism
IVS145
O G
IVS2-16
O T
381
G>T
IVS7+61
G>A
IVS7 -27 
G>A
25 G
T G G G
G T G G G
26
G T G G G
C C G G G
27 C c G
- G
G T G - G
28 G C G
- G
C C G - G
29 G T G G A
C C G G G
30 G T G G A
G T G G A
31 G T G G A
C C G G G
32 G T G A A
G C G A G
33 G T G G G
C C G A G
34 G T G G A
G T G G A
36 C C G G G
C C G G G
37 G T G
- A
G T G - A
38 G C G
- G
C C G - G
39 G T G G A
C C G G G
40 G T G
- G
C C G - G
41 G T G G G
G C G A G
42 G C G G G
C c G A G
43 G T G G G
G c G A G
44 G c G G G
C c G A G
48 G T G G A
G T G G A
49 G T G G A
G T T G A
50 G T G G A
G T G G A
Possible regions of the haplotype matching those reported previously (Zwaenepoel, et 
al., 2001) are highlighted in yellow and samples homozygous for the reported 
haplotype across the 7 kb region are numbered in red. N.B. the DNA samples are not 
numbered contiguously.
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Table 3.4. A 7 kb sub-section of the USH1C haplotype surrounding the 
238-239insC mutation found in fifty-three Pakistani control DNA samples.
Polymorphism Polymorphism
IVS145 IVS2-16 381 IVS7+61 IVS7-27 IVS145 IVS2-16 381 IVS7+61 IVS7^7
C>G C>T G>T G>A G>A O G  O T  G>T G>A G>A
42 c o g g a
______ c______ C_____ G____ G____ G 
Possible regions of the haplotype matching those reported previously (Zwaenepoel, et 
al., 2001) are highlighted in yellow and samples homozygous for the reported 
haplotype across the 7 kb region are numbered in red. N.B. the DNA samples are not 
numbered contiguously.
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Table 3.5. Frequencies of SNP alleles associated with 238-239insC 
mutation in two control populations.
*
IVS1-45
C>G
IVS2-16
C>T
381
G>T
IVS7+61G>A
IVS7-27
G>A
Greek Cypriot 66% 52% 98% 84% 40%
Pakistani 57% 32% 100% 62% 24%
The allele of each SNP associated with the 238-239insC mutation is indicated in red 
type. A blue asterik denotes the position of the 238-239insC mutation between SNPs
IVS2-16C>T and 381 G>T in the haplotype.
3.3.1.4. Summary
In fourteen British Usher type 1 patients, disease-causing mutations in USH1C 
were identified in two individuals (14% of cohort). A Greek Cypriot was 
homozygous for the recurring mutation 238-239insC, while a Caucasian was 
heterozygous for the same mutation and a second change could not be 
identified. A third patient of Zulu and Ghanaian parentage had two novel coding 
missense changes that appear to occur in c/s, reducing the likelihood that they 
are disease-causing mutations. The 238-239insC mutation may be a recurring 
mutation and is not necessarily due to a founder effect as previously reported 
(Zwaenepoel, et al., 2001).
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3.3.2. Patients with non-syndromic deafness
At the start of this study Usher type 1C and the non-syndromic recessive 
deafness, DFNB18, were hypothesized to be allelic disorders since the two loci 
had already been shown to overlap (Jain, et al., 1998). To ascertain whether 
mutations in USH1C were also responsible for DFNB18 a cohort of patients, 
described in section 2.1.3.2., with non-syndromic recessive deafness was 
screened.
From a larger cohort of 133 (Navarro-Coy, et al., 2001), a group of sixteen 
Caucasian sib pairs with congenital/childhood onset non-syndromic deafness 
from the UK and two small consanguineous families showed concordance for 
polymorphic markers flanking the DFNB18 locus. All twenty-eight exons of 
USH1C in this cohort were screened, but there was no evidence of mutations in 
the coding region of USH1C in these patients with autosomal non-syndromic 
recessive deafness.
3.3.2.1. Summary
No disease causing mutations were found in the USH1C gene in our cohort of 
patients with non-syndromic autosomal recessive deafness.
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3.3.3. Polymorphisms
The USH1C gene is proving to be fairly polymorphic and as a result, of the 
thirty-two patients, as well as the control DNAs that were screened during this 
study, eight novel polymorphisms have been identified in the USH1C gene 
(Table 3.6).
Table 3.6. Polymorphisms identified in the USH1C gene.
Nucleotide change* Location Predicted effect Novel?
IVS1-41insCC Intron 1 None No
IVS1-45C>G Intron 1 None No
IVS1-47G>T Intron 1 None No
IVS2-16C>T Intron 2 None No
IVS6+2T>G Intron 6 None Yes
IVS6+56A>G Intron 6 None Yes
IVS7+61G>A Intron 7 None No
IVS7-27G>A Intron 7 None No
IVS8-53G>C Intron 8 None Yes
IVS12-42C>T Intron 12 None Yes
IVS13-12G>A Intron 13 None Yes
+1188A>G Exon 14 P396P No
IVSA+83C>G Intron A None Yes
IVSA-34C>T Intron A None No
IVSB+52T>C Intron B None No
IVSB-34G>A Intron B None No
Exon D nt 240 C>T* Exon D A>A No
IVSE-10delT Intron E None Yes
IVSF+43C>T Intron F None Yes
IVS16+120T Intron 16 None No
+1440C>T Exon 18 V480V No
+1557G>C Exon 19 E519D No
IVS19+12G>C Intron 19 None No
+1737T>C Exon 21, 3’UTR None No
+1877C>T Exon 21, 3’UTR None No
+1902A>G Exon 21, 3’UTR None No
The novel polymorphisms are highlighted in yellow.
# nucleotide numbering is according to Kobayashi, et al., 1999.
* the numbering here refers to the nucleotide position within exon D
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3.4. Discussion
3.4.1. Usher type 1 patients
Until recently, Usher syndrome type 1C was believed to be a disease exclusive 
to the Acadian population of Louisiana (Astuto, et al., 2000). In a study of 151 
families with type 1 Usher syndrome in the United States, only the two Acadian 
families included as controls showed evidence of linkage to the USH1C region, 
whilst linkage to this region was excluded in all other families. However, since 
the USH1C gene has been identified, mutations have been reported in 
individuals of diverse ethnic origins, including Pakistani families (Bitner- 
Glindzicz, et al., 2000), Lebanese families (Verpy, et al., 2000), Caucasian 
families from Germany,. Switzerland and Denmark (Zwaenepoel, et al., 2001), 
an Indian family (Ahmed, et al., 2002) and here, in a Greek Cypriot family. 
Thus, in Europe, mutations in the USH1C gene may account for a greater 
proportion of Usher type 1 than originally thought. In our cohort of patients with 
a firm diagnosis of Usher syndrome type 1, 14% (2/14) were found to be due to 
mutations in USH1C.
3.4.2. USH1C alleles
3.4.2.1. Missense coding changes
To date, missense mutations in USH1C have not been identified in Usher type 
1C patients, only splicing, frameshift and truncating mutations (see Table 3.1). 
The possibility of missense mutations in USH1C is intriguing and has the 
potential to yield more information about the function of this protein than is 
currently known.
In this study two novel coding missense changes were identified in sisters of 
Zulu and Ghanaian parentage. The nucleotide change 388G>A, is predicted to 
translate to a V130I change in PDZ1 of the protein sequence, while 1447G>T is 
thought to lead to a A483S change in PDZ3 of harmonin. Although these two 
changes are predicted to result in fairly conservative amino acid changes, i.e., 
a hydrophobic valine to a hydrophobic isoleucine and a hydrophobic alanine to 
an uncharged serine, both residues are conserved in the mouse harmonin 
sequence and they lie within the first and third PDZ domains, respectively 
(Fig. 3.7). Hence, it is possible that these changes have an important role to 
play in the folding or ligand recognition of these PDZ domains.
When the amino acid sequences of the USH1C PDZ domains are compared 
with PDZ domains found in other proteins (Fig. 3.7), it can be seen that an 
isoleucine or serine residue does occur at these positions in other functional 
PDZ domains. Furthermore, these changes do not affect the critical residues, 
pB5 and aB1, thought to be involved in defining the ligand specificity of a PDZ 
domain (Bezprozvanny and Maximov, 2001; Bezprozvanny and Maximov, 
2002), and so it is likely that harmonin is able to function normally with these 
changes.
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Figure 3.7. Alignment of PDZ domains (adapted from the PROSITE entry #PS50106, http://ca.expasy.org/prosite/).
A selection of PDZ domains aligned in CLUSTAL format with the three human harmonin PDZ domains at the top (indicated in red text) 
and the three mouse harmonin PDZ domains below (indicated in green text). The residues involved in the six p-sheets (Pa-Pf) in the 
PDZ domain are denoted by blue text, while the residues involved in the two a-helices (aA-aB) are identified with pink text. The two 
amino acid residues, pB5 and aBi, denoted by appropriately coloured arrows at the bottom, are considered to be critical for determining 
the ligand binding specificity of a PDZ domain. The more highly conserved residues are highlighted in grey, while the PDZ1 and PDZ3 
changes, V130I and A438S, respectively, are labelled in red. Amino acid residues that are identical to those changes found in the 
patient are highlighted in yellow.
In addition, the allele-specific PCRs (Fig. 3.6) indicate that the two coding 
changes, 388G>A and 1447G>T, are present in cis in these sisters, since the 
PCRs using either wild type primers or variant primers amplified products 
(Fig. 3.6, lanes 1 and 4). Although there also appears to be some amplification 
from the variant forward primer with the wild type reverse primer (Fig. 3.6, lane 
3), the specificity of amplification from allele-specific primers depends on 
various PCR conditions, including primer design, Taq polymerase 
concentration and MgCk concentration, whilst the conditions for long-range 
PCR are equally critical (Barnes, 1994; Zainuddin, et al., 2003). Modification of 
the allele-specific primers, so that they have a mismatch base located at the 
penultimate 3' position rather than at the 3’ end, may avoid this non-specific 
amplification. The missense changes, 388G>A and 1447G>T, probably 
represent rare polymorphisms in the USH1C gene, and the sisters are sharing 
alleles by chance. By random segregation, sib pairs will share two parental 
haplotypes 25% of the time.
The missense changes 388G>A and 1447G>T have not been observed 
previously, but the patient has a Zulu father and a Ghanaian mother and 
ethnically matched controls could not be easily obtained at the time. So 
although these changes may not be present or may be extremely rare in other 
populations, they may be more common in either the Zulu or Ghanaian 
population. It is interesting that two novel intronic changes were also identified 
in these sibs and, together with the additional novel coding changes, this may 
reflect the greater genetic diversity observed in African populations (Tishkoff, et 
al., 1996).
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The sisters also showed co-segragation with markers flanking USH1B 
(Fig. 3.4), therefore, the Usher type 1 phenotype observed in these sibs could 
be due to mutations in the USH1B gene, MY07A. However, there is also the 
possibility that this variant USH1C allele is acting as a modifier, since the 
retinitis pigmentosa observed in these sibs is unusually severe, or there could 
be digenic inheritance.
Digenic inheritance between two other Usher genes, USH1B and USH3, has 
already been proposed. Two affected brothers in a family of Jewish Yemenite 
origin were found to have different Usher phenotypes; one had a typical USH1 
phenotype, while the other had a typical USH3 phenotype. Both showed 
linkage to the USH3 locus. However, the brother with the USH1 phenotype had 
also inherited a mutated MY07A  allele from his mother. The mother and two 
unaffected siblings, who were all double heterozygotes for the mutated MY07A  
allele and for a single USH3 haplotype, showed no evidence of an Usher 
phenotype or deafness. Hence, this recessive MY07A  allele was only 
phenotypically expressed on the background of two defective USH3 alleles, 
indicating a possible interaction between the two gene products (Adato, et al., 
1999).
Myosin VIIA and harmonin have now been shown to interact at the protein level 
and the harmonin b isoform is mislocalized in shaker-1 mice, the mouse model 
for Usher type 1B (Boeda, et al., 2002). Hence, it is feasible that the single 
USH1C allele identified here could modify the expression of a MY07A  allele in 
some way.
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3A .2.2. 238-239insC frameshift mutation
The 238-239insC mutation identified here in the homozygous state in a Greek 
Cypriot Usher type 1 patient and in the heterozygous state in a Caucasian 
Usher type 1 patient, appears to be presenting as a common mutation in the 
USH1C gene. Two-thirds of the non-Acadian Usher type 1C patients reported 
to date have at least one 238-239insC allele (Ahmed, et al., 2002; Bitner- 
Glindzicz, etal., 2000; Verpy, etal., 2000; Zwaenepoel, etal., 2001; this study). 
This has important implications for a future diagnostic genetic testing strategy 
of Usher type 1 patients.
Most Usher type 1 patients are phenotypically similar and, without a family 
history, yield no clues as to the gene responsible. Although mutations in 
MY07A  (USH1B) are the most common cause of Usher syndrome type 1, with 
42% of patients in an American study being positive for USH1B mutations 
(Astuto, et al., 2000), this gene does not appear to have any common 
mutations and comprises forty-nine exons. Furthermore, CDH23 (USH1D) and 
PCDH15 (USH1F), together the second most common cause of Usher type 1 
(Astuto, et al., 2000), are also large genes, sixty-nine and thirty-three exons, 
respectively, and also do not appear to have common mutations. Mutations in 
USH1C now appear to be more prevelant than originally thought and the 238- 
239insC mutation is presenting as the first common mutation in an Usher type 
1 gene. As a diagnostic strategy it would be sensible to screen new patients for 
common mutations first, particularly when a disease, such as Usher syndrome 
type 1, is genetically heterogenous and the genes involved are large.
143
What is the mechanism of this common mutation, an insertion of a cytosine in a 
run of six? Slipped-strand mispairing is a mechanism by which nucleotides may 
be inserted or deleted during DNA replication. A misalignment of base-pairs 
may occur at the replication fork within a run of identical nucleotide bases, or a 
short tandem repeat, such that a base (or tandem repeat) may be either 
misincorporated or lost, depending on whether the newly synthesised strand 
slips backwards or forwards with respect to the template strand (Kunkel, 1990). 
Slipped-strand mispairing has been found to be a significant cause of deletion 
and insertion ‘hotspots’ in human genes, whereby a mutation has occurred 
several times independently, (Cooper and Krawczak, 1991; Darvasi and 
Kerem, 1995) and it is reasonable to assume that the 238-239insC mutation 
may also represent such a ‘hotspot’.
Analysis of USH1C intragenic SNPs (Zwaenepoel, etal., 2001), showed that in 
a Muslim family and individuals from Europe the 238-239insC mutation occurs 
on the same haplotype, and it was concluded that the prevalence of this 
mutation was likely to be due to a founder effect (Zwaenepoel, et al., 2001). If a 
mutation is very old, the region that is identical by descent surrounding the 
mutation can be very small. When the same USH1C intragenic SNPs were 
analysed in our Greek Cypriot patient carrying the 238-239insC mutation 
(Table 3.2), the haplotype shared with other patients carrying this mutation was 
reduced from 39 kb down to 7 kb. Therefore, if 238-239insC is due to a founder 
effect then it can be assumed to be ancient.
However, when the haplotype, GTGGA, associated with the 238-239insC 
mutation was studied in the general population, something not done previously,
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it did not appear to be particularly rare in the Pakistani and Greek Cypriot 
populations (Tables 3.3 and 3.4). This suggests that 238-239insC is not 
necessarily due to a founder effect, but could have arisen on more than one 
occasion on the same, relatively common, haplotypic background and hence, 
represent a mutational ‘hotspot’ within the USH1C gene. This is in contrast to 
the GJB2 gene where the SNP alleles associated with the common 35delG 
mutation, a deletion of a guanine in a run of six guanines, were found to be 
significantly very rare in the control population tested (Van Laer, et al., 2001). 
The most informative SNP genotype associated with the 35delG mutation was 
found in only 1.4% of the control population (Van Laer, et al., 2001). This 
compares with the AA genotype of the most informative SNP associated with 
238-239insC, IVS7-27G>A, being present in 5% of Pakistani and 16% of Greek 
Cypriot controls (Tables 3.3 and 3.4).
3.4.3. Non-syndromic deafness patients
Although no mutations were identified in USH1C in our cohort of sib pairs with 
non-syndromic deafness, mutations have since been identified in DFNB18 
patients. In one study missense mutations were identified in the alternative 
exons B and D expressed in the ear, but not the eye (Ouyang, et al., 2002). In 
another study, a splice site mutation was found to lead to ‘leaky’ skipping of 
exon 12 such that both the wild type transcript and a variant transcript, which 
lacked exon 12, were generated in an in vitro exon-trapping assay (Ahmed, et 
al., 2002).
There appears to be a preliminary genotype-phenotype correlation emerging 
with the identification of USH1C mutations in patients with non-syndromic
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deafness. It is becoming apparent that protein truncating mutations of USH1C 
lead to the more severe Usher type 1 phenotype, whilst missense mutations in 
the alternative exons, or a ‘leaky’ splice site mutation, that still allows the 
production of some wild type transcript, result in a non-syndromic form of 
deafness. The alternative exons (A-F and G/G’) are utilized in the production of 
the longer harmonin b isoform, which was originally thought to be ‘ear-specific’ 
(Verpy, et a/., 2000) and, indeed, harmonin b has now been shown to be 
important for the developing hair cell stereocilia in the mouse cochlea (Boeda, 
et al., 2002). However, it also seems that the ear is more sensitive than the eye 
to any loss in wild type harmonin protein since a ‘leaky’ splicing mutation 
appears to affect the ear, but not the eye (Ahmed, et al., 2002).
Our failure to demonstrate that DFNB18 and USH1C are allelic is most likely 
because the deafness in our cohort of families was not truly linked to the 
DFNB18 locus. Only one family linked to DFNB18 was published in the 
literature (Jain, et al., 1998), and an offer of collaboration was not accepted, so 
we chose to screen sib pairs with autosomal, non-syndromic recessive 
deafness. There is a 25% chance that any sib pair will be concordant for 
markers at any given locus of the genome. Therefore, our sample of 16 sib 
pairs concordant for markers flanking DFNB18, derived from the original cohort 
of 133, is too small to have a >95% chance of having any truly linked families.
In this cohort, no other DFNB loci appeared to make a significant contribution to 
autosomal recessive deafness, after GJB2 (connexin 26), (Navarro-Coy, et al., 
2001). With thirty-seven loci identified to date (HHH), non-syndromic autosomal 
recessive deafness (DFNB) is extremely genetically heterogeneous. Since
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there are no real phenotypic markers available to distinguish between the 
different DFNB loci, the contribution made by each locus in a population 
becomes an important question when attempting to identify the gene 
responsible in a family with non-syndromic autosomal recessive deafness. 
However, the absence of USH1C mutations in the cohort screened here, in 
itself suggests that the contribution of DFNB18 to non-syndromic deafness as a 
whole in the UK is likely to be very minor.
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4. Alternative USH1C Isoforms
4.1. Introduction
The USH1C protein, harmonin, exists as several alternatively spliced isoforms 
(Scanlan, eta!., 1999; Verpy, et al., 2000) (Fig. 4.1), although the physiological 
significance of all of these is not yet known. Some isoforms of harmonin appear 
to have tissue specific expression patterns. For example, the longer harmonin b 
isoforms, with the additional exons spliced in between exons 14 and 16 
(Fig. 4.1), were shown by Verpy, et al., to be expressed specifically in the ear 
(Verpy, et al., 2000). Hence, it is possible that there are additional, alternative 
isoforms of harmonin with tissue-specific patterns of expression.
Some putative harmonin isoforms lack one or two of the PDZ domains 
(Fig. 4.1) and, therefore, are not able to form all of the same interactions as can 
the longer isoforms. Furthermore, the C-terminus of harmonin itself contains a 
PDZ-binding motif that can bind to PDZ1 of an adjacent harmonin molecule 
(Siemens, et al., 2002). Hence, isoforms of harmonin with novel C-termini may 
loose this interaction, but may also gain novel interactions, depending on 
whether or not the new C-terminus forms a PDZ-binding motif. Consequently, it 
can be seen how the USH1C gene has the ability to produce several protein 
products, each with slightly different binding abilities and the possibility of 
different functions in different tissues.
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Figure 4.1. Alternative isoforms of USH1C identified to date (adapted from 
Verpy, et al., 2000).
Alternatively spliced isoforms of USH1C reported by Verpy, et al., and Scanlan, et al. 
Exons are represented by boxes. Constitutive exons are numbered in black, whilst 
alternatively spliced exons are numbered in pink. In-frame stop codons are denoted by 
asterisks. Isoforms are grouped into three classes according to the structure of the 
putative protein isoforms they encode. Transcript a1 represents the major isoform of 
USH1C. The alternative exon 15 is replaced by exon A in the minor transcript a2 and 
by a 974 bp sequence encoded by exons A-F in the minor transcripts b1, b2 and b3, 
which differ by the presence or absence of exon G or G’. PDZ-59 is a minor transcript 
with exons E and F spliced onto exon 15. Transcripts containing a combination of exon
15 and exons A-F (c2) or none of them (c1/PDZ-45), or exon 15 with exon A (c3) or 
exon F (PDZ-54), premature stop codons are present in exon B, at the exon 14/exon
16 junction, in exon 18 and in exon 16, respectively. The putative transcript PDZ-37 
lacks the N-terminus and protein translation is initiated from an alternative start codon 
in exon 12. Red font indicates transcripts described by Verpy, et al., (a1, a2, b1, b2, 
b3, c1, c2 and c3) and green font indicates those transcripts described by Scanlan, et 
al., (PDZ-73, PDZ-45, PDZ-54, PDZ-59 and PDZ-37).
Intriguingly, the family that led to the identification of the USH1C gene, by our 
group, presented with profound congenital sensorineural deafness in
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association with severe hyperinsulinism, enteropathy and renal tubular 
dysfunction (Bitner-Glindzicz, et al., 2000). A contiguous gene deletion that 
included all but the first two exons of USH1C and twenty-one of thirty-nine 
exons of the adjacent ABCC8 gene was found to account for the phenotype in 
these patients (Bitner-Glindzicz, et al., 2000). ABCC8 encodes one of the two 
components of ATP-sensitive K+ (Katp) channels found in pancreatic p-cells 
and mutated in non-syndromic hyperinsulinism (Thomas, et al., 1995); hence, 
partial deletion of this gene accounts for the severe hyperinsulinism observed 
in the deletion patients. USH1C has since been shown to be the gene 
underlying Usher syndrome type 1C and non-syndromic deafness, DFNB18. 
Therefore, the deafness in these patients is explained by deletion of the 
majority of the USH1C gene. However, how can the enteropathy and renal 
tubular dysfunction observed in the deletion patients be explained?
The enteropathy suffered by the contiguous gene deletion patients included 
symptoms such as severe diarrhoea and malabsorption, which are not found to 
this degree in patients with hyperinsulinism. Furthermore, the enteropathy 
observed in the patients resembled that of auto-immune enteropathy (Hussain, 
et al., 2004 in press), with associated severe inflammation. Harmonin, the 
protein encoded by USH1C, was previously identified as an auto-antigen in 
patients suffering from a variant form of X-linked auto-immune enteropathy 
associated with tubulonephropathy (Kobayashi, et al., 1999). Therefore, it 
appears that deletion of USH1C may also account for the intestinal, and 
possibly the renal, phenotype in these patients. However, it then becomes 
difficult to explain why Usher type 1C patients with protein-truncating mutations, 
such as R31X and 238-239insC (Bitner-Glindzicz, et al., 2000; Verpy, et al.,
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2000; Zwaenepoel, et al., 2001), at the 5’ end of USH1C do not have an 
observable gut phenotype.
It is possible, in the presence of a truncating mutation at the 5’ end of USH1C, 
that an alternative isoform of harmonin is still expressed, which is sufficient for 
the proper functioning of the gut and/or the kidney. The existence of such an 
isoform, known as PDZ-37, was shown by Scanlan, et al. Northern blot analysis 
of human brain tissue revealed a harmonin hybridization signal that 
corresponded to a size of 1.2 kb, i.e. half the expected size for full length 
harmonin. Furthermore, 5’ RACE products, obtained from human brain cDNA, 
had 5’ ends equivalent to the sequence of exon 11 of USH1C (Scanlan, et al.,
1999). Hence, whilst the deletion patients lack the ability to make any protein, 
patients with truncating mutations at the 5’ end of the gene may still be able to 
produce short isoforms, such as PDZ-37, which could be sufficient for normal 
gut and kidney function.
However, as PDZ-37 expression had only been detected in the brain, we 
decided to investigate the distribution of alternative splice forms of USH1C 
more fully. A combination of RACE and RT-PCR methods were used to identify 
novel and existing isoforms of USH1C.
4.2. Methods in Brief
4.2.1. RNA extraction
Various tissues were collected from human foetuses ranging from just under 
eight weeks (fifty-four days) up to thirteen weeks of development (Table 4.1).
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Total RNA was extracted from each sample (see section 2.2.2.1.) and first 
strand cDNA was synthesized using random nonamer oligonucleotides in 
combination with a poly-dT oligonucleotide (see section 2.2.22.). The quality of 
each cDNA sample was confirmed by amplification with gene-specific 
oligonucleotides for the house-keeping gene hypoxantine phospho- 
ribosyltransferase (HPRT). The HPRT amplification also confirmed that the 
samples were not contaminated by genomic DNA, since the oligonucleotides 
used were specific for different exons of HPRT. The cDNA samples were then 
ready for gene-specific analysis.
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Table 4.1. Human foetal tissue samples
Stage of 
Development* Tissue
Stage of 
Development* Tissue
79 dy Stomach 11 wk (564) Ear
13 wk Eye 9 wk (566) Ear
13 wk Ear 9 wk (567) Ear
17 wk Brain 54 dy (568) Heart
8 wk (537) Heart it Tongue
12 wk (538) Adrenal glands it Stomach
8 wk (539) Eye it Ears
u Kidney ii Lungs
it Stomach it Kidneys
8 wk (540) Eye 11 wk (573) Lungs
<i Ear ii Stomach
10 wk (544) Cochlea ii Tongue
55 dy (555) Liver ii Ears
it Heart 13 wk (579) Ears
ic Lungs ii Heart
it Eyes ci Eye
ic Ear ii Kidney
12 wk (560) Ear 65 dy (595) Heart
11 wk (564) Brain ii Ears
* dy = days, wk = weeks, number in brackets = foetus id no.
4.2.2. 5’ RACE
To investigate the possibility of additional alternative isoforms of USH1C, 
5’ RACE was performed on total RNA extracted from eight-week human foetal 
ear tissue. Briefly, first-strand cDNA was synthesised from total RNA extracted 
from the human foetal ear tissue using a gene-specific oligonucleotide located 
in exon 18 (5’GSP1) of USH1C. Next, a polycytosine tail was added to the 5! 
end of the first-strand products. Finally, the dC-tailed first-strand products were 
amplified using forward oligonucleotides specific to the dC-tail and reverse 
gene-specific oligonucleotides, in a set of nested PCRs (Fig. 4.2).
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Figure 4.2. Schematic outlining the 5’ RACE procedure used (adapted from 
Invitrogen manual).
i) The gene-specific first strand primer, GSP1, is annealed to the mRNA and the 
mRNA is copied into cDNA. ii) The RNA is degraded with RNAse and the cDNA is 
purified, iii) The purified cDNA is tailed with dCTP and, iv) a nested gene-specific 
primer, GSP2, is used with a primer complimentary to the dC-tail (AAP) to amplify the 
dC-tailed cDNA. v) The primary PCR product is then re-amplified using a second 
nested gene-specific primer (GSP3) and a primer complimentary to the 5’ end (AUAP).
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4.2.3. RT-PCR
RT-PCR analysis of USH1C was performed to investigate the tissue-specific 
distribution of previously reported alternative USH1C isoforms (Scanlan, et al., 
1999; Verpy, et al., 2000), as well as to look for novel isoforms of USH1C. 
Gene-specific amplification was performed on various human foetal cDNA 
samples using oligonucleotide primers designed to various exons of USH1C 
(Appendix A, Table A.3).
4.3. Results
4.3.1. 5’ RACE analysis
5’ RACE was performed on total RNA extracted from eight-week-old human 
foetal ear tissue and the products were amplified using a nested gene-specific 
primer (GSP3) located in exon 13 of USH1C. A number of products were 
amplified (Fig. 4.3). The largest product observed, at approximately 1.2 kb 
(Fig. 4.3, arrow), could represent the major harmonin isoform a, where the 
translation start site is located in exon 1. Just below the largest product there is 
also evidence of at least one transcript of approximately 900 bp in size. This 
could represent a transcript that either lacks one or more of the constitutive 
exons 1-12, or that has an alternative 5’UTR. In addition, there are also smaller 
products evident between 250 and 450 bp (Fig. 4.3, bracket). These may 
represent transcripts with alternative 5’UTRs, in which alternative translation 
initiation sites may be used. One of these smaller products may be the putative 
short isoform, PDZ-37, in which protein translation starts from an alternative 
site in exon 12 (Scanlan, et al., 1999). A product relating to the PDZ-37 isoform
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would be expected to be approximately 250-450 bp in this experiment, 
depending on the size of the 5’UTR.
1 2
1500 K -
Figure 4.3. 5’ RACE using cDNA 
from eight-week human foetal ear 
tissue.
100
600
}
Agarose gel showing 5’ RACE 
products: lane 1 is the blank, whilst 
lane 2 shows the products obtained 
after nested, gene-specific cDNA 
synthesis. Size in base pairs is 
indicated on the left.
The 5’ RACE indicated the possibility of alternative isoforms of harmonin in the 
human foetal ear, other than those reported previously. However, it was not 
possible to gel-purify any of these products and sequence them to confirm the 
nature of the putative transcripts. These transcripts appeared to be present in 
low abundance and it is not known if they are of any physiological relevance. 
Subsequently, we decided to use RT-PCR for further analysis of alternative 
isoforms of USH1C.
4.3.2. RT-PCR analysis
4.3.2.1. USH1C RT-PCR
The products of 5’ RACE were amplified using a nested primer (GSP3) located 
in exon 13. Therefore, using this strategy, it was not possible to identify the 
longer ear-specific isoforms that were subsequently reported (Verpy, et al.,
2000). Hence, once the alternative exons, A-F and G/G\ situated between
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exons 14 and 16 were described and published (Verpy, et al., 2000) various 
oligonucleotides were designed to investigate these exons further. It was 
necessary to confirm the tissue-specific expression pattern of the alternative 
exons and identify any further alternative splicing patterns (Table 4.2).
Table 4.2. Oligonucleotides used to analyse USH1C expression in human 
foetal tissues with expected product sizes.
Location of 
forward primer
Location of 
reverse primer
Isoforms that might 
be amplified*
Expected product 
sizes (bp)
Exon 13 Exon 17
a1, a2, b1,2,3, c1, c2, 
c3,PDZ-54, PDZ-59
280, 255, 1175, 205, 
1250, 330, 450,
Exon B Exon 17 b1, b2, b3 and c2 900
Exon F Exon 21 b1, b2, b3 and c2 400, 490 or 510
Exon F Exon G/G’ B2 and b3 350
Intron 11 Exon 14 PDZ-37 280
* isoforms identified previously (Scanlan, et al., 1999; Verpy, et al., 2000), shown in 
Fig. 4.1.
First, to investigate alternative splicing between exon 14 and exon 16 of 
USH1C, a forward oligonucleotide in exon 13 was used in combination with a 
reverse oligonucleotide in exon 17. Gene-specific amplification was performed 
on all the cDNAs obtained from the human foetal tissue samples (Fig. 4.4). 
Some of the samples appeared to have more than one product present and 
some of these were re-run on a fresh agarose gel (Fig. 4.5) to see if the 
alternative products could be isolated and sequenced. However, it was not 
possible to isolate any potential alternative USH1C isoforms for sequencing, 
since they were present in such small quantities. In addition, the major isoform, 
type a1, was often the smallest PCR product and therefore, was amplified 
preferentially.
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100
280 bp (major isoform, a1)
Figure 4.4. Amplification of the exon 13 to exon 17 region of USH1C.
First strand cDNA samples, processed from human foetal tissues at various stages of 
development, were amplified using USH1C gene-specific oligonucleotides located in 
exons 13 and 17. The major product, indicated in red, at 280 bp represents the main 
USH1C isoform a1. There is also some evidence of both larger and smaller alternative 
isoforms (see Fig. 4.5), indicated by yellow arrows. Size in base pairs is indicated on 
the left, wk = week and dy = day.
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Figure 4.5. Detailed view of some products from amplification of the exon 
13 to exon 17 region of USH1C.
Some of the products from the USH1C gene-specific amplification of human foetal 
cDNA samples shown in Figure 4.3 were re-loaded on agarose gel to better visualize 
possible alternative isoforms. The major isoform a1, indicated in red, gives a product of 
280 bp. Alternative products at approximately 1300 bp, 1100 bp, 400 bp and 200 bp, 
which may represent either previously identified isoforms or novel ones, are indicated 
on the right. Size in base pairs is indicated on the left, wk = week and dy = day.
To make the PCR more specific for alternative isoforms, a forward 
oligonucleotide in the alternative exon B was used in combination with the 
reverse oligonucleotide in exon 17 (Table 4.2). This amplification was 
performed on cDNA samples from human foetal ear tissue at various stages of 
development and three distinct products of 150 bp, 250 bp and 900 bp in size 
were obtained (Fig. 4.6). Each product was isolated and sequenced. The 
largest product was found to contain the alternative exons B through to exon F 
spliced onto exons 16 and 17. This confirms the finding of Verpy, et al., 2000, 
of the alternative isoforms b1, b2, b3 or c2 (Fig. 4.1).
However, sequencing of the 250-bp product revealed a transcript with exons B 
and C spliced onto 16 and 17, and the sequence of the smallest product 
showed exon B alone spliced onto exons 16 and 17 (Fig. 4.6). These splice 
products have not been described before and represent novel putative 
isoforms. Both exons B and C represent cassette exons, which, if spliced in 
together or separately in addition to either exon A or exon 15, maintain the 
protein reading frame. Interestingly, exons B and C encode the second coiled- 
coil domain. Hence, the protein represented by the 250 bp RT-PCR product 
would be expected to contain all three PDZ domains and both the coiled-coil 
domains, but not the putative protein degradation domain (PEST).
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Figure 4.6= USH1C gene-specific PCR using a forward primer in the 
alternative exon B in combination with a reverse primer in exon 17.
Amplification of first-strand cDNA prepared from human foetal-ear tissue at various 
stages of development, as indicated above each lane. The splice products confirmed 
by sequencing are indicated to the right. The 900-bp product could reflect the 
expression of any or all of the b1, b2, b3 or c2 isoform, while the 250-bp and 150-bp 
products reflect novel splicing patterns that have not been reported previously. Size in 
base pairs is indicated on the left, wk = week and dy = day.
To further investigate the expression of alternative USH1C isoforms, gene- 
specific amplification was performed using a forward oligonucleotide in the 
alternative exon F in combination with a reverse oligonucleotide in either exon 
21 or the alternative exon G (Table 4.2). Tissues in which more than one 
product is amplified with the exon F and exon 21 oligonucleotides could be 
expressing any of the class b isoforms and/or the class c2 isoform (Verpy, et 
a/., 2000) (Fig. 4.7). Only tissues that express isoforms b2 or b3 would be 
expected to amplify with the exon F and exon G oligonucleotides (Fig. 4.8).
The results of these two amplifcation reactions (Figs 4.7 and 4.8) indicate that 
the b isoforms of USH1C are not only expressed in the ear, as reported 
previously (Verpy, et al., 2000), but also in human foetal heart, kidney and gut 
tissue and, to a lesser extent, in the eye.
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Figure 4.7. USH1C gene-specific PCR using a forward primer in 
alternative exon F in combination with a reverse primer in exon 21.
Amplification of first-strand cDNA prepared from various human foetal tissues. Most 
tissues appear to express a 400-bp product, indicated in red, which may correspond to 
either the b1 or the c2 isoform (Fig. 4.1). Additional products, that may represent the 
alternative isoforms b2 and b3, were amplified in some tissues (examples indicated by 
yellow arrows). Size, in base pairs, indicated on the left, wk = week and dy = day.
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Figure 4.8. USH1C gene-specific PCR using a forward primer in 
alternative exon F in combination with a reverse primer in alternative 
exon G.
Amplification of first-strand cDNA prepared from various human foetal tissues. The 
expected product of 350 bp, indicated in red, represents both the b2 and b3 USH1C 
isoforms. Size in base pairs is indicated on the left, wk = week and dy = day.
400 bp 
(isoform b1 and/or c2)
4.32.2. COCH RT-PCR
Alternative USH1C isoforms, previously reported to be ear-specific (Verpy, et 
al., 2000), were also present in some of the other foetal tissues tested here 
(Figs 4.7 and 4.8). Therefore, the possibility of cross-contamination between 
tissues during processing was examined. Oligonucleotides were designed to 
amplify a gene that was thought to be ear-specific, COCH (cochlin), in all the 
first strand cDNA samples processed from the various human foetal tissues. As 
expected most of the tissues, apart from the ear samples, did not amplify for 
COCH (Fig. 4.9). However, a product of the expected size (300 bp) was also 
amplified in some of the eye and brain tissue samples. Low levels of COCH 
expression have also previously been detected in human foetal-eye and -brain 
tissue on Northern blot (Robertson, et al., 1994). Therefore, COCH expression 
was detected only in the tissues that have previously demonstrated expression 
of this gene, and not in the heart, kidney or gut, indicating that cross­
contamination is unlikely to have occurred during the processing of these tissue 
samples.
Since cross-contamination cannot be the reason for detecting expression of 
alternative USH1C exons in the heart, kidney and gut, then these results are 
probably true. Hence, the alternative USH1C b isoforms do not appear to be 
ear-specific.
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Figure 4.9. COCH gene-specific PCR.
Gene-specific amplification of COCH, a gene expressed abundantly in the ear, in all 
the human foetal cDNA samples obtained. The expected product size of 300 bp is 
indicated in red. Size in base pairs is indicated on the left, wk = week and dy = day.
4.3.2.3. PDZ-3 7 isoform
From both the 5’ RACE results (Fig. 4.2) and the published work of Scanlan, et 
al., we hypothesized that the presence of a short isoform, possibly PDZ-37, in 
the gut might account for the different phenotypes observed between Usher 
type 1C patients and the patients with a contiguous gene deletion. Patients with 
5’ truncating mutations might still be able to express short protein isoforms, 
which could explain the absence of an observable gut phenotype in these 
patients.
To support this hypothesis, it was necessary to determine whether PDZ-37 
expression could be detected in the gut. However, there are no coding 
differences between the PDZ-37 isoform and the main harmonin isoform a1. 
Therefore, a PDZ-37-specific amplification reaction was designed using a
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forward oligonucleotide in intron 11 (putative 5’ UTR) in combination with a 
reverse oligonucleotide in exon 14.
A product of the expected size (-280 bp) was amplified in a number of human 
foetal tissues (Fig. 4.10). Interestingly, although originally described in adult 
brain, PDZ-37 expression did not seem to be apparent in foetai brain tissue. 
However, expression was detected in human foetal ear, heart, kidney and, 
most importantly, the gut (Fig. 4.10). Furthermore, these results were 
reinforced by the subsequent detection of PDZ-37 mRNA in two human gut 
epithelial cell lines, HT29 and Caco-2, as will be shown in Chapter 5 (Fig. 5.3).
Figure 4.10. PCR assay for the putative USH1C isoform PDZ-37.
First-strand cDNA from human foetal tissues of various stages of development was 
amplified using a forward oligonucleotide in intron 11 in combination with a reverse 
oigonucleotide in exon 14 of USH1C. The expected product size of 280 bp is indicated 
in red. Size in base pairs is indicated on the left, wk = week and dy = day.
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Other accessible tissues sources were then examined for PDZ-37 expression. 
Desquamated uroepithelial cells (from fresh urine) and cheek scrappings were 
assayed (Fig. 4.11), since such samples might be obtainable from Usher 
patients.
Blank
Figure 4.11. PCR assay for PDZ-37 in normal urine sample.
Total RNA was extracted from urine samples and cheek cells and first-strand cDNA 
synthesis was performed. (A) First-strand cDNA was first amplified for the major 
USH1C isoform a1 (280 bp) using a forward primer in exon 13 with a reverse primer in 
exon 17. First-strand cDNA from human foetal gut was used as a positive control for 
amplification. Size in base pairs is indicated on the left. (B) First-strand cDNA was 
amplified for the alternative transcript PDZ-37 using a forward primer in intron 11 with 
a reverse primer in exon 14 (upper gel). To check for low levels of expression of PDZ- 
37, PCR products from the first round of PCR were then subjected to a nested PCR 
using primers also in intron 11 and exon 14 (lower gel). First strand cDNA from the 
human gut epithelial cell lines, HT29 and Caco-2, were used as positive controls for 
the amplification of PDZ-37. Size in base pairs is indicated on the right.
Although low levels of USH1C isoform a1 could be detected in the first-strand 
cDNA synthesised from one of the urine samples assayed (Fig. 4.11 A), PDZ-37
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expression could not be detected in this urine sample, even when nested RT- 
PCR was performed (Fig. 4.11B). The other urine sample and the cheek 
scrapping may not have contained any RNA, since these samples did not 
amplify for the USH1C isoform a1 (Fig. 4.11 A)
To confirm our hypothesis, alternative RNA sources need to be obtained and 
tested for expression of PDZ-37 in Usher type 1C patients.
4.3.3. Summary of results
4.3.3.1. 5’ RACE
A primer in exon 13 was used to amplify the 5’ RACE products. Therefore, it 
was not possible to identify the ‘ear-specific’ b isoforms of USH1C using this 
method of analysis. However, the 5’ RACE did show evidence of additional 
novel USH1C transcripts (Fig. 4.2), although these could not be cloned and 
sequenced.
4.3.3.2. RT-PCR analysis
4.3.3.2.1. Alternative exons A -F and G/G’
When the region between exons 14 and 16 of USH1C was amplified, faint 
bands at the appropriate size (Fig. 4.4, ~1300 bp) indicated the presence of the 
‘ear-specific’ b isoforms. Furthermore, products were amplified when 
oligonucleotide primers situated in the alternative ‘ear-specific’ exons were 
used, confirming that these isoforms do exist at low levels. However, the b 
isoforms do not appear to be specific to the ear as described previously (Verpy, 
et al., 2000) (Figs 4.6 and 4.7), but are also found in human foetal gut, kidney, 
heart and eye tissues. It was demonstrated that the presence of the b isoforms
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in these additional tissues is unlikely to be due to contamination by ear tissue 
during processing (Fig. 4.8). I
Novel isoforms of USH1C were identified (Fig. 4.6), which include transcripts 
containing exon B and exons B and C spliced onto exon 16.
4.3.3.2.2. PDZ-37
Expression of mRNA for a 5’ truncated isoform of harmonin, PDZ-37, was
i
demonstrated in gut, kidney, heart and ear human foetal tissues (Fig. 4.10). '
4.4. Discussion
4.4.1. 5’ RACE analysis
5’ RACE was used to investigate the possibility of additional, alternative 
isoforms of USH1C in the human foetal ear. A number of products were 
amplified using this method (Fig. 4.3), however, in the absence of any 
sequence data for these products it can only be hypothesized what they may 
represent. Unfortunately, when the oligonucleotide primers were designed for 
the 5’ RACE experiment, the alternative splicing that leads to the expression of 
longer, ‘ear-specific’ harmonin b isoforms (Verpy, et al., 2000) had not been 
reported. Hence, the b isoforms were not identified in the 5’ RACE analysis, 
since the nested oligonucleotide used for amplifying the 5’ RACE products was 
located in exon 13 and the alternative exons are situated between exons 14 
and 16.
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Interestingly, the 5’ RACE procedure identified a group of products of 
300-400 bp in size (Fig. 4.3, bracket), shorter than expected. These may 
represent novel USH1C isoforms; either with alternative 5’ UTRs or that lack 
one or more of the constitutive exons between 1 and 12. This was felt to be 
particularly significant because expression of isoforms with alternative 
translation start sites may still be possible in Usher patients with 5’ protein 
truncating mutations, which would prevent expression of the major isoform of 
USH1C. The 400-bp product, which has amplified in the greatest quantity, 
might encode the previously reported putative 5’ truncated PDZ-37 isoform 
(Scanlan, et al., 1999), thought to utilize an alternative translation start site in 
exon 12.
There are a number of putative, in-frame, start codons located upstream of the 
gene-specific oligonucleotide, in exon 13 (GSP3), used to amplify the 5’ RACE 
products. However, only one of these start codons falls within a putative kozak 
sequence, GCCA/GCCAUGG, the consensus sequence considered to be the 
optimal sequence allowing the translation machinery to recognize the initiation 
codon efficiently. Further studies would be required to identify which alternative 
start codon(s) might be utilized. This may be achieved by cloning PDZ-37 
cDNA for expression, and using site-directed mutagenesis to alter potential 
translation start sites in turn.
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4.4.2. Alternative USH1C isoforms in human foetal tissues
4.4.2.1. Alternative exons 15 and A-F
Since it was not possible to identify the USH1C mRNA isoforms observed using 
5’ RACE, use of the. alternative exons in splicing was studied further using RT- 
PCR analysis.
All the human foetal tissues collected, were shown to express the main 
harmonin isoform a1 (with exon 15 spliced between exons 14 and 16) as 
demonstrated by the 280-bp product amplified using oligonucleotides in exons 
13 and 17 of USH1C (Fig. 4.4). These PCRs were not quantitative, so it is not 
possible to comment on the level of expression of USH1C mRNA in the 
different tissues, only whether or not expression could be detected.
Some of the tissues showed evidence of expression of more than one variant 
of USH1C mRNA (Fig. 4.5). Unfortunately, the level of expression of these 
alternative products was too low for them to be isolated for sequence analysis. 
However, many alternative isoforms of USH1C have been reported (Scanlan, 
et al., 1999; Verpy, et al., 2000) and it is possibe to hypothesize which ones 
may be represented here.
The larger products seen in the ear and the heart (Fig. 4.5) may indicate the 
presence of the class b transcripts, in which the alternative exons A -F are 
spliced between exons 14 and 16 in place of exon 15, or the class c2 transcript 
(Verpy, et al., 2000) (Fig. 4.1). This was the first evidence that the alternative 
exons may not be ear-specific. There is also evidence of isoforms of USH1C 
that are smaller than the a1 isoform, in particular in the ear, kidney, stomach,
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brain and heart (Figs 4.4 and 4.5, smallest bands). One of these products could 
represent the isoform c1 (~205 bp), also known as PDZ-45 (Scanlan, et al., 
1999), in which exon 14 is spliced onto exon 16 introducing a stop codon and 
leading to a truncated protein product (Fig. 4.1). PDZ-45 expression has 
previously been detected by RT-PCR in various adult human tissues including 
the stomach, brain and kidney (Scanlan, et al., 1999). This would correlate with 
the findings here, in addition to observation of expression in the human foetal 
ear (Fig. 4.4).
Some of the samples also appeared to have products of approximately 400 bp 
in size (Fig. 4.5) and these could relate to the isoforms PDZ-54 (~ 332 bp) and 
PDZ-59 (-452 bp), whose mRNA have only been detected previously in the 
kidney, brain and bladder by RT-PCR (Scanlan, et al., 1999), or they could 
represent yet more alternative splice products. These alternative products, 
though, are present in quite low abundance and it is not known if they are 
physiologically relevant. They may represent transcripts produced by aberrant 
splicing events, which would not be expected to code for functional proteins 
and would be broken down via the nonsense-mediated decay pathway.
4.4.2.1.1. Ear-specific b isoforms
Not all of the tissues tested here showed evidence of expressing the longer 
alternative isoforms b1, b2, b3 and c2 which include the exons A - F  with or 
without exon G/G’ spliced between exons 20 and 21 (Fig. 4.1). This was to be 
expected since expression of the b isoforms was reported to be ear-specific 
(Verpy, et al., 2000). However, human foetal eye, brain, gut, heart, kidney and 
ear tissue all showed expression of the b1 USH1C transcript (or c2) (Fig. 4.7).
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Most of these tissues also showed expression of the transcripts that include 
exon G/G’, b2/b3 (Fig. 4.8). Therefore, the b isoforms of USH1C appear to 
have a wider expression pattern than originally thought and hence, they may 
also have a role in other tissues. This is of particular interest when considering 
the allelism observed between Usher syndrome type 1C and non-syndromic 
deafness, DFNB18. Given that there is now evidence that the b isoforms of 
harmonin are also expressed in human foetal-eye tissue, mutations in the 
alternative exons A -F  and G/G’ would not necessarily be expected to lead to 
deafness in the absence of an eye phenotype. Therefore, the ear maybe more 
sensitive than the eye to mutations in the USH1C gene.
4.4.2.1.2. Novel alternative transcripts
When a forward primer in exon B was used in combination with the reverse 
primer in exon 17 on the human foetal ear samples it was possible to isolate 
USH1C mRNA transcripts that utilize the alternative exons. Two novel 
products, of 150 bp and 250 bp, were obtained in addition to the expected 
product of 900 bp (Fig. 4.6). Sequencing revealed these variants to consist of 
exon B (150 bp) and both exons B and C (250 bp) spliced on to exon 16. These 
transcripts have not been reported previously and both have the potential to 
produce in-frame protein products if the alternative exons are spliced in 
combination with either exon A or 15. Together, exons B and C encode the 
second coiled-coil domain, although exon B encodes the majority of this 
domain. The addition of exons B and C would not be expected to have an 
effect the PDZ domains. However, an isoform of harmonin that includes exons 
B and C in the absence of exons D -  F would differ from the b isoforms by 
including the second coiled-coil domain in the absence of the putative protein
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degradtion motif (PEST) encoded by exons D and E. Therefore, it may be 
envisaged that these novel isoforms could allow the additional protein-protein 
interaction, afforded by the second coiled-coil domain, in a protein with a longer 
half-life than the b isoforms.
r
4.4.3. PDZ-37 isoform
PDZ-37, a 5’ truncated isoform of harmonin that was previously only detected 
in adult brain and spinal cord tissue by Northern blot analysis (Scanlan, et al., 
1999), has received little attention. Protein translation is hypothesized to start 
from an alternative initiation site in exon 12 (Scanlan, et al., 1999) and the 
putative protein product contains most of the first coiled-coil domain and the 
third, most C-terminal, PDZ domain. However, the existence of PDZ-37 had not 
been confirmed at either the molecular level or the protein level since Scanlan’s 
report (Scanlan, et al., 1999). It has been shown here that it is possible to 
amplify a transcript from intron 11 using RT-PCR (Fig. 4.10).
We are interested in investigating this isoform of harmonin further. If PDZ-37 is 
a true variant of harmonin, and it is expressed in the gut, then it may explain 
why a family with a contiguous gene deletion, that encompasses most of 
USH1C, have the Usher phenotype combined with an enteropathy (Bitner- 
Glindzicz, et al., 2000). This gut phenotype has not been observed in Usher 
type 1C patients with null mutations, which occur at the 5’ end of the USH1C 
gene. A PCR assay was designed on the assumption that the 5’UTR of this 
isoform encompasses intron 11 of the gene. The results of this PCR were 
particularly convincing since it is not usual to find intronic sequence present in 
cDNA and secondly the PCR was designed across two further introns (introns
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12 and 13), such that if the cDNA was contaminated with genomic DNA then 
the PCR product would have been much larger than expected.
As expression of the putative PDZ-37 transcript has now been confirmed at the 
RNA level in a variety of human foetal tissues (Fig. 4.10). It would be 
interesting to show that Usher type 1C patients with 5’ truncating mutations, 
238-239insC, for example, are still able to express the PDZ-37 isoform. This 
might explain why they do not have a gut phenotype. However, an accessible 
tissue is needed to test for PDZ-37 mRNA expression in Usher patients. PDZ- 
37 mRNA expression was not detected in RNA extracted from a urine sample 
(Fig. 4.11), and so alternative sources will need to be investigated if this 
hypothesis is to be pursued. Furthermore, it is also important to show 
expression of PDZ-37 at the protein level, see Chapter 5 (Fig. 5.5).
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5. Immunolocalization
5.1. Introduction
PDZ domain-containing proteins have been implicated in a number of different 
functions within different cell types, including the clustering, targetting and 
routing of associated proteins (reviewed by van Ham and Hendriks, 2003). In 
most of these roles, PDZ proteins tend to localize to the cell membrane where 
they may interact, either directly, or via other proteins as part of a 
macromolecular complex, with integral membrane proteins and/or the 
cytoskeleton of the cell. However, some PDZ-domain proteins have been 
shown to shuttle between the cytoplasm and the nucleus (Islas, et a/., 2002) 
and, hence, also appear to have a role in cell signalling. To understand more 
about the role played by a novel PDZ protein it is important to establish its 
intracellular localization.
To confirm the intracellular localization of harmonin, human gut epithelial cell 
lines were studied using fluorescent immunocytochemistry. In addition, to get a 
better understanding of the role played by harmonin in the inner ear, 
localization studies, using fluorescent immunohistochemistry, were attempted 
on mouse inner-ear sections.
Furthermore, having confirmed the existence of PDZ-37 mRNA in foetal 
tissues, it was also necessary to assess whether it is expressed in human cell 
lines and, particularly, whether it could be detected at the protein level. Finding
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intact PDZ-37 protein in gut cell lines would be more supportive evidence as to 
why patients with 5’ truncating point mutations have no gut phenotype. Initially, 
expression of PDZ-37 in human gut cell lines was studied using RT-PCR, 
before studying protein extracts on immunoblot for presence of the PDZ-37 
protein.
5.2. Methods in Brief
5.2.1. Immunohistochemistry
For localization of harmonin within the cochlea, mouse cochleae were removed 
as described in section 2.2.8.1. and fixed in 4% paraformaldehyde (section
2.2.8.2.). For cutting frozen sections, cochleae were then embedded in the 
appropriate orientation within an Optimal Cutting Temperature compound 
(OCT), frozen on dry ice (section 2.2.8.3.) and sectioned on a cryostat (section 
2.2.8.4.). Frozen mouse cochlea sections were then stained as described in 
section 2.2.8.6. Briefly, sections were incubated with a 1 in 50 dilution of rabbit 
polyclonal anti-harmonin antibody (Kobayashi et a/., 1999), followed by a 1 in 
100 dilution of an anti-rabbit-FITC conjugate and then a 1 in 100 dilution of 
Phalloidin-Rhodamine for F-actin staining and a 1 in 200 dilution of Hoechst 
nuclear stain. The immunofluorescent sections were viewed under a 
fluorescent microscope.
5.2.2. Immunocytochemistry
Intracellular localization of harmonin in gut epithelial cell lines, HT29 and Caco- 
2, was studied using immunocytochemistry.
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5.2.2.1. RT-PCR
Expression of USH1C in the cell lines was first checked. Total RNA was 
extracted from the cell lines using TRIZOL™, as described in section 2.2.2.1., 
and first-strand cDNA synthesis was performed using Superscript™ II Reverse 
Transcriptase (Section 2.2.2.2.). USH1C gene-specific amplification was 
carried out using oligonucleotide primers specific for exons of USH1C 
(Appendix A, Table A.3).
5.2.2.2. Immunoblotting
Once expression of USH1C mRNA had been confirmed, expression of 
harmonin in the cell lines was also confirmed on immunoblot. Proteins were 
extracted from cell lines using RIPA buffer as described in section 2.2.10.1. 
The protein content of cell extracts was then assayed (section 2.2.10.2.) and 
50-100 fig of total protein extract was run on an SDS-PAGE gel (section
2.2.10.3.) and the proteins were then transferred to nitrocellulose membrane 
(section 2.2.10.4.).
Harmonin was detected using a colourimetric method to develop the 
immunoblot. As described in section 2.2.10.5, the membrane was first 
incubated with a 1 in 1000 dilution of mouse monoclonal anti-harmonin 
antibody (Scanlan, et al., 1999), followed by a 1 in 1000 dilution of biotinylated 
anti-mouse IgG and then a 1 in 2500 dilution of streptavidin-alkaline 
phosphatase conjugate. Finally, the colour of the protein bands was developed 
using Western Blue™ stabilized substrate for alkaline phosphatase. To study 
expression of different isoforms of harmonin in the gut cell lines, immunoblots 
were also developed using a 1 in 500 dilution of the rabbit polyclonal anti-
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harmonin antibody (Kobayashi et al., 1999) with a 1 in 1000 dilution of 
biotinylated anti-rabbit IgG.
5.2.2.3. Fluorescent staining
Once expression of harmonin in the gut cell lines had been confirmed, 
immunocytochemistry was used, as detailed in section 2.2.9.2., to study the 
intracellular localization of harmonin. Briefly, cultured cells were fixed using 4% 
paraformaldehyde, permeabilized in 1% Triton, blocked with 5% goat serum 
and then incubated with a 1 in 50 dilution of rabbit polyclonal anti-harmonin 
antibody (Kobayashi, et al., 1999), followed by a 1 in 50 dilution of anti-rabbit- 
FITC IgG. Stained cells were mounted on glass slides and viewed using 
confocal microscopy.
5.3. Results
5.3.1. Immunohistochemistry of mouse inner-ear sections
Frozen mouse cochleae sectioned on the cryostat and viewed as phase 
contrast images (Fig. 5.1) confirmed that sections were cut in the correct 
orientation and that all the relevant structures, most importantly the organ of 
Corti, were present.
Cochlear section stained with rabbit polyclonal anti-harmonin antisera (Fig. 
5.2B), showed no obvious difference to the negative control, in which PBS was 
used in place of the primary anti-harmonin antisera (Fig. 5.2E).
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During the course of this work, Boeda, et al., reported their study on the 
distribution of harmonin within the developing mouse inner-ear hair bundle 
(Boeda, et al., 2002). Therefore, no further immunohistochemical experiments 
were pursued in this study.
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Figure 5.1. Phase contrast image of a section through the cochlea from a P14 mouse.
Figure 5.1. Phase contrast image of a P14 mouse cochlea section.
(A+B) Schematic diagrams of a cross-section through a single turn of the cochlear ___ _
spiral (Forge and Wright, 2002) provide a reference for the structural features of the 
cochlea duct, (A), and the Organ of Corti, (B). IHC, inner hair cell; OHC, outer hair cell;
Dc, Defiers’ cell; ip, inner pillar cell; op, outer pillar cell; He, Hensen’s cells; TM, 
tectorial membrane; BM, basilar membrane.
(C) The mouse cochlea was sectioned in the correct orientation for viewing the 
components of the Organ of Corti, the sensory epithelia of the cochlea duct. The 
locations of the outer and inner hair cells of the Organ of Corti are indicated, as are 
other structural features of the cochlea duct: including the basilar membrane, cochlea 
nerve, stria vascularis, spiral ligament and outer pillar cell (OP). Furthermore, delicate 
structures; such as Reissner’s membrane, which separates the endolymph of the 
cochlea duct from the perilymph of the temporal bone, and the tectorial membrane, 
remain intact.
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Figure 5.2. Immunofluorescent images of frozen P14 CD1 mouse cochlea 
sections.
(A-C) Double staining for F-actin and harmonin in the organ of corti. Rhodamine- 
phalloidin staining of stereocilia bundles on cochlear hair cells (A, red channel). 
Staining for harmonin in cochlea using rabbit polyclonal anti-USH1C antiserum 
(Kobayashi, et al., 1999) (B, green channel). Double staining for harmonin and F-actin 
overlayed with Hoerscht nuclei stain for orientation purposes (C). (D-F)Negative 
control showing a cochlea section double stained for F-actin and background FITC 
staining. Rhodamine-phalloidin staining of stereocilia bundles on cochlear hair cells (D, 
red channel). Background staining shown using PBS alone in place of the primary anti- 
USH1C antibody (E, green channel). F-actin staining overlayed with background FITC 
staining and the Hoerscht nuclei stain for orientation purposes (F).
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5.3.2. Immunocytochemistry of human gut epithelial cell lines
To ascertain the intracellular localization of harmonin, two human colon 
adenocarcinoma epithelial cell lines, Caco-2 and HT29, were studied. 
Harmonin expression has already been detected in the postnatal small intestine 
(Bitner-Glindzicz, et al., 2000; Scanlan, et al., 1999), but expression of USH1C 
mRIMA in these cell lines was first established by RT-PCR. The presence of 
harmonin protein was confirmed by immunoblotting and the intracellular 
localization of harmonin was studied using immunocytochemistry.
5.3.2.1. Detection ofUSHIC mRNA
Fig. 5.3A shows that USH1C mRNA can be detected in HT29 and Caco-2 cell 
lines using gene-specific oligonucleotides. The presence of PDZ-37 was also 
confirmed using the isoform-specific oligonucleotides designed previously (as 
described in section 4.3.2.3.) (Fig. 5.3B). Amplification of the house-keeping 
gene, HPRT, is shown for comparison (Fig. 5.3C).
Figure 5.3. Amplification of 
USH1C from cDNA extracted 
from HT29 and Caco-2 human gut 
epithelial cell lines.
(A) USH1C gene-specific PCR using a 
forward primer in exon 13 with a 
reverse primer in exon 17 (Appendix A, 
Table A.3), (B) PDZ-37 isoform-specific 
PCR (Appendix A, Table A.3) and (C) 
HPRT PCR.
A) USH1C
B) PDZ-37
C) HPRT
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5.3.2.2. Detection of harmonin protein
To confirm that harmonin is expressed at the protein level as well as at the 
RNA level, protein extracts were prepared from both HT29 and Caco-2 cell 
lines and analysed on immunoblots. Figure 5.4 shows that harmonin was 
detected in both cell lines, when a mouse monoclonal anti-harmonin antibody 
(Scanlan, et a!., 1999) was used to develop the immunoblot. The monoclonal 
anti-harmonin antibody is specific for in v/fro-translated harmonin (see chapter 
6, section 6.3.1.), which is included on the immunoblot as a positive control 
(Fig. 5.4, lane 1). To detect alternative isoforms of harmonin that may be 
expressed in these cells, a second immunoblot of both cell extracts was 
developed using the rabbit polyclonal anti-harmonin antisera (Kobayashi, etal., 
1999) (Fig. 5.5B). The polyclonal anti-harmonin antiserum also specifically 
identifies in wfro-translated harmonin (Fig. 5.5A).
The major harmonin isoform a1 was identified on both immunoblots. However, 
there was also evidence of a larger isoform, at -130 kDa, in the protein 
extracted from Caco-2 cells (Fig. 5.4, green arrow), which may represent the 
longer b isoforms of harmonin. This would agree with the RT-PCR results, 
which showed that the alternative exons are also expressed in human foetal- 
gut tissue (Figs 4.7 and 4.8). Furthermore, when a blot was developed using 
the polyclonal anti-harmonin antisera, a similiar band was evident at -130 kDa 
(Fig. 5.5, green arrow), as well as a smaller band, at -4 0  kDa, which may 
correspond to the 5’ truncated PDZ-37 isoform (Fig. 5.5, red arrow).
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Figure 5.4. Immunoblot of HT29 and Caco-2 protein extracts developed 
with mouse monoclonal anti-harmonin antibody.
Protein extracts from the human embryonic kidney cell line, HEK293, and the human 
gut epithelial cell lines HT29 and Caco-2 were compared to in wfro-translated 
harmonin. Endogenous harmonin at -75 kDa is indicated by the red arrow. The green 
arrow indicates a possible larger isoform of harmonin. Size in kiloDaltons is indicated 
on the left.
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Figure 5.5. Immunblots of in 
Wtro-translated harmonin, HT29 
and Caco-2 protein extracts deve­
loped with rabbit polyclonal anti- 
harmonin antisera.
(A) In wfro-translated harmonin is 
detected on an immunoblot developed 
with the rabbit polyclonal anti-harmonin 
antisera. (B) Immnuoblot of protein 
extracts from the human gut epithelial 
cell lines HT29 and Caco-2 developed 
using rabbit polyclonal anit-harmonin 
antisera. The main harmonin isoform is 
present at -75 kDa (black arrow), as 
well as a possible larger (green arrow) 
and a smaller (red arrow) alternative 
isoforrrT Size in kiloDaltons is indicated 
on the left.
5.3.2.3. Immunocytochemistry
The rabbit polyclonal anti-harmonin anti-serum (Kobayashi, et al.t 1999) was 
used for intracellular localization of harmonin in the Caco-2 human gut 
epithelial cell line.
Specific staining for harmonin was observed in the cytoplasm of Caco-2 cells, 
not in the nucleus, and appeared to be sub-membranous (Fig. 5.6A). The two 
controls, in which PBS (Fig. 5.6B) and rabbit serum (Fig. 5.6C) were used in 
place of the primary anti-harmonin antisera, were negative, confirming that 
staining was specific for harmonin.
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Figure 5.6. Immunolocalization of harmonin in Caco-2, human gut 
epithelial cells.
(A) Harmonin was detected in human gut epithelial cells using a 1 in 50 dilution of 
rabbit anti-USH1C antiserum (Kobayashi, et al., 1999). Negative controls confirmed 
the staining was due to the presence of harmonin in the cells and not background 
staining of the secondary anti-rabbit-FITC IgG conjugate (B), or a non-specific reaction 
to an antigen in the rabbit serum (C).
5.3.3. Summary of results
Harmonin could not be detected in frozen mouse cochlea sections using the 
rabbit polyclonal anti-harmonin anti-serum (Kobayashi, et al., 1999) (Fig. 5.2).
The human gut epithelial cell lines HT29 and Caco-2 have been shown, by RT- 
PCR, to express USH1C mRNA (Fig. 5.3A) and, more specifically, the mRNA 
transcript for the shorter PDZ-37 isoform was also detected (Fig. 5.3B). The 
protein extracts from both cell lines were then shown, on immunoblot, to 
contain the major isoform of harmonin at approximately 75 kDa (Figs 5.4 and
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5.5B). Immunoblots of the protein extracts developed using the polyclonal anti- 
harmonin anti-serum, showed evidence that these cell lines may also express 
other isoforms of harmonin, in particular the shorter PDZ-37 isoform (Fig. 5.5B).
Immunocytochemistry on Caco-2 cells confirmed a cytoplasmic, sub- 
membraneous, intracellular localization for harmonin.
5.4. Discussion
5.4.1. Harmonin localization in mouse inner-ear sections
The aim of this part of the study was to analyse the localization of harmonin 
within mouse inner-ear sections, with the purpose of understanding when and 
where harmonin is required for its function. However, in our hands, the 
polyclonal anti-harmonin antibody (Kobayashi, et al., 1999) used was not very 
effective at identifying harmonin in the mouse cochlear sections, even at a 
dilution of 1 in 50 (Fig. 5.2) and there was not enough of the antibody available 
to us to utilize it at a greater concentration. There are a number of explanations 
for the inability of this antibody to identify harmonin in these inner ear sections: 
1) the protein is not present, 2) the structures where the protein is localized 
have not been adequately preserved during the processing of the sections or 3) 
the epitopes required for recognition by the antibody are not available.
Phase-contrast imaging of mouse cochlear sections prior to staining (Fig. 5.1) 
verified that the structure of the cochlea, in particular the organ of Corti, had 
been sufficiently preserved during processing. The actin-rich stereocilia were
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readily identified by a Rhodamine-Phalloidin conjugate in these sections (Fig. 
5.2A and D), confirming that the hair cells were not lost during processing.
Other groups have successfully used the rabbit polyclonal anti-harmonin 
antibody, used in this study, to identify harmonin on frozen tissue sections. 
Kobayashi, et al., fixed the tissues in a periodate/lysine/paraformaldehyde 
solution for 6-12 h (Kobayashi, et al., 1999) and Verpy, et al., and more 
recently Boeda, et al., fixed mouse cochlear in 4% paraformaldehyde for only 
2 -5  h (Boeda, et al., 2002; Verpy, et al., 2000). In this study, mouse cochleae 
were fixed in 4% paraformaldehyde for 24 h. Therefore, it is possible that the 
appropriate harmonin antigens required by the antibody have become masked 
in the inner-ear sections used in this study during the extended fixation 
process. Formalin fixation is known to induce such antigen masking due to the 
cross-linking of protein amino acid residues..............................................................
There are a number of methods that may be employed to ‘unmask’ antigenic 
sites, including the use of chemicals, enzymatic pre-digestion using proteolytic 
enzymes or heat-mediated retrieval methods. Verpy, et al., incubated sections 
with 50 mM NH4CI prior to staining, which may have aided in unmasking 
harmonin antigens (Verpy, etal., 2000). However, this polyclonal anti-harmonin 
antibody has also been successfully employed recently to localize harmonin in 
unfixed rat and mice retina sections (Reiners, etal., 2003).
During the course of this study, a similar study, investigating the expression of 
harmonin in mouse inner-ear sections, was published (Boeda, et al., 2002). 
Using an antibody raised specifically to the b isoform, Boeda, et al. reported
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that expression of harmonin b could be detected in the mouse cochlea as early 
as embryonic day 15, where it is restricted to the stereocilia, but delineates its 
entire length. At PO, however, harmonin b was found to be concentrated at the 
apex of the maturing stereocilia, while from P30 onwards this isoform of 
harmonin was found to be completely absent from the mouse cochlea. In 
contrast, the rabbit polyclonal anti-harmonin antibody (Kobayashi, et al., 1999), 
able to recognize all three harmonin isoform classes (a, b and c), showed 
protein expression in both the cuticular plate and along the stereocilia during 
embryonic and postnatal life of the mouse.
In this study, the same ‘pan-harmonin’ antibody, which was raised against the 
major harmonin isoform a1 and will detect all harmonin isoforms 
simultaneously, was used. Therefore, it would not have been possible to make 
any distinctions between the fates of the different isoforms. In particular, it 
would not have been possible to detect the disappearance of harmonin b, the 
longer isoform that is thought to be ear-specific (Verpy, et al., 2000).
Boeda, et al., have also demonstrated that harmonin b is absent from the 
stereocilia of the Myo7a4626SS shaker-1 mice, the mouse model for Usher type 
1B (Boeda, et al., 2002). In these mice, harmonin b was located around the 
periphery of the cuticular plate, while harmonin a and c were found to be 
present in the stereocilia and distributed as in wild type mice. Consequently, 
Boeda, et al. suggested that myosin VIIA is involved in the transport of 
harmonin b up to the tip region of the stereocilia, and went on to show that 
myosin VIIA interacts with harmonin (Boeda, etal., 2002).
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In a study on the inner ears of waltzer mice, the mouse model for Usher type 
1D, it was demonstrated that cadherin 23 is not required for the expression and 
localization of myosin VIIA in PO hair cells (Holme and Steel, 2002). However, it 
has been shown that harmonin and cadherin 23 interact directly (Boeda, et al., 
2002; Siemens, et al., 2002) and, hence, it may be hypothesized that the 
expression and/or localization of harmonin might differ in the inner ears of 
waltzer mice when compared to wild type mice.
5.4.2. Human gut epithelial cells
5.4.2.1. Expression of USH1C
Caco-2 and HT29 human gut epithelial cell lines both express USH1C mRNA 
(Fig. 5.3) and the harmonin protein (Figs 5.4 and 5.5B). Furthermore, PDZ-37 
mRNA was detected in both cell lines and a product that may represent the 
truncated PDZ-37 protein was seen on immunoblot of both cell extracts 
(Fig. 5.5B).
Intriguingly, the endogenous harmonin protein extracted from the cell lines, 
appears to be of a slightly higher molecular weight when compared to the in 
w'fro-translated USH 1C (Figs 5.4 and 5.5). The reasons for this are not clear, 
but it may reflect a difference in processing of the native protein in vivo. For 
example, harmonin may undergo some form of post-translation modification, 
such as phosphorylation. When the prosite database of protein families and 
domains was searched using the harmonin isoform a1 amino acid sequence 
(http://ca.expasv.org/prosite/), fourteen potential phosphorylation sites were 
predicted (Appendix E). Possible post-translational modifications may be
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investigated by treating the protein with the appropriate enzymes prior to 
immunoblotting.
When an immunoblot of the cell extract from HT29 and Caco-2 cells was 
processed using the monoclonal anti-harmonin antibody, expression of the 
major harmonin isoform a1 (Fig. 5.4) was detected, at around 75 kDa, in both 
cell lines. However, when an immunoblot of HT29 and Caco-2 cell extracts was 
processed using the polyclonal anti-harmonin antibody there appeared to be 
additional bands present, which may indicate that these cell lines express 
alternative isoforms of harmonin (Fig. 5.5B). In particular, there appeared to be 
a larger product, at approximately 130 kDa in size, present in the Caco-2 
lysate, which could represent the b isoforms of harmonin, with the additional 
alternative exons A -F  and G/G’ (Fig. 5.5B, green arrow). This would agree with 
the RT-PCR data obtained in Chapter 4, where primers located in the 
alternative exons found in the b isoforms showed amplification in human foetal- 
gut tissues (Figs 4.6 and 4.7) and is more evidence that the b isoforms are not 
‘ear-specific’. Of even greater interest, though, was the presence of a band just 
above the 37 kDa mark, which could indicate expression of the PDZ-37 isoform 
by both of these gut cell lines (Fig. 5.5, red arrow). This would correlate with the 
detection of a mRNA transcript in these cell lines, thought to represent the 
PDZ-37 isoform (Fig. 5.3B).
5.4.2.2. Intra-cellular localization of harmonin
The polyclonal anti-harmonin antibody was used on the Caco-2 human gut 
epithelial cell line to demonstrate that, in these cells, harmonin is localized to 
the cytoplasm of these cells and not the nucleus (Fig. 5.6). Furthermore,
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harmonin appears to have a sub-membranous localization, as would be 
hypothesized for a PDZ domain-containing protein. PDZ proteins frequently act 
as scaffolding molecules, holding together components of multimolecular 
complexes situated at the plasma membrane (reviewed by Fanning and 
Anderson, 1999).
5.4.2.3. Possible role for harmonin in gut epithelial cells 
Harmonin was originally described as a gut-associated protein and there is 
strong positive staining for harmonin in normal post-natal human gut tissue 
(Bitner-Glindzicz, et al., 2000; Kobayashi, et al., 1999). Furthermore, 
immunohistochemistry of gut biopsy from children affected by the contiguous 
gene deletion of USH1C confirmed the absence of harmonin expression, in 
addition to an inflammatory enteropathy (Bitner-Glindzicz, et al., 2000). The 
existence of the 5’ truncated PDZ-37 isoform of harmonin in Usher patients 
might explain their lack of a similar gut phenotype.
It has been confirmed here that PDZ-37 exists as mRNA (Fig. 5.3B) and 
preliminary evidence for its translation in gut cell lines has been provided 
(Fig. 5.5B). It has also been shown here that harmonin does have a 
cytoplasmic localization (Fig. 5.6A) close to the cell membrane, where most 
PDZ proteins identified to date are found to carry out their functions. However, 
the third PDZ domain of harmonin, the only one found in PDZ-37, currently has 
no known protein ligands. Therefore, it is only possible at this stage to 
speculate on the possible function of this isoform of harmonin in the gut, should 
it turn out to be of any physiological relevance.
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In Crohn’s disease, a distinct type of inflammatory enteropathy, there is 
evidence to suggest that barrier dysfunction is an early event in mucosal 
inflammation and that this may be a disorder of the tight junctions (Hollander, 
1988). Here, the tight junctions in non-inflamed ileum have been reported to be 
more reactive to a luminal stimulus, and this is thought to contribute to the 
development of mucosal inflammation (Soderholm, et al., 2002). Could the 
mechanism of inflammatory enteropathy be similar in the USH1C deletion 
patients?
Tight junctions are the most apical of several lateral cell-cell contacts (see 
section 1.2.2.). They form a circumferential seal around epithelial cells that 
maintains cell polarity by separating the apical from the basolateral plasma 
membrane. Furthermore, tight junctions are able to regulate the passage of 
ions and molecules, between extracellular compartments, through the 
paracellular pathway (reviewed by Tsukita, et al., 2001). The tight junction is 
composed of at least three transmembrane proteins: occludin, junction- 
adhesion molecule (JAM) and claudins (a family of -2 0  proteins) as well as 
intracelluar tight junction-associated proteins, located at the submembranous 
region of the junction. The intracellular proteins act as linkers between the 
proteins of the tight junction strands and the actin-based cytoskeleton and 
stabilize the cell-cell junction (the work of others has shown that isoforms of 
harmonin can link directly and indirectly to the actin cytoskeleton (Boeda, etal.,
2002)).
Many of the tight junction-associated linker proteins that have been identified 
are PDZ domain-containing proteins: ZO-1, ZO-2, ZO-3, PAR3, PAR6 and the
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multi-PDZ domain protein MUPP1 (reviewed by Gonzalez-Mariscal, et al.,
2003). Thus it may be that PDZ-37 is also a component of tight junctions in the 
gut, and when absent, the permeability of the mucosal barrier may be altered, 
such that non-specific inflammatory responses occur.
A number of proteins were found to share a degree of homology with the third 
PDZ domain of harmonin when a BLAST search was performed (URL: 
http://www.ncbi.nih.gov/BLAST/). Some of these have been demonstrated to 
have a role in tight junctions, for example, PATJ and MUPP1. PATJ (protein 
associated to tight junctions) contains ten PDZ domains and has been shown 
to localize to tight junctions in human epithelial cells (Lemmers, et al., 2002), 
and MUPP1, a possible paralogue of PATJ, is exclusively concentrated at tight 
junctions, where it has been shown to interact with claudins and JAM 
(Hamazaki, et al., 2002)...............................................................................................
If the 5’ truncated isoform of harmonin, PDZ-37, is found to be an important 
component of the tight junctions in gut epithelial cells then, only a deletion of 
the entire gene, as seen in the contiguous gene deletion patients, or perhaps a 
null mutation occuring 3’ of exon 12, in the constitutive exons, would be 
expected to lead to an enteropathy phenotype. To date, no such mutations 3’ of 
exon 12 in USH1C have been identified, while all the mutations found in Usher 
type 1C patients occur 5’ of exon 12.
As a next step, it would be important to establish whether harmonin, particularly 
PDZ-37, is localized to the tight junctions in the Caco-2 cell line by growing the 
cells to confluence (such that tight junctions may be formed) and double
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staining with an antibody against a tight junction marker, such as ZO-1. 
Furthermore, co-immunoprecipitation experiments may be performed on the 
lysate from these cells to investigate candidate tight junction-associated 
proteins that might interact with harmonin.
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6. Harmonin Interactions
6.1. Introduction
At the start of this study little was known about the function of harmonin, the 
protein mutated in Usher syndrome type 1C. However, since it is a PDZ 
domain-containing protein it may be hypothesized to have some sort of 
scaffolding role upon which other proteins bind to perform a specific function 
within both the hair cell of the inner ear and the photoreceptors of the eye. 
Alternatively, harmonin may have a role targetting other proteins to their correct 
localization within these two cell types, such that they are able to perform their 
function. Identification of proteins that interact with harmonin will provide clues 
to the role of harmonin in the inner ear and eye.
Obvious candidates for proteins that may bind to harmonin are the other Usher 
type 1 proteins, including: myosin VIIA, cadherin 23, protocadherin 15 and 
sans. Cadherin 23, protocadherin 15 and sans have been identified during the 
course of this study (Ahmed, et al., 2001; Bolz, et al., 2001; Weil, et al., 2003). 
Mutations in all five Usher type 1 proteins result in the same phenotype of 
sensorineural hearing loss with retinitis pigmentosa, suggesting that they could 
be involved in the same pathway, and all are expressed in the hair cells of the 
cochlea. The respective mouse models are all phenotypically similar, and have 
disorganized stereocilia bundles on the hair cells of the inner ear (Alagramam, 
et al., 2001a; Di Palma, et al., 2001; Kikkawa, et al., 2003; Self, et al., 1998). 
Therefore, it is possible that these proteins are all part of the same
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macromolecular complex within the stereocilia, with an important role in 
maintaining the structure and/or function of these hair cell projections.
Cadherin 23 and protocadherin 15 belong to a superfamily of adhesion 
molecules that mediate Ca2+-dependent homophilic cell-cell adhesion (calcium- 
dependent adherent protejn) in all solid tissues of the body (reviewed by Nollet, 
et al., 2000). The majority of the cadherin superfamily are transmembrane 
glycoproteins that pass the membrane only once, such that the N-terminal is 
located outside the cell, while the C-terminal is located inside (Fig. 6.1).
The extracellular portion of the molecule consists of a varying number of 
cadherin domains (designated EC, ectodomains) that are highly homologous to 
each other. It is these ectodomains that confer specific calcium-dependent 
homophilic binding between parallel dimers of cadherin molecules on adjacent 
cells (reviewed by Patel, et al., 2003). Cadherin 23 and protocadherin 15 
contain twenty-seven and eleven cadherin ectodomains, respectively. 
Following the single transmembrane domain is the intracellular C-terminal 
domain that, in classical cadherins, is usually found to associate with p-catenin, 
which serves as a linker to a-catenin that, in turn, is thought to interact directly 
with the actin cytoskeleton of the cell (Fig. 6.1). It has become clear that the 
interactions mediated by the cytoplasmic tail of cadherin molecules are 
important in strengthening the adhesive-binding activity of the cadherin 
ectodomain (reviewed by Ivanov, et al., 2001; Yap, et al., 1997). Interestingly, 
the cytoplasmic domain of cadherin-23 does not contain any known protein 
motifs and in particular it does not have a p-catenin binding site (Di Palma, et
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al., 2001), so it may represent a new class of cadherin-like proteins with novel 
interacting protein partners.
The protocadherins represent the largest subfamily within the cadherin 
superfamily (reviewed by Nollet, et al., 2000). Protocadherins can also mediate 
homophilic adhesion, although it is weaker than that seen for the classical 
cadherins. Furthermore, the cytoplasmic domains of the classical cadherins are 
well conserved, but the cytoplasmic domains of protocadherins are highly 
variable and many of the cytoplasmic interacting partners have yet to be 
identified.
Sans, the protein product of the USH1G gene, SANS, represents the most 
recently identified Usher type 1 protein (Kikkawa, et al., 2003; Weil, et al.,
2003). Sans is a scaffold protein containing three ankyrin repeats at its N-
cadherin^
Figure 6.1. Schematic of a 
classical cadherin molecule and
how it may link to the actin 
cytoskeleton via catenins. (Prom 
Yap, etal., 1997).
(5-catemrv
u-catenin
actin
The extracellular N-terminal cadherin 
repeats (EC) confer calcium-dependent 
homophilic binding between parallel 
dimers of cadherin molecules on 
adjacent cells, while the intracellular C- 
terminus stabilizes this binding by 
linking the cadherin molecule to the 
actin cytoskeleton via the a- and p- 
catenin proteins.
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terminus and a C-terminal SAM (sterile alpha motif) domain. Ankyrin repeats 
are tandem repeats of approximately thirty-three amino acid residues, that are 
involved in protein-protein interactions with diverse, unrelated proteins. SAM 
domains are modules of around seventy amino acids that have been shown to 
mediate homo- and hetero-dimerization.
During the course of this study, the Usher type 1 proteins cadherin 23, myosin 
VIIA and sans were all shown to interact with harmonin (Boeda, et al., 2002; 
Siemens, et al., 2002; Weil, etal., 2003). As the C-terminus of protocadherin 15 
possesses a PDZ-domain-binding interface (PBI) and it currently has no known 
protein interacting partners, it is also a good candidate for interacting with 
harmonin.
The possibility of an interaction between the C-terminus PBI of protocadherin 
15 and harmonin was investigated using an in vitro GST pull-down assay. As a 
positive control for this assay the C-terminus of a novel protein, MCC2, a 
homologue of MCC tumour suppressor, which is mutated in colon cancer, was 
used. MCC2 was recently identified as a harmonin interacting protein in a yeast 
two-hybrid screen that used the full-length harmonin isoform a1 as bait 
(Ishikawa, etai., 2001).
6.2. Methods in Brief
6.2.1. In wfro-translation of USH1C
A full-length clone of USH1C isoform a1 cDNA was donated by Dr Matthew 
Scanlan at the Ludwig Institute for Cancer Research in New York. To translate
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the USH1C cDNA into protein in vitro, USH1C cDNA was first subcloned into 
the pZErO™-2 vector, as described in section 2.2.7. USH1C was then 
trancribed and translated from the Sp6 promoter using the TNTR Quick 
Coupled Transcription/Translation system as outlined in section 2.2.11.1. 
Protein translation was confirmed using the Transcend™ Non-radioactive 
Translation Detection System (section 2.2.11.2.) as well as a monoclonal anti- 
harmonin antibody on immunoblot (section 2.2.10.5.).
To investigate possible post-translation modifications of in wfro-translated 
harmonin, it was treated with a phosphatase enzyme, calf intestinal alkaline 
phosphatase, CIP, (section 2.2.10.7.).
6.2.2. GST-fusion proteins
C-terminal cDNA fragments of protocadherin 15 (candidate harmonin 
interacting protein) and MCC2 (positive control for GST pull-down assay) were 
cloned in-frame of a GST moiety in the pGEX-4T-1 vector, as described in 
section 2.2.7. GST-fusion proteins were then expressed in BL21 E. coli cells 
under appropriate growth conditions using IPTG (Isopropyl-thiogalactosidase) 
to induce expression, as detailed in section 2.2.11.3. GST-fusion proteins were 
extracted from E. coli cell pellets (section 2.2.11.4.) and the cell lysates were 
applied to pre-equilibrated glutathione Sepharose beads (section 2.2.11.5.). 
The protein-protein interaction assay was then performed as outlined in section 
2.2.11.7. After the final washes the bound proteins were eluted from the beads 
by denaturing in SDS-loading buffer and subject to SDS-PAGE (section 
2.2.10.3.). Proteins were transferred to nitrocellulose membrane (section
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2.2.10.5.) and harmonin was detected using a monoclonal anti-harmonin 
antibody (section 2.2.10.6.).
6.3. Results
6.3.1. In vitro transcription and translation of USH1C
Biotinylated in i/rtro-translated USH1C was detected on immunoblot using a 
streptavidin-alkaline phosphatase (AP) conjugate (Fig. 6.2A, lane 1) and no 
protein was detected when DNA was excluded from the in wfro-translation 
reaction (Fig. 6.2A, lane 2).
A non-biotinylated protein product of ~75 kDa was also detected on 
immunoblot, when a mouse monoclonal anti-harmonin antibody, raised to the 
full-length human harmonin a1 isoform (Scanlan, et a/., 1999), was used 
(Fig. 6.2B, lane 2), confirming that the translated protein was harmonin.
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Figure 6.2. Detection of in wtro-translated harmonin.
(A) Colorimetric detection of harmonin in vitro-translated with the incorporation of biotino
groups. A protein product of the expected size (~75 kDa) was detected on immunoblot 
when incubated with a streptavidin-AP conjugate and developed with a substrate for 
alkaline phosphatase (lane 1). No protein was detected when DNA was excluded from 
the in vitro-translation reaction (lane 2). (B) Immuno-detection of in wfro-translated 
harmonin. A protein of ~75 kDa was detectable on immunoblot developed using a 
mouse monoclonal anti-harmonin antibody (lane 2). No protein was detected when the 
DNA template was excluded from the in wfro-translation reaction (lane 1). Size in 
kiloDaltons is indicated on the left.
6.3.1.1. De-phosphorylation of harmonin
Harmonin was detected as three bands on immunoblots and not as a single 
band. In w'fro-translated harmonin treated with calf intestinal alkaline 
phosphatase (CIP) appeared more diffuse on immunoblot (Fig. 6.3, lane 2) 
when compared to untreated protein (Fig. 6.3, lane 3). However, there was no 
positive control for this experiment and it is not known if the enzyme was active. 
The reaction was repeated three times, each with similar, inconclusive results. 
Therefore, it is not known if the extra bands seen on immunoblot are due to 
alternatively phosphorylated species of the in w'fro-translated harmonin.
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atase, CIP.
In vitro-translated harmonin treated 
with CIP (lane 2) was compared with 
untreated harmonin (lane 3). Lane 1 
shows the negative control for the in 
vitro-translation reaction. Size in
kiloDaltons is indicated on the left.
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6.3.2. Candidate protein expression
The C-terminal 573 bp, including the PDZ-binding interface (PBI), of 
protocadherin 15, (Fig. 6.4), was cloned in-frame with a Glutathione S- 
transferase (GST) moiety in the pGEX-4T-1 vector and sequenced. Induction of 
protein expression in E. coli cells, would then result in expression of the 
protocadherin 15 fragment with a GST tag attached to its N-terminus. As a 
positive control for the GST pull-down assay, the last 500 bp of cDNA coding 
for the novel protein MCC2 was also cloned in-frame with GST in the pGEX-4T- 
1 vector. The C-terminus of MCC2 contains a PBI shown previously to bind to 
harmonin in a similar assay (Ishikawa, et al., 2001).
Figure 6.4. Schematic illustration of protocadherin 15 domain structure.
Eleven extracellular cadherin ectodomains at the N-terminus and a C-terminal 
cytoplasmic domain. The fragment of PCDH15 cDNA cloned into the GST vector, 
pGEX-4T-1, is indicated in red. TM, transmembrane; PBI, PDZ-binding interface.
Cadherin ectodomains TTVI
NH
Cytoplasmic domain PBI
|  COOH
C lo n e d  for 
G S T -fo s io n  protein
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Protein expression in E. coli was optimized by inducing at different 
temperatures, with different concentrations of IPTG and for different periods of 
time (Figs 6.5 to 6.10). As a negative control for the assay, the GST moiety was 
expressed from the wild type vector (Fig. 6.7).
Initial experiments, inducing expression of GST-fusion proteins at 37°C with 
1 mM IPTG for 5 h, revealed that GST-PCDH15 was a much less stable protein 
than GST-MCC2. GST-MCC2 expression was optimal by 2 h post-induction 
and stable up to 5 h post-induction (Fig. 6.5, arrow). GST-PCDH15 expression 
was also optimal at 2 h post-induction, but the protein then appeared to rapidly 
decay after this time point (Fig. 6.6, arrow).
Wild type GST was over-expressed using 1 mM IPTG at 37°C and the protein 
remained stable up to 4 h post-induction (Fig. 6.7).
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Figure 6.5. SDS-PAGE gel of 
GST-MCC2 protein expression 
over 5 h.
GST-MCC2 protein expression was 
induced in BL21 E. coli by the addition 
of 1 mM IPTG. Samples were taken 
prior to addition of IPTG (Oh) and at 
every hour post induction for a total of 
5 h. The 44.5 kDa GST-MCC2 fusion 
protein, not present pre-induction, is 
indicated by a red arrow. GST-MCC2 
expression is maximal by 2 h post 
induction and is stable up to 5 h after 
induction. Size, in kiloDaltons, is 
indicated on the left. Time, in hours 
post-induction, is indicated along the 
top of the gel.
Figure 6.6. SDS-PAGE gel of 
GST-PCDH15 protein expression 
over 5 h.
GST-PCDH15 protein expression 
induced in BL21 E. coli by 1 mM IPTG. 
Samples were taken prior to addition of 
IPTG (Oh) and at every hour post­
induction up to 5 h. The 47.5 kDa GST- 
PCDH15 fusion protein, not present 
pre-induction, is indicated by the red 
arrow. GST-PCDH15 expression is 
maximal by 2 h post induction, but 
begins to degrade 3 h post-induction. 
Size, in kilo-Daltons, is indicated on the 
left. Time, in hours post induction, is 
indicated along the top of the gel.
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Figure 6.7. SDS-PAGE gel of GST 
protein expression over 4 h.
Wild type GST protein expression 
induced from the pGEX-4T-1 vector in 
BL21 E. coli by 1 mM IPTG. Samples 
were taken prior to addition of IPTG 
(Oh) and at every hour post-induction 
up to 4 h. The -25 kDa protein, not 
present pre-induction, is indicated by 
the red arrow. GST protein is over­
expressed by 1 h post-induction and 
expression is maximal by 2 h and 
stable up to 4 h after induction. Size, in 
kiloDaltons, is indicated on the left. 
Time, in hours post induction, is 
indicated along the top of the gel.
Expression of the GST-fusion proteins in E. coli incubated at different 
temperatures revealed that greater quantities of GST-PCDH15 could be 
obtained by incubating at 30°C for 3 h (Fig. 6.9, red asterisk). Expression of 
GST-MCC2 was still maximal when incubated at 37°C for 2 h (Fig. 6.8, red 
asterisk).
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Figure 6.8. SDS-PAGE gel of GST-MCC2 protein 
expression at different temperatures.
GST-MCC2 protein expression was induced in BL21 E. coli at three 
temperatures (28°C, 30°C and 37°C) by the addition of 1 mM IPTG. 
Samples were taken prior to addition of IPTG (Oh) and at every hour 
post induction, up to 3 h. The red asterisk indicates the sample with 
the most efficient production of the 44.5 kDa fusion protein. Size, in 
kiloDaltons, is indicated on the left. Time, in hours post induction, is 
indicated along the top of the gel.
Figure 6.9. SDS-PAGE gel of GST-PCDH15 protein 
expression at different temperatures.
GST-PCDH15 protein expression was induced in BL21 E. coli at 
three temperatures (28°C, 30°C and 37°C) by the addition of 1 mM 
IPTG. Samples were taken prior to addition of IPTG (Oh) and at every 
hour post induction up to 3 h. The red asterisk indicates the sample 
with the most efficient production of the 47.5 kDa fusion protein. Size, 
in kiloDaltons, is indicated on the left. Time, in hours post induction, 
is indicated along the top of the gel.
When the total concentration of IPTG used for inducing protein expression was 
reduced from 1 mM to 0.1 mM, a further increase in the expression of both 
GST-fusion proteins was observed (Fig. 6.10, asterisks).
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Figure 6.10. SDS-PAGE gel of GST-MCC2 and GST-PCDH15 protein 
expression at different IPTG concentrations.
GST-PCDH15 and GST-MCC2 protein expression were induced in BL21 E. coli, at 
30°C and 37°C, respectively, by the addition of either 1 mM or 0.1 mM IPTG. Samples 
were taken prior to addition of IPTG (Oh) and at every hour post induction up to 2 or 
3 h. The asterisk indicates the sample, in each case, with the most efficient production 
of fusion protein. The expression of both GST-MCC2 and GST-PCDH15 was induced 
more efficiently with 0.1 mM IPTG. Size, in kiloDaltons, is indicated on the left. Time, in 
hours post induction, is indicated along the bottom of the gel. The final concentration of 
IPTG used is indicated along the top of the gel.
This series of induction experiments revealed that the optimal conditions for 
GST-PCDH15 fusion protein expression are 0.1 mM IPTG for 3 h at 30°C 
(Fig. 6.10, yellow asterisk). Meanwhile, GST-MCC2 expression is optimal with 
0.1 mM IPTG for 2 h at 37°C (Fig. 6.10, red asterisk).
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To confirm that the proteins expressed by the transformed E. coli were the 
correct proteins, the, cell lysates were purified using glutathione Sepharose 
beads (section 2.2.11.6.) and the eluted proteins were run on an SDS-PAGE 
gel.
The results in Fig. 6.11 show that the expected protein bands of 44.5 kDa and 
47.5 kDa for GST-MCC2 and GST-PCDH15 fusion proteins, respectively, are 
still present after purification, indicating that these bands do indeed represent 
the GST proteins (Fig. 6.11B and C, red arrows). Wild type GST, a 25-kDa 
protein, was also present after purification (Fig. 6.11 A, red arrow).
There appears to be an additional protein present in the unpurified cell lysate at 
approximately 40 kDa that is also carried through in the purified GST and GST- 
MCC2 protein samples (Fig. 6.11 A and B, green arrows). It is not known what 
this protein is, but it does not appear to be recognised by the monoclonal anti- 
GST antibody on the immunoblot of purified GST-PCDH15 fusion protein 
(Fig. 6.11C).
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Figure 6.11. Purification of GST-fusion proteins.
BL21 E. coli protein extracts were incubated with glutathione Sepharose beads, the 
beads were then washed and the proteins eluted and run on an SDS-PAGE gel. 
Purified wild type GST (A, lane 2) and GST-MCC2 fusion protein (B, lane 4) were 
visualised directly by staining the SDS-PAGE gel with Coomassie Brilliant blue dye 
and comparing with unpurified samples of cell lysate (lanes 1 and 3, respectively). 
Purified GST-PCDH15 fusion protein (C, lane 6) was visualized by transferring the 
proteins to nitrocellulose membrane, probing with a monoclonal anti-GST antibody and 
comparing to a sample of unpurified cell lysate (lane 5). A red arrow in each case 
indicates the purified protein products. Green arrows indicate an unidentified protein in 
purified samples. Size, in kiloDaltons, is indicated on the left of each panel.
6.3.3. In vitro binding assay
GST-PCDH15 fusion protein was bound to glutathione Sepharose beads and 
the conjugated beads were then incubated with in wfro-translated harmonin. 
After washing, any protein complexes that remained bound were eluted from 
the beads and run on an immunoblot. Bound harmonin was detected using the 
mouse monoclonal anti-harmonin antibody (Scanlan, etal., 1999). As a positive
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control, GST-MCC2 was bound to the glutathione Sepharose beads in place of 
GST-PCDH15, whilst, as a negative control, wild type GST was used.
This assay was repeated three times and each time harmonin showed binding 
to the positive control, GST-MCC2, confirming that the assay was effective 
(Fig. 6.12, lane 2). Harmonin did not show binding to the C-terminal 191 amino 
acids of protocadherin 15 fused to GST, GST-PCDH15 (Fig. 6.12, lane 3). 
When wild type GST protein was applied to the glutathione Sepharose beads, it 
appeared to be able to pull-down a small amount of harmonin 
(Fig. 6.12, lane 4). It is not known why this should occur, especially as it was 
not seen previously (Ishikawa, et al., 2001). However, harmonin shows no 
binding at all in the mock pull-down experiment, where harmonin was added to 
the glutathione Sepharose beads in the absence of any other protein (Fig. 6.12, 
lane 5). Therefore, it may be concluded that harmonin does not interact with the 
C-terminal 191 amino acids of protocadherin 15.
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Figure 6.12. GST pull-down assay of harmonin a1 isoform with the 
C-terminus of protocadherin 15.
Monoclonal anti-harmonin antibody was used to detect harmonin, on immunoblot, in 
samples eluted from glutathione Sepharose beads after the GST pull-down assay was 
performed. In wfro-translated harmonin is shown in lane 1 as a reference. GST-MCC2, 
applied to the glutathione Sepharose beads as a positive control, was successful at 
pulling down in w'fro-translated harmonin (lane 2). However, the candidate protein, 
GST-PCDH15, was unable to pull down harmonin (lane 3). Lanes 4 and 5 are negative 
controls where either unmodified GST protein or buffer alone has been applied to the 
glutathione Sepharose beads, respectively, prior to the addition of in vitro-translated 
harmonin. Red arrow indicates harmonin. Size, in kiloDaltons, is indicated on the left.
6.4. Discussion
6.4.1. In wfro-translated harmonin
USH1C was in vitro-translated successfully. However, it is not known why the 
in wfro-translated harmonin appears as three bands on immunoblot. When in 
wfro-translated harmonin was treated with CIP (Fig. 6.3) to ascertain if
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phosphorylation might be responsible for the extra bands, the results were 
inconclusive.
When an immunoblot of extracts from human epithelial cell lines was 
developed using the same monoclonal anti-harmonin antibody, endogenous 
harmonin was not detected as three bands (Fig. 5.4), indicating that the 
presence of three bands may be a consequence of the in vitro-translation 
system.
6.4.2. Expression of GST-fusion proteins
To obtain the best possible yield of GST-fusion proteins for use in the pull-down 
assay, protein expression was induced at different temperatures (28°C, 30°C 
and 37 °C) (Figs 6.8 and 6.9), with two different concentrations of IPTG 
(0.1 mM and 1.0 mM) (Fig. 6.10) and sampled hourly for up to 5 h.
Since it was found that GST-PCDH15 was quite an unstable protein (Fig. 6.6), 
the GST pull-down assay was carried out the next day, immediately after 
protein expression and extraction from E. coli cells had been performed. 
Furthermore, both fusion proteins, GST-MCC2 and GST-PCDH15, were 
purified following the GST pull-down assay and detected on a Coomaisse- 
stained gel or immunoblot (Fig. 6.11B and C), confirming that they had not 
degraded prior to use in the assay.
6.4.3. Interaction of Usher type 1 proteins
PDZ domains are globular protein-protein binding domains consisting of 6 p- 
strands that sandwich two a-helices and are organized in such a way that a
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peptide-binding groove is left exposed between the pB-strand and the aB-helix 
(see Fig. 1.13). In general, PDZ domains interact with the last four to five amino 
acids at the C-terminus of a protein ligand (Doyle, et al., 1996). Furthermore, 
PDZ domains may be classified according to the peptide sequence of their 
binding partners (Songyang, et al., 1997). Therefore, it is possible to 
hypothesize that a candidate protein may bind to a PDZ domain based upon 
the presence of a PDZ-binding consensus sequence at its C-terminus.
During the course of this work, interactions between harmonin and myosin 
VIIA, cadherin 23 and sans were demonstrated by other groups (Fig. 6.13). The 
first PDZ domain of harmonin has been shown to have an affinity for the C- 
terminal MyTH4 + FERM repeat of myosin VIIA (Boeda, et al., 2002) as well as 
for sans (Weil, et al., 2003). The second PDZ domain of harmonin has been 
shown to bind to the C-terminus of cadherin 23 (Boeda, et al., 2002; Siemens, 
et al., 2002).
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Figure 6.13. Schematic representation of the predicted interactions of 
three Usher type 1 proteins in the inner ear. (Adapted from Boeda, et al., 
2002).
The longer harmonin b isoform is thought to interact with the F-actin cytoskeleton via 
its C-terminal portion (Boeda, et al., 2002). The intracellular C-terminus of cadherin 23 
contains a PDZ-binding interface that has been shown to interact with PDZ2 of 
harmonin in the stereocilia (Siemens, et al., 2002). Myosin VIIA is an actin-based 
motor protein that moves along the actin cytoskeleton towards the tip of the stereocilia 
(arrows). PDZ1 of harmonin has been shown to have affinity for the C-terminal MyTH4 
+ FERM repeat of myosin VIIA (Boeda, et al., 2002). EC = cadherin ectodomains, PDZ 
= PDZ domain, CC = coiled-coil domain, PEST = protein degradation domain, FERM = 
FERM domain, MyTH4 = myosin tail homology 4 domain, SH3 = SH3 domain, IQ = 
isoleucine-glutamine motifs.
Protocadherin 15, which like harmonin is expressed in the hair cells of the 
mouse innner ear (Alagramam, et al., 2001b; Verpy, et al., 2000), has a very 
similar consensus sequence at its C-terminus (Ser-Thr-Ser-Leu) to cadherin 23
215
(Ile-Thr-Glu-Leu). However, the GST pull-down experiment performed in this 
study indicates that the C-terminus of protocadherin 15 does not interact with 
harmonin a, the major isoform of harmonin. The in wfro-translated harmonin 
did, however, interact with the C-terminus of MCC2 (Fig 6.12, lane 2), 
indicating that the assay was effective.
There did appear to be some non-specific binding occuring between harmonin 
and wild type GST (Fig. 6.12, lane 4), despite the use of stringent washes. 
However, since harmonin showed no binding at all to GST-PCDH15 (Fig. 6.12, 
lane 3), or in the mock binding experiment (Fig. 6.12, lane 5), the non-specific 
binding to GST would not be expected to affect the results.
Although the C-terminus of protocadherin 15 does not appear to interact 
directly with harmonin a, it cannot be ruled out that harmonin and protocadherin 
15 are still part of the same macromolecular complex. Harmonin and 
protocadherin 15 may interact indirectly, via one or more other proteins. 
Furthermore, it is still possible that the ear-specific harmonin b isoform, which 
includes an extra coiled-coil domain, may interact with protocadherin 15.
PDZ domains do not only interact with consensus sequences located at the C- 
termini of their ligand proteins, some PDZ domains have been shown to bind to 
internal PDZ binding sequences (Cuppen, et al., 1998; Hillier, et al., 1999). 
These interactions are normally possible because the 3-D structure of the 
internal protein sequence forms a p-hairpin “finger” that structurally mimicks the 
classical carboxyl terminus ligand. The cytoplasmic domain of cadherin 23 has
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been shown to bind to the PDZ1 domain of harmonin via an internal PDZ 
binding motif (Siemens, et al., 2002).
Only the last 191 bp of the C-terminus of protocadherin 15 were cloned for use 
in the GST pull-down assay. However, the cytoplasmic domain of 
protocadherin 15 cohtains another 368 bp of DNA, which could contain an 
internal PDZ-binding motif. There are no consensus sequences for internal 
PDZ-binding motifs, but it might be possible to identify potential motifs by 
looking for homology to known internal PDZ-binding motifs.
Interestingly, cadherin 23 and protocadherin 15 have exactly the same amino 
acid residue in two out of the last four residues at their C-terminus (leucine and 
threonine at positions 0 and -2 , respectively). Cadherin 23 interacts with PDZ2 
of harmonin (Boeda, et al., 2002; Siemens, et al., 2002), whilst protocadherin 
15 does not, illustrating just how specific are the ligand-binding properties of 
PDZ domains. PDZ domains seem to lack specificity for recognition of their 
peptide ligands at the -1 position, which, in the case of the peptide ligand for 
PDZ3 of PSD-95, has been shown to point away from the PDZ domain 
interaction surface (Doyle, et al., 1996). Therefore, in this situation, the binding 
specificity of PDZ2 of harmonin may be determined by amino acid residues that 
are more N-terminal in the binding protein, as demonstrated for other PDZ 
domains (Songyang, etal., 1997).
It has been suggested that harmonin b bridges cadherin 23, a transmembrane 
protein involved in cell-cell adhesion via homophilic interaction, to the actin 
cytoskeleton in the developing stereocilium. This anchoring of cadherin 23 is
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thought to strengthen cohesion between the individual stereocilia (Boeda, et al., 
2002). Furthermore, it has also been suggested that the F-actin bundling 
property of harmonin b could stabilize the actin core of stereocilia and further 
contribute to their stiffness (Boeda, et al., 2002).
Cadherin 23 has been observed along the length of the developing stereocilia 
(Boeda, et al., 2002), but recent evidence shows that in mature hair cells 
cadherin 23 is a component of the tip link that forms between adjacent 
stereocilia (Siemens, et al., 2004; Sollner, et al., 2004). Protocadherin 15 is 
also present along the entire length of the stereocilia as soon as they become 
apparent and its presence persists in adult mice (Ahmed, et al., 2003). 
Therefore, it is possible that protocadherin 15 may have a similar role to 
cadherin 23 and forms part of another type of link found between the 
stereocilia, for example, the shaft connectors or top links...............................
Currently, protocadherin 15 is an orphan protein with no known interacting 
protein partners. The ames waltzer mouse has a similar phenotype to the other 
Usher type 1 mouse models with disorganized, splayed stereocilia in the inner 
ear. Hence, prospective binding partners for protocadherin 15 would be 
expected to link the intracellular C-terminus of protocadherin 15 to the actin 
cytoskeleton forming a complex that strengthens the cohesion between mature 
stereocilia in a similar way to cadherin 23 in the developing stereocilia (Boeda, 
et al., 2002). Since the PDZ-binding motif at the C-terminus of protocadherin 15 
does not appear to bind to harmonin, this suggests that another PDZ protein 
may be involved.
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A yeast two-hybrid study, using the 191 bp of the C-terminus of protocadherin 
15 as bait, attempted in our group was unsuccessful as the. protocadherin 15 
fragment used was found to be toxic to the yeast cells. It would be interesting to 
repeat the GST pull-down experiment with the whole of the cytoplasmic domain 
of protocadherin 15, in case there are any internal PDZ binding motifs, or other 
unidentified protein-interaction domains.
Potential candidate binding partners for protocadherin 15 could include the 
proteins defective in mouse models with a similar phenotype to the Usher type 
1 mouse models. For example, in the whirler mouse, the model for non- 
syndromic deafness DFNB31, the defective protein, whirlin, is a novel PDZ 
protein that also contains three PDZ domains (Mburu, et al., 2003). 
Furthermore, the genes responsible for Usher type 1A and 1E have not been 
cloned and are also potential binding partners for protocadherin 15....................
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7. Discussion
Usher syndrome type 1C is a subtype of the deaf blindness condition that was 
originally thought to be confined to the French Acadian population of 
Louisianna. The gene underlying Usher syndrome in the Acadians was mapped 
to chromosome 11 p15 in 1992 (Smith, et al., 1992), but the gene was not 
identified until 2000 (Bitner-Glindzicz, et al., 2000; Verpy, et al., 2000). 
However, since the discovery of the USH1C gene, and during the course of this 
study, a number of mutations have been identified in Usher type 1 patients from 
a variety of populations around the world (Ahmed, et al., 2002; Bitner-Glindzicz, 
et al., 2000; Verpy, et al., 2000; Zwaenepoel, et al., 2001) (Fig. 7.1). 
Furthermore, mutations in USH1C have also been shown to cause non- 
syndromic deafness in the absence of a retinal phenotype (Ahmed, et al., 2002; 
Ouyang, etal., 2002) (Fig. 7.1).
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Figure 7.1. Schematic of USH1C indicating the locations of mutations 
found in Usher type 1C families to date.
The constitutive exons are represented by black rectangles and the alternatively 
spliced exons are represented by pink rectangles, exons numbers are indicated below. 
Mutations found in Usher type 1C patients are indicated in blue type and mutations 
found in patients with non-syndromic deafness, DFNB18, are in green type. Intronic 
mutations are annotated below the gene and coding mutations are above, a, (Bitner- 
Glindzicz, et al., 2000); b, (Verpy, et al., 2000); c, (Zwaenepoel, et al., 2001); d, 
(Ahmed, et al., 2002); e, (Ouyang, etal., 2002).
7.1. Mutations in USH1C
Disappointingly, our mutation analysis did not uncover any new mutations in 
our cohort of Usher type 1 patients, but it did reveal USH1C to be a more 
important contributor to type 1 Usher syndrome than other studies had 
indicated (Astuto, et al., 2000). All of the USH1C mutations identified in Usher 
type 1 patients, to date, are frame-shift or splice-site mutations, which are 
predicted to lead to a truncated protein product. Currently, no missense 
mutations in the USH1C gene have been identified in Usher type 1 patients.
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7.1.1. Usher type 1C alleles
Usher syndrome type 1C is still most prevalant in the Acadian population of 
Louisianna, where a founder effect explains the relatively high frequency of 
Usher syndrome type 1C in this population (Keats, et al., 1994). In other 
populations, the 238-239insC mutation, also identified in this study in a Greek 
Cypriot patient, appears to be presenting as a common mutation, and accounts 
for 50% of the USH1C alleles identified to date (Ahmed, et al., 2002; Bitner- 
Glindzicz, et al., 2000; Ouyang, etal., 2002; Verpy, et al., 2000).
It has been hypothesized that the 238-239insC mutation is also due to a 
founder effect. Individuals from Pakistan and Europe were found to carry the 
238-239insC mutation on the same genetic background (Zwaenepoel, et al., 
2001). However, the nature of the mutation, an insertion of a cytosine in a run 
of six cytosines, is such that it could represent a mutation hotspot, occurring by 
the mechanism of slipped-strand mispairing (Darvasi and Kerem, 1995). This 
led us to investigate the genetic background associated with 238-239insC in 
our Greek-Cypriot patient (Table 3.2).
The genetic background on which 238-239insC occurs in our Greek-Cypriot 
patient differs from that reported previously, due to a recombination event that 
has reduced the shared haplotype to only 7 kb (Table 3.2). Furthermore, we 
found that the haplotype associated with the 238-239insC mutation is not 
particularly rare in either the Greek Cypriot or Pakistani populations (Tables 3.3 
and 3.4). Therefore, 238-239insC is not necessarily due to a founder effect, but 
if it is, it must be quite ancient, since the region shared by all the patients found
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to carry the mutation is now relatively small (7 kb). Interestingly, a recent 
investigation into the ancestry of three populations from northern Pakistan has 
demonstrated that in certain Pakistani populations there is a small Greek 
contribution to the genetic pool. Similar admixture estimates were also obtained 
when the populations were compared with a European population sample that 
excluded the Greeks (Mansoor, et al., 2004). This indicates that there could be 
an ancient genetic relationship between the three populations, Pakistani, 
European and Greek, in which the 238-239insC mutation has been identified.
Regardless of the origin of the 238-239insC mutation, it is the first common 
mutation identified in the five cloned USH1 genes, some of which are 
composed of fifty or more exons. We have, therefore, proposed that a simple 
screening strategy would be to screen Usher type 1 patients for this recurrent 
mutation first.
7.1.2. DFNB18 patients
USH1C mutations in patients with non-syndromic autosomal recessive 
deafness, DFNB18, have now been identified (Ahmed, et al., 2002; Ouyang, et 
al., 2002). However, we have shown here that the DFNB18 locus is not a 
significant contributor to non-syndromic sensorineural hearing loss. From an 
original cohort of 133 Caucasian sib pairs with non-syndromic hearing loss 
(Navarro-Coy, et al., 2001), only sixteen showed concordance for markers 
flanking the DFNB18 locus. In our mutation screen of these sixteen sib pairs, 
no coding or splice-site mutations were identified in USH1C.
It is not always obvious how different mutations within the same gene can give
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rise to either syndromic or a non-syndromic form of hearing loss (Prasad, et a/.,
2004), but a pattern does seem to be emerging for USH1C mutations. 
Mutations at the 5’ end of USH1C that affect splicing and/or introduce a 
premature stop codon are found in patients with Usher syndrome. In contrast, 
DFNB18 patients, with deafness in the absence of retinitis pigmentosa, 
possess hypomorphic alleles of USH1C. The DFNB18 alleles identified, so far, 
either have missense mutations in the alternative exons (Ouyang, et al., 2002), 
or a splice-site mutation that leads to ‘leaky’ splicing, resulting in the production 
of both wild type mRNA and an aberrant mRNA, in which the reading frame is 
shifted (Ahmed, et al. 2002) (Fig. 7.1). This has turned out to be similar to the 
situation found in CDH23 and PCDH15, the genes for Usher syndrome type 1D 
and 1F, respectively. Missense mutations segregate in families with non- 
syndromic forms of deafness, DFNB12 (Bork, et al., 2001) and DFNB23 
(Ahmed, et al., 2002), respectively, whilst truncating nonsense and splice site 
mutations are found in families with Usher type 1D and 1F (Ahmed, et al., 
2001; Alagramam, eta!., 2001b; Bork, et al., 2001).
7.2. Alternative Isoforms of Harmonin
USH1C is an alternatively spliced gene leading to the production of various 
isoforms of harmonin, which can include: 1-3 PDZ domains, one or two coiled- 
coil domains and the presence or absence of a putative protein degradation 
motif (PEST). Both PDZ domains and coiled-coil domains are important 
protein-protein interaction domains. A variety of harmonin isoforms have been 
identified (Scanlan, et al., 1999; Verpy, et al., 2000) and are depicted in 
Fig. 4.1. Essentially, the majority of the alternative splicing occurs between
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exons 14 and 16 with the inclusion or exclusion of exons 15 and A -F  
determining whether or not the second coiled-coil domain and the protein 
degradation domain are present. Alternatively, the exclusion of exons 15 and 
A -F  and the splicing of exon 14 directly onto exon 16 introduces a premature 
stop codon, which results in a truncated isoform of harmonin (c1/PDZ-45) that 
lacks the third PDZ domain.
7.2.1. Harmonin b isoforms and the eye
It is already apparent that harmonin may have different roles within the ear and 
the eye. Usher type 1C patients have profound congenital sensorineural 
deafness, indicating that harmonin may be required for the development of the 
sensory areas of the inner ear. In contrast, retinitis pigmentosa develops after 
birth and the effects on eyesight only become apparent around puberty. Hence, 
harmonin is probably not required for the correct formation of the photoreceptor 
cells, but is more likely to have a role in the maintenance of the sensory cells of 
the eye.
It was reported that the harmonin b isoforms are only expressed in the inner 
ear (Verpy, et al., 2000) and we and others hypothesized that mutations in the 
alternative exons would cause non-syndromic deafness and not affect the eye. 
However, our RT-PCR analysis of the expression of the b isoforms in human 
foetal tissues has revealed that harmonin b is not ear-specific. We also
identified harmonin b mRNA in foetal gut, heart and kidney tissue as well as£
/
small traces in the eye (Figs 4.7 and 4.8). Expression of harmonin b in the 
mammalian retina was recently confirmed. Immunolabelling of rat and mouse 
retina sections, using an antibody raised against the PEST motif found in the b
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isoforms, detected harmonin b expression in the light-sensitive outer segments 
of the photoreceptor cells (Reiners, etal., 2003).
Since harmonin b now appears to be expressed in both organs, mutations in 
the alternative exons could potentially also affect the eye as well as the ear. 
However, it appears that the mechanism of action of mutations in the 
alternative exons may be one of dosage, since the eye does not seem to be as 
sensitive to the loss of harmonin b. This, in turn, may relate to the different 
roles of this isoform in each organ.
7.2.2. Novel USH1C mRNA transcripts
In this study, novel USH1C transcripts were identified in human foetal ear 
tissue (Fig. 4.6). These included exons B and C or exon B alone spliced onto 
exon 16. It is not known how important these isoforms are, however, it is 
interesting to note that they could code for in-frame protein products if spliced 
onto exon 15 or exon A. Exon B and part of exon C encode the second coiled- 
coil domain found in the harmonin b isoforms. These novel isoforms would lack 
the putative protein degradation motif (PEST) encoded by exons D and E and, 
therefore, could be predicted to be more stable than the harmonin b isoforms, 
whilst retaining the ability to perform additional interactions through the second 
coiled-coil domain.
The harmonin b isoforms, detected by an antibody specific for the PEST 
domain, are present in the mouse developing stereocilia, but are no longer 
detected in the cochlea from P30 onwards (Boeda, et al.} 2002). It would be 
interesting to use an antibody directed to the second coiled-coil domain of
226
harmonin to investigate whether the novel transcripts identified in this study 
have a role in the mature stereocilia, when the longer harmonin b transcripts 
can no longer be detected.
7.2.3. Harmonin in the gut and kidney (PDZ-37)
As well as being important in the ear and the eye, harmonin may have a role in 
the normal function of the gut and the kidney. Prior to its designation as the 
protein that is mutated in Usher syndrome type 1C patients, harmonin was 
originally identified as an auto-antigen in two cohorts of patients. In one cohort, 
the patients had colon cancer (Scanlan, et al., 1999), while in the other cohort 
the patients suffered from an X-linked autoimmune enteropathy (AIE) 
associated with tubulonephropathy (Kobayashi, etal., 1999).
USH1C was cloned in our group when a family presenting with a phenotype of 
enteropathy and renal tubular dysfunction in combination with severe 
hyperinsulinism and profound congenital sensorinueral deafness, were found to 
have a contiguous gene deletion (Bitner-Glindzicz, et al., 2000). The deletion 
includes the majority of the USH1C gene and half of the adjacent ABCC8 gene, 
a component of an ATP-sensitive K+ channel mutated in some patients with 
hyperinsulinism (Thomas, et al., 1995). While it is clear that mutations in 
USH1C cause Usher syndrome and non-syndromic sensorinureal hearing loss 
(Ahmed, etal., 2002; Bitner-Glindzicz, etal., 2000; Ouyang, etal., 2002; Verpy, 
et al., 2000; Zwaenepoel, et al., 2001), it is hypothesized in this thesis that 
deletion of the USH1C gene in these patients may be the cause of both the gut 
and renal phenotype as well.
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We have proposed that expression of PDZ-37, a putative 5’ truncated isoform 
of harmonin reported previously (Scanlan, et al., 1999), by USH1C patients, 
with frame-shift and splice-site mutations at the 5’ end of USH1C, may be 
sufficient for normal gut and kidney function in these patients. We have 
successfully designed an RT-PCR assay for PDZ-37 and identified expression 
of PDZ-37 mRNA in gut, kidney, heart and ear human foetal tissues (Fig. 4.10). 
Previously, PDZ-37 was only identified, by northern blot, in post-natal human 
brain tissue (Scanlan, et al., 1999). Furthermore, we identified PDZ-37 mRNA 
in two human gut epithelial cell lines, HT29 and Caco-2 (Fig. 5.3B) and 
observed a ~40 kDa product on an immunoblot of HT29 and Caco-2 cell 
extracts that may represent the translated PDZ-37 protein (Fig. 5.5B, red 
arrow).
Now that we have confirmed the expression of a 5’ truncated transcript, which 
could be PDZ-37, it is important to show that Usher type 1C patients are still 
able to express PDZ-37. RNA extraction from a fresh urine sample was 
attempted to see if PDZ-37 expression could be detected in urothelial cells. It 
was possible to amplify the major transcript of USH1C in one urine sample, 
indicating that an RNA sample was obtained, but the PDZ-37 isoform, could not 
be amplified, even when nested amplification was performed (Fig. 4.11b). RNA 
extraction from other easily accessible samples, for example, blood and cheek 
scrapings, could be attempted to test further for expression of PDZ-37. Should 
it be confirmed that USH1C patients are still able to express PDZ-37, it would 
be interesting to study the role of this isoform of harmonin within the gut and/or 
kidney. This may also give insights into the pathogenesis of autoimmune 
enteropathy.
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7.2.4. Mouse models for USH1C and DFNB18
Recently, mouse models for both Usher syndrome type 1C and the non- 
syndromic autosomal recessive deafness, DFNB18, were identified (Johnson, 
et al., 2003b). These models appear to be compatible with our theory of 
PDZ-37 expression being sufficient for the normal functioning of the gut, but 
they do not provide any additional information.
Deaf circler (dfct), the model for Usher syndrome type 1C, has a 12.8 kb 
intragenic deletion of Ushlc that includes the constitutive exons 12-14 and the 
alternatively spliced exons 15 and A-D. This mutation would be predicted to 
affect all known isoforms of harmonin, however, in-frame splicing of exon 11 
onto either exon 16 or exon E was observed (Johnson, et al., 2003b). In the 
model for non-syndromic deafness, DFNB18, Deaf circler 2 Jackson (dfcr-2J), 
the mutation is a 1 bp deletion in the alternatively spliced exon C creating a 
frame-shift and introducing a premature stop codon, which only affects the b 
isoform transcripts.
It appears that the large intragenic deletion of the deaf circler mouse may not 
be completely null. The in-frame splice products lack the coding information for 
the coiled-coil domains and the PEST (proline, glutamic acid, serine, threonine- 
rich) degradation domain found in harmonin b isoforms, but the codons for all 
three PDZ domains are still present. Since the mouse is deaf, it appears that 
the coiled-coil and PEST domains of harmonin are essential for the normal 
functioning of the inner ear. Indeed, it has been shown that a C-terminal 
fragment of harmonin b, that includes the second coiled-coil and the PEST
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motif with the third PDZ domain, is involved in the interaction of harmonin b 
with the actin cytoskeleton (Boeda, etal., 2002).
7.2.4.1. USH1C mouse model and PDZ-37
Does the deaf circler mouse model have a gut and/or kidney phenotype? If not 
then it may be hypothesized that although the coiled-coil domains and/or the 
PEST domain are important for the normal functioning of the ear, they are not 
required for the correct functioning of the gut and/or the kidney. The intragenic 
deletion found in Ushlc in the deaf circler mouse includes exon 12. Therefore, 
this mouse model would not be expected to possess the alternative start site, 
located in exon 12, for translation of the 5’ truncated isoform, PDZ-37. 
Nevertheless, these mice are still able to produce in-frame splice forms of 
harmonin that encode all three PDZ domains, which may be sufficient for a 
normal gut and kidney phenotype...............................................................................
Taken together with the information available from the USH1 C-deleted family, it 
may be hypothesized that the presence of the PDZ3 domain of harmonin is 
sufficient for normal gut and kidney function. Whether the PDZ3 domain occurs 
alone, in the form of the truncated isoform PDZ-37, or in association with the 
other PDZ domains in longer isoforms of harmonin, may not be of importance.
7.3. Functions of Harmonin
7.3.1. Interactions between Usher type 1 proteins
Since the start of this study, three new Usher type 1 proteins have been 
identified, cadherin 23 (USH1D), protocadherin 15 (USH1F) and sans
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(USH1G). Recently, harmonin, myosin VIIA (USH1B), cadherin 23 and sans 
were demonstrated to interact, forming a macromolecular complex believed to 
be important for the correct functioning of the inner ear (Boeda, et al., 2002; 
Siemens, et al., 2002; Weil, et al., 2003).
It was hypothesized here that protocadherin 15, which possesses a PDZ- 
binding consensus sequence, similar to cadherin 23, at its C-terminus, might 
also interact with harmonin and form part of the same macromolecular 
complex. However, a GST pull-down assay, performed using a 191 bp 
C-terminal fragment of protocadherin 15, showed that the C-terminus of 
protocadherin 15 does not interact with harmonin. This means that 
protocadherin 15 currently has no known binding partners. It is still possible 
that protocadherin 15 forms part of the same Usher type 1 macromolecular 
complex by binding to another protein. In particular, one of the unidentified 
Usher type 1 proteins, USH1A or USH1E, may turn out to be a PDZ protein, or 
another type of protein involved in protein-protein interactions.
7.3.2. Harmonin in the ear
It is now becoming clear how harmonin might function in the ear. Through its 
interactions with other Usher type 1 proteins, it is hypothesized that harmonin 
links integral membrane proteins (cadherin 23), involved in cell-cell ahesion, to 
the actin cytoskeleton of the stereocilia. This will strengthen and stabilize the 
connections between individual stereocilia and allow them to move together as 
a bundle when deflected by sound-waves entering the inner ear. Furthermore, 
harmonin b has been demonstrated, in vitro, to possess an actin-bundling
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activity, which has been implicated in the development of the actin core of the 
stereocilia on hair cells in the inner ear (Boeda, et al., 2002).
7.3.3. Harmonin in the eye '
The function of harmonin in the eye, however, is not so clear. Harmonin b 
expression was recently demonstrated to be restricted to the outer segments of 
the photoreceptor cells, while harmonin a expression was detected in both the 
outer and inner segments of the photoreceptors, as well as in the synapses 
(Reiners, et al., 2003). Furthermore, although harmonin b was shown to 
interact with cadherin 23 and myosin VIIA within the stereocilia (Boeda, et al., 
2002), co-localization of cadherin 23 and myosin VIIA expression with 
harmonin has only been observed in the synapses of the photoreceptors and 
hence, these proteins do not appear to co-localize with the harmonin b isoform 
(Reiners, et al., 2003). In light of these observations, harmonin b currently has 
no known binding partners in the photoreceptors and may have a different 
function to that hypothesised for it the inner ear.
To identify novel binding partners for harmonin and gain more insight into its 
function within the eye, a yeast two-hybrid study using a retinal cDNA library, is 
currently being carried out in our group.
The deaf circler mouse model for USH1C may also prove useful in elucidating 
a role for harmonin in the eye. Until recently none of the Usher type 1 mouse 
models appeared to have an eye phenotype (Gibson, et al., 1995; Alagramam, 
et al., 2001; Di Palma, et al., 2001; Kikkawa, et al., 2003), something which 
was attributed to some species-specific manifestation. However, more detailed
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analyses of the retinas of mice with Myo7a mutations has revealed some 
anomalies (Libby, et al., 2001; Gibbs, et al., 2003). Likewise, some histological 
evidence of a slight peripheral degeneration in the deaf circler mouse has also 
been detected (Johnson, et al., 2003). Since a transcript encoding all three 
PDZ domains, in the absence of either of the coiled-coil domains or the PEST 
motif, has been identified in the Usher type 1C mouse model, this also points to 
an important role for the longer harmonin isoforms within the eye.
7.3.4. Harmonin in the gut
Apart from obviously being important for the correct functioning of the ear and 
the eye, it is now becoming apparent that harmonin is also required for the 
normal function of the gut, and possibly the kidney too. As discussed above, it 
seems that the PDZ3 domain of harmonin and the interactions that it may form 
could be important for its role in the gut. PDZ3 of harmonin currently has no 
known binding partners. A yeast two-hybrid study, using the PDZ3 domain as 
bait, may identify novel interacting proteins and point to a role for this domain 
and to a possible function for the PDZ-37 isoform.
It has been speculated in this thesis that harmonin, or at least the PDZ-37 
isoform, may have a role in the tight junctions of the epithelial cells of the gut. 
As discussed in Chapter 5, it is possible that the inflammatory nature of the 
enteropathy observed in the patients with the USH1C-ABCC8 contiguous gene 
deletion could be due to a barrier dysfunction in the gut. PDZ domain- 
containing proteins are known to be associated with tight junctions, functioning 
as scaffolding molecules, linking integral proteins of the tight junction strands
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with both the cell cytoskeleton and signalling proteins (reviewed by Gonzalez- 
Mariscal, et al., 2003).
The possibility of harmonin localizing to tight junctions could be investigated in 
human gut epithelial cell lines. The cells would first have to be cultured in a way 
that allowed tight junctions to form between neighbouring cells. Then double- 
staining for endogenous harmonin and a marker protein of the tight junctions, 
such as the PDZ protein ZO-1, could be performed using fluorescently-labelled 
antibodies. To study localization of the PDZ-37 isoform specifically it would 
have to be tagged, for example with GFP, and the cells transfected with the 
tagged protein prior to staining for a tight junction marker. If harmonin does 
appear to localize to the tight junctions, it might be possible to perform 
knockdown studies, using RNAi technology, to investigate the effect that 
knocking out harmonin has on the cultured cells and their tight junctions.
7.3.5. Other possible roles for harmonin
Finally, it is also intriguing that auto-antibodies to harmonin should be raised in 
patients with colon cancer (Scanlan, et al., 1999). The basis for the 
immunogenicity of harmonin in cancer patients is not known. Nevertheless, 
harmonin is not the only PDZ domain protein implicated in cancer. For 
example, AlPC is a PDZ domain-containing protein that is activated in prostate 
cancer and its accumulation is thought to be closely associated with the 
initiation or early promotion of tumorigenesis (Chaib, et al., 2001). It is not 
necessarily surprising to find PDZ proteins playing a role in cancer, since their 
main functions tend to involve organizing proteins in signal transduction 
cascades, or organizing cell junction complexes. Disruption of either of these
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functions could lead to a breakdown in cellular communication and, hence, 
tumorigenesis.
Some PDZ proteins have been shown to shuttle between the nucleus and the 
cell membrane (Cuppen, et al., 1999; Islas, et al., 2002). ZO-1, a PDZ protein 
associated with tight junctions, has been demonstrated to bind to a 
transcription factor, indicating a role for this PDZ protein in the regulation of 
gene expression (Baida and Matter, 2000). Interestingly, harmonin also 
possesses a putative nuclear localization signal (Appendix E). Could harmonin, 
or one of its isoforms, have a role in signalling to the nucleus that is somehow 
disrupted in patients with colon cancer?
7.4. Future Directions
There are a number of avenues of research that could be pursued as a result of 
the work presented in this thesis. The most interesting line of investigation 
would be to study the PDZ-37 isoform of harmonin further. First, to confirm the 
hypothesis that PDZ-37 is required for normal gut and kidney function, it is 
important to establish whether Usher type 1C patients are still able to express 
the PDZ-37 isoform. This may be achieved either by analysing RNA samples or 
by staining the relevant biopsy samples from Usher type 1C patients, if they 
can be obtained. A yeast two-hybrid study might identify novel binding partners 
for PDZ-37. Association of PDZ-37 with the tight junctions could be 
investigated, as discussed above, by double-staining human epithelial gut cells 
for co-localization of harmonin and/or PDZ-37 with tight junction-associated 
proteins. Interactions with candidate tight junction-associated proteins could be
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tested in co-immunoprecipitation experiments. Similar studies may also be 
performed on kidney cells to establish if the USH1C deletion is also responsible 
for the renal tubular dysfunction observed in the deletion patients.
Now that a mouse model for Usher type 1C has been identified, it would be 
interesting to study it further. In particular, does the USH1C mouse model deaf 
circler have a gut or kidney phenotype? Histological examination of both the 
kidney and intestines of the deaf circler mouse should be performed and 
sections of both organs could be checked for expression of harmonin using 
fluorescent immunohistochemistry.
However, since the deaf circler mouse allele is not predicted to be completely 
null, it does not mimic the situation observed in either the USH1C patients 
identified to date, or the contiguous USH1C-ABCC8 gene deletion patients. 
Therefore, it may be more informative to create a knockout mouse that forms a 
closer approximation to the situation found in the USH1C patients, and/or in the 
deletion patients, to help confirm our hypothesis about PDZ-37.
It should also be possible to gain more information about the interactions of 
harmonin and its role within the inner ear, and/or the eye, by studying the 
localization of the other Usher type 1 proteins in the USH1C mouse model and 
comparing to wild type mice.
It is intriguing that protocadherin 15 is the only Usher type 1 protein, of the five 
that have been cloned, for which no binding partners have been identified. The 
C-terminus of protocadherin 15 does not interact with harmonin. It should be
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possible to identify potential interacting proteins for protocadherin 15 using 
yeast two-hybrid. However, this has been attempted unsuccessfully in our 
group because the fusion protein containing the C-terminal 191 bp of 
protocadherin 15 was found to be toxic to the yeast cells. It may be that a yeast 
two-hybrid study using a larger portion of the protocadherin 15 gene would be 
more successful, although the classical system may have to be adapted since 
protocadherin 15 is a transmembrane protein and is not thought to localize to 
the nucleus.
7.5. Concluding Remarks
Identification of the USH1C gene has helped to further our understanding of 
how the inner ear functions. In the absence of full-length harmonin, the 
stereocilia in the inner ears of the deaf circler mouse are disorganized and 
splayed (Johnson, et al., 2003b), indicating that harmonin has a crucial role to 
play in the correct formation of the stereocilia. Harmonin interacts with other 
Usher type 1 proteins, forming part of a network that is important for 
maintaining stereocilia cohesion (Boeda, et al., 2002; Siemens, et al., 2002). 
However, it has been shown in this work that harmonin does not form a direct 
interaction with the C-terminus of the USH1F protein, protocadherin 15.
Our understanding of the function of harmonin in tissues other than the ear, 
particularly the eye, but also in the gut and kidney is not so clear. It is apparent 
that harmonin exists as several alternatively spliced isoforms (Scanlan, et al., 
1999; Verpy, et al., 2000), which may have different roles to play in different 
tissues. Some isoforms of harmonin were thought to be ear-specific, but our
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work and that of others (Reiners, et al., 2003) has shown that this is not 
necessarily so. We have shown here that the harmonin b isoforms are 
expressed by other human foetal tissues, including the eye.
Careful examination of mutations and correlation with the clinical features found 
in the patients, has also suggested that alternatively spliced isoforms, for 
example PDZ-37, may have a different role in different tissues. It has been 
shown here that PDZ-37, previously identified only in brain tissue, is also 
expressed in the gut and may account for the discrepancy in phenotype 
between patients with point mutations and those with a large deletion.
Further investigations into the alternative isoforms of harmonin and their tissue- 
specific functions will lead to a greater understanding of the role of harmonin 
and may eventually lead to possible gene therapy for patients with Usher 
syndrome type 1C.
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APPENDIX A: Oligonucleotide primers
A.1. Primers for amplifying USH1C exons
Exon Forward Primer (5’-3’) Reverse Primer (5’-3’)
Product 
Size (bp)
Annealing Temperature 
(°C)
1 CCCAACCAG AGCCAT CAG GACTCAGCACCTTCGACTCC - 351 54
2 TCCCT GAAGACAAAGGAACC CGGTACTCCTGTGGCCAC 336 62
3 TT CCT GCCACACAGGAGAG CAGGAGT GGT CTACTCCATTCC 377 65
4 T GACC AT GTT GTGCCACAC TCCAGGT GCAGAGGAAGC 345 66
5 ATGGAGTACTGCCCTGCTCT GGAGCAT CT GGTGGT GAGT C 354 65
6 TAGAGCCTCCAGCCTCCACT GAGCT GT CCTAACCCCT GT G 181 66
7 CTCTAGAGCAAGCCCTCCCT GTTCCT CAAACGT CT CTCGC 201 66
8 GACAGTCACACCCCTGGTG G ACGGAAT GAT GAT CT GGCT 306 66
9 GGTGGGTAGGGCTCCTACTC GGACACAG AGGCT GAAGAGG 346 67
10 CAGCAGTCCAGGCAGAGAG CCT GCAGAT GAGCGAGT GTA 232 66
11 T GT GT GGCAGAGAT CAAAGG CTCCACACCCCACTT CT CAT 246 66
12 GCT AGGT GGGGT CGT GT G TT CT GCCCAGCAAGAAGTTT 359 64
13 AGGGGAT GAGAGAACCAGGT AAACCACGCAAGAGCACAG 365 66
14 ACAGCCCAGAGCACCAAG GGGTT CT GACTCCAGTAACAGG 276 66
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Exon Forward Primer (5’-3’) Reverse Primer (5’-3’)
Product 
Size (bp)
Annealing Temperature 
(°C)
15 AAGCT GGGT GT CTGCACT G AACTCCT GAGAAGGTTCTCCG 241 61
A T GTT CT GCAACCAAGGCAAGG AACAGGCCAAGT C ACACCATT 350 67
B GGCCTT CCT GT CCTAAACCT G GCTCACTCCACCCTTGTATGC 441 68
C CCTTGAGGGCCAGTTGGAACA GCACT GT GAGGCTAGT GACG 391 67
D TGCTCGCTGTATT GT GAAGT G GAGGACATGGGAAACAGCAGT 625 59
E GCCGCT CAGTAGTTT CT GT G CT GC ATTTTT GTCCC ACCT C 445 67
F ACT GCTCGGGGAGGGACAT CAGGCAAT GGAGGACACAGC 330 67
16 TTT GG AAGGAAT CTTCGTGG TGCTGTGTTGCCCTAAAGC 248 64
17 TT GAGAGTAGAGGCAGGAGACC TTCCCCTTCCAGCCCTAC 212 61
18 CCCCGTCTAACCACTGTATCA AGGCTGCTGTCTGCTTGG 202 61
19 GGGGTATGGTGTCACCAAAG TT CT GCT GT CT GGCAAT GAC 347 66
20 AAGGAAGAAGAGGT CT CAGGC CATCCAACT GAGT GTGCCC 143 65
G/G’ GGAGCCCAGT GAAAGGAGAA GACGCCAGTCCAAAGAACCT 295 67
21 AATTAGAGCAGAGGGCAGAGG CTGTATCCACCTGGGCTGTT 449 65
A.2. Primers for 5’ RACE analysis of USH1C
Primer Sequence (5’-3’)* Location in 
USH1C
MWG/ 
Invitrogen ™#
GSP1 TCATACACAGCAGAAACGACC Exon 18 MWG
GSP2 AT CCCT CCTT CTT GAT GCGTAGG Exon 17-18 m w g :
Nested GSP3 TTCC AT CTCCTT CCGGTAT CT Exon 13 MWG
Abridged Anchor Primer (AAP) GGCCACGCGTCGACTAGTACGGGIIGGGIIGGGIIG N/A Invitrogen
Abridged Universal Amplification 
Primer (AUAP)
GGCCACGCGTCGACTAGTAC N/A Invitrogen
* I = inosine
# Primers were either designed and ordered from MWG, or were provided with the 5’ RACE System purchased from Invitrogen™
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A.3. Primers for RT-PCR analysis of USH1C
Forward
Primer
Sequence (5’-3’) Reverse Primer Sequence (5’-3’)
Annealing 
Temperature (°C)*
Exon 13 TACCGGAAGGAGATGGAACA Exon 17 AT GAT CTGCTCTGGGGT GAA 58
Exon B GGAGTTT GAGCAAAAGCTTTACA 53
Exon F TGGTGGTTTAT C AG AC AGC ATT Exon 21 T CCTAACGCGT G AATTTGGT 56
Exon G/G’ ACCACAAGGTCGAT CCAGT C 56
Intron 11 GGCCT CTTTT CT CCCAT GAG Exon 14 TTT GAGCCCCAGT CTT CTT C TD
Intron 11 nff CCCCAGGGGT GT GT CAGG Exon 14n# GGGT GTACCT CAGCAGT GA TD
* TD = only touchdown PCR was used (see section 2.#.#)
# primer pair located outside Intron 11 and Exon 14 primer pair and used as 1st round primers for nested amplification of PDZ-37 
transcript
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A.4. USH1C allele-specific oligonucleotides (ASO)
ASO Sequence (5’ - 3’)* Tm# (°C)
Exon 5 wildtype CCT CT CT CT GT GGT CAAGG 58.8
Exon 5 variant CCT CT CT CT GT GGT C AAG A 56.7
Exon 18 wildtype T CCCCGCT CATAC AC AGC 58.2
Exon 18 variant TCCCCGCT CATAC AC AG A 56.0
*the variant 3’ nucleotide for each ASO is indicated in bold.
#an annealing temperature of 59°C was used to amplify DNA using all possible combinations of primers.
A.5. Other gene-specific primers
Gene Forward primer sequence (5’-3’) Reverse primer sequence (5y-3’) Product size 
(bp)*
Annealing 
Temperature (°C)
COCH ACCAGAGGCTT GGACAT CAG CCTGTGGCCTCCTGT GTACT 299/1287 62
HPRT CCACGAAAGTGTTGGATATAAGC GGCGATGTCAATAGGACTCCAGATG 205/1719 58
PCDH15 CGACC AACTT G ATGCCT GCC CCTT GTTTT GTT CAGAT GT G 691 58
*where two numbers are given the smaller one is the expected size of the cDNA product, whilst the larger size is that expected if the 
sample is contaminated with genomic DNA.
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A.6. Primers used for cloning
A.6.1. Vector primers
Vector ForwardPrimer Sequence (5’-3’)
Reverse _ /c, 
Primer Sequence (5 -3 )
Annealing 
Temp. (°C)
pZErO™-2 Sp6 GATTTAGGTGACACTATAG T7 GTAATACGACTCACTATAGGG 55
pGEX-4T-1 pGEX-F GGGCTGGCAAGCCACGTTTGGTG pGEX-R CCGGGAGCT GCAT GTGT CAGAGG 65
A.6.2. Gene-specific oligonucleotides for sequencing clones
Gene Primer * Sequence (5’-3’)
PCDH15 3’PCDH15-R2 CT GT GGAC AGAAAT GAAGCT G
USH1C Exon 1F AAGGAACGGGTCGTGCAACG
USH1C Exon 5F CCTCATTCGAACCAAGAAAAC
USH1C Exon 11F CCT GACCAT CT CCATT GTAGC
USH1C Exon 14F GGCT CAAAGGAACAGCTACT CTT GC
• .......................- ............................
USH1C Exon 17F AAGGATGTCCGGCTCCTAC
USH1C Exon 21R TCCTAACGCGTGAATTTGGT
*R denotes a reverse primer, while F denotes a forward primer
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A.7. Markers for haplotype analysis of the major USH1 loci
Locus Marker* Distance from previous marker cM/kb Primers#
Size Range 
(bp)
Label1, Annealing Temp. (°C)“
D11S1321 N/A AGCT GAGATCGCACCAT TTCACTGCCATTTGTTGAC
197-215 Fam 58
m
. T  - .
D11S4179* 1.65/734 GGATGTAAGAGTAACTGGCTCCG GAAAAT GTT CT GCCT GAGGG
236-256 Hex 58
CO
D
D11S4186* 0.55/572 ATTCTCCCAATCTATCGCTC GGGCAGTAAT GAT GAT GT G
154-175 Hex 50
D11S4166 1.28/1479 GGAAGGCACCATGATACTTG GT GAAGT CT GGGATTT CAGC
110-130 Fam 58
D11S4160 N/A CTTTTGGCATAGGAGGCT 245-277 Fam 58CAGCGAGCTGATATGGC
D11S1981 0.0/41 AATTCCTTTACTCC AGAAAGG CAGATTT CTGCTTT CCCAGA
161- Fam 58
O^P“T
D11S921 0.0/198 TGCATT CAACAAAT CAACACTT G G ACC ATTTAAT CTAAAGTAAT
243-255 Tet 58
CO
ID D11S902* 0.0/204 CCCGGCTGTGAATATACTTAATGC CCCAACAGCAAT GGGAAGTT
145-163 Hex 58
D11S4138* 0.0/267 GT GCT GACCGCTCCAAGG CCAAAGGGGTTAATAGGGGTCCA
181-211 Tet 58
D11S1888 0.0/22 CCCCAGTACCCTGTATAGGCCACTTGTGTGTTTGTATCGAGTCA
225- Hex 58
D10S1685 N/A ACAT CAAATT GT CC ACT GAG AC 267-283 Fam TD
Q CAAAGCAAGACCCTACCTCTAAT-T D10S1650* 1.68/814 GAAGCCT GTGGT CTAAT GAG 124-148 Fam 61CO TTCTGGCCT CTGCAGC
3 D1OS1694* 0.56/134 CCT GT CT GGCCCAGGTA AGTAGGGGTGCT GCTT GA
141-161 Hex 54
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Locus Marker* Distance from previous marker cM/kb Primers#
Size Range 
(bp)
Label* Annealing Temp. (0C)°°
D10S1790 N/A AGTGAAATGGCTACAACCAAGCCTGAGATACATAAGGTGCT
191- Fam TD
Li.
x
D1OS1643* 0.0/66 ACATAAGCCCAATTT CT GAT CTT CT CAGTGCCAAAAT CT
121-151 Tet 54
(0
D D10S1124* 1.07/1817 CCAT GGAGCAT GT CTTATTT CCACAGATT GT G AAAG AT G AC
197-235 Hex TD
D10S1788 0.0/913 TGACAGGTAACAAAAGTGG AT CAAAT CAATGGT CAAAAC
246-258 Tet TD
* Markers are arranged in the order they are found on the chromosome, from centromere to telomere. An asterisk denotes the 
markers that lie closest to the gene at each locus, except for the USH1D locus where D10S1650 and D10S1694 both lie within the 
USH1D gene, CDH23.
# forward oligonucleotides are shown on top in each case and reverse are below. 
f Only the forward oligonucleotides are labelled with a fluorescent dye.
Fam = 6-carboxyfluorescein, Tet = tetrachlorofluorescein and Hex = 4,7,2’,4’,5’,7,-hexachloro-6-carboxyrhodamine.
00 All PCRs were carried out with 1.5 mM MgCfe using HotStarTaq polymerase and at the annealing temperature indicated, or using a 
touchdown PCR protocol, TD, (section 2.2.1.1.).
APPENDIX B: Plasmid Vectors
B.1. pZErO™-2
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Figure B.1. Schematic of pZErO™-2 Vector (http://www.invitrogen.com) 
used for cloning PCR fragments and in vitro-translation.
pZErO™-2 is 3297 nucleotides. The multiple cloning site (bases 269-381) is indicated 
at the top between the T7 promoter/priming site (bases 388-407) and the Sp6 
promoter/priming site (bases 239-256). The Lac promoter/operator region is found at 
bases 95-216, while the LacZa ORF is at bases 217-558. The ccdB Lethal Gene ORF 
(bases 568-870) provides lethal selection against non-recombinant vector. The f1 
origin is located at bases 895-1307 and the vector carries Kanamycin resistance 
(bases 2116-1322). The ColE1 origin (bases 2502-3175) allows high copy replication 
and maintenance of the plasmid in E. coli.
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B.2. pGEX-4T-1
Glu Phe Pro Gly Arg Leu Gl 
.GAATTCCCG GGT CGA C,TC G£
EcoR 1 Sma I Sal 1 XhoT
pSj10ABam7Stop7
________Thrombin_______
I Leu Vai Pro Arg ^  Gly Seri Pro 
CTG GTT CCG CGTGGATCC
BamH I
lu Arg Pro His Arg Asp 
Ap CGG CCG QAT CGT GAC TGA 
Mot I Stop codons
T th111 I 
Aat II
BspM I
A lw N  I
pBR322
ori
Nar I
EcoR V 
BssH II
Apa I
BstE II
Figure B.2. Schematic of pGEX-4T-1 vector (Amersham Pharmacia 
Biotech Inc) used for preparing GST-fusion proteins for analysis in GST 
pull-down assays.
The multiple cloning site (bases 930-966) indicated at the top is preceeded by a coding 
region for thrombin cleavage (bases 918-935), which allows easy removal of the 
Glutathione S-transferase (GST) protein moiety, whose gene region, including the tac 
promoter, is found at bases 183-918. The p-lactamase gene region (bases 1307-2235) 
confers ampicillin resistance.
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APPENDIX C: Accession Numbers
Table C.1. mRNA and Protein accession numbers
Gene Isoform mRNA Protein
USH1C A1 NM_005709 AAH16057
USH1C B3 NM_153676 NP_710142
PCDH15 NM_033056 NP_149045
MCC2 NM_031941 NP_114147
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APPENDIX D: Websites
D.1. Genome resources
Sequence similarity search
http://www.ncbi.nih.gov/BLAST/
Primer design
http://www-qenome.wi.mit.edu/cqi-bin/primer/primer3 www.cgi
Ensembl Genome browser
http://www.ensembl.org/
UK MRC Human Genome Mapping Project 
http://www.hqmp.mrc.ac.uk/
Marshfield Centre for Medical Genetics -  genetic map building resource
http://research.marshfieldclinic.org/genetics/Default.htm
Online Mendelian Inheritance in Man -  database of human genetic disorders
http://www3.ncbi.nlm.nih.gov/entrez/querv.fcqi?db=OMIM
D.2. Proteomics resources
Expert Protein Analysis System
http://ca.expasv.org/
Database of protein families and domains 
http://ca.expasv.org/prosite/
D.3. Hearing loss resources
Hereditary Hearing Loss Homepage 
http://dnalab-www.uia.ac.be/dnalab/hhh/
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Hereditary Hearing Impairment in Mice
http://www.iax.org/hmr/index.html
List of mouse inner ear mutants
http://www.ihr.mrc.ac.uk/hereditarv/MutantsTable.shtml
A compendium of mouse knockouts with inner ear defects
http://tbase.iax.org/docs/inner-ear-ko-compendium.html
D.4. Retinitis pigmentosa resources
Retinal information network 
http://www.sph.uth.tmc.edu/retnet/
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APPENDIX E: Search harmonin sequence against PROSITE
Harmonin isoform a1 sequence:
MDRKVAREFR HKVDFLIEND AEKDYLYDVL RMYHQTMDVA VLVGDLKLVI NEPSRLPLFD
AIRPLIPLKH QVEYDQLTPR RSRKLKEVRL DRLHPEGLGL SVRGGLEFGC GLFISHLIKG
GQADSVGLQV GDEIVRINGY SISSCTHEEV INLIRTKKTV SIKVRHIGLI PVKSSPDEPL
TWQYVDQFVS ESGGVRGSLG SPGNRENKEK KVFISLVGSR GLGCSISSGP IQKPGIFISH
VKPGSLSAEV GLEIGDQIVE VNGVDFSNLD HKEGRELFMT DRERLAEARQ RELQRQELLM
QKRLAMESNK ILQEQQEMER QRRKEIAQKA AEENERYRKE MEQIVEEEEK FKKQWEEDWG
SKEQLLLPKT ITAEVHPVPL RKPKYDQGVE PELEPADDLD GGTEEQGEQD FRKYEEGFDP
YSMFTPEQIM GKDVRLLRIK KEGSLDLALE GGVDSPIGKV VVSAVYERGA AERHGGIVKG
DEIMAINGKI VTDYTLAEAD AALQKAWNQG GDWIDLVVAV CPPKEYDDEL TFF
PROSITE Release 18.25, of 26-Apr-2004
>PDOCOOOQ3 PS00Q03 SULFATION Tyrosine sulfation site [rule] [Warning: rule with a high probability 
of occurrence].
18 - 32 endaekdYlydvlrm 
519 - 533 avcppkeYddeltff
>PDOCOOOQ5 PS00005 PKC_PHOSPHO_SITE Protein kinase C phosphorylation site [pattern] [Warning: 
pattern with a high probability of occurrence].
7 8 - 8 0  TpR 
82 - 84 SrK 
101 - 103 SvR 
156 - 158 TkK
253
161 - 163 SiK
280 - 282 TdR
308 - 310 SnK
>PDOCOOOO6 PS00006 CK2_PH0SPH0_SITE Casein kinase II phosphorylation site [pattern] [Warning: 
pattern with a high probability of occurrence].
146 - 149 TheE
174 - 177 SspD
175 - 178 SpdE
267 - 270 SnlD
280 - 283 TdrE
495 - 498 TlaE
>PDOCOOOQ7 PS00007 TYR_PHOSPHO_SITE Tyrosine kinase phosphorylation site [pattern] [Warning: 
pattern with a high probability of occurrence].
329 - 337 KaaeEnerY
>PDOCOOOQ8 PS00008 MYRISTYL N-myristoylation site [pattern] [Warning: pattern with a high
probability of occurrei
97 - 102 GLglSV
105 - 110 GLefGC
111 - 116 GLfiSH
121 - 126 GQadSV
127 - 132 GLqvGD
193 - 198 GGvrGS
194 - 199 GVrgSL
200 - 205 GSpgNR
203 - 208 GNreNK
254
221 - 226 GLgcSI
223 - 228 GCsiSS
235 - 240 GIfiSH
244 - 249 GSlsAE
251 - 256 GLeiGD
263 - 268 GVdfSN
476 - 481 GivkGD
>PDQC00015 PSQ0015 NUCLEAR Bipartite nuclear targeting sequence [rule] [Warning: rule with a high 
probability of occurrence].
323 - 339 RKeiaqkaaeeneryrk 
338 - 354 Rkemeqiveeeekfkkq
>PDQC50099 PS50313 GLU_RICH Glutamic acid-rich region [profile].
The following hit is below threshold (may be spurious)
273 - 416 Egrelfmtdrerlaearqrelqrqellmqkrlamesnkilqeqqemerqrrkeiaqkaae 
eneryrkemeqiveeeekfkkqweedwgskeqlllpktitaevhpvplrkpkydqgvepe 
lepaddldggteeqgeqdfrkyeE
>PDQC50106 PS50106 PDZ PDZ domain [profile].
87 - 155 EVRLDRLHPEG.LGLSVRGGLEFGC--GLFISHLIKGGQADSV-GLQVGDEIVRINGYSI
SSCTHEEVINLIR--------------
211 - 278 KVFISLVGSRG.LGCSISSGPIQKP--GIFISHVKPGSLSAEV-GLEIGDQIVEVNGVDF
SNLDHKEGRELF---------------
4 33 - 506 DVRLLRIKKEGsLDLALEGGVDSPIGK-VVVSAVYERGAAERHGGIVKGDEIMAINGKIV 
TDYTLAEADAALQKA------------
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Denaturing high-performance liquid chromatography (DHPLC) was 
used to screen 14 UK patients with Usher syndrome type 1, in order to 
assess the contribution of mutations in USH1C to type 1 Usher. In 
addition, 16 Caucasian sib pairs and two small consanguineous families 
with non-syndromic deafness, who were concordant for haplotypes 
around DFNB18, were also screened for mutations in the USH1C gene. 
Two Usher type 1 patients were found to have the 238-239insC 
mutation reported previously; one of Greek Cypriot origin was 
homozygous for the mutation and another Caucasian was heterozygous. 
This indicates that mutations in the USH1C gene make a greater 
contribution to Usher syndrome type 1 than originally thought, which 
has implications for the genetic testing of families with Usher syndrome 
in the UK. Analysis using intragenic single nucleotide polymorphisms 
(SNPs) revealed that the haplotypic background bearing this common 
mutation was not consistent across the gene in two families, and that 
there are either two haplotypes on which the mutation has arisen or that 
there has been a recombination on a single haplotype. We found no 
evidence of mutations in USH1C in the patients with non-syndromic 
deafness, suggesting that the gene is not a major contributor to 
autosomal-recessive non-syndromic deafness in the UK.
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Usher syndrome type 1 is an autosomal-recessive 
condition in which profound, congenital sensor­
ineural deafness is found in association with 
vestibular hypofunction and childhood-onset 
retinitis pigmentosa. This condition is further 
subdivided, based on linkage analysis, into types 
1A to 1G. Type 1C Usher was originally mapped 
to chromosome Ilpl5.2-pl4 in the Acadian 
population of Louisiana (1) but was always 
thought to be rare outside this population. The 
causative gene for Usher type 1C (USH1C) has 
recently been identified as a PDZ domain-con­
taining gene located at l ip  15.1 (2,3). Mutations 
have since been found in patients from Pakistan, 
India, Lebanon and Europe. The gene comprises 
28 exons, 20 of which are constitutive (exons 1-14 
and 16-21) and eight that are alternatively spliced 
(15, A -F and G /G \ see Fig. lb) (3).
DFNB18 is a recessive, non-syndromic form of 
deafness for which the locus was shown, by link­
age, to overlap with the USH1C region (4) 
(Fig. la). As transcripts containing the alternative 
exons A-F and G/G’ do not appear to be 
expressed in the eye (3) it was hypothesized that 
mutations in these exons could lead to hearing 
defects without retinal degeneration and that 
DFNB18 and USH1C are allelic variants of the 
same gene. Allelism has recently been confirmed 
by mutation analysis of the original DFNB18 
family, in which a leaky splice-site mutation in 
a constitutive exon was shown to produce wild- 
type transcripts as well as transcripts lacking exon 
12 (5).
Given the recent findings of USH1C mutations 
in individuals of diverse ethnic backgrounds, we 
wanted to know whether mutations in USH1C
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11p cen, USH1C r 11 p tel
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Fig.. 1. Scheme indicating how the loci for Usher syndrome 
type 1C and non-syndromic deafness (DFNB18) overlap 
andl illustrating the constitutive and alternatively spliced 
exo'ns o f the USH1C gene, (a) The markers used to map 
both loci are shown below, with D11S2368 and D l l  SI 307 
defiining the larger DFNB18 region (4) and D11S1890 and 
D1 1S902 defining the USH1C loci (15). The relative 
position of the USH1C gene is also indicated, (b) The 
comstitutive exons (1-14 and 16-21) are shown in black, 
whiilst the alternatively spliced exons (15, A -F  and G /G ’) are 
shown in grey. Exons 15 and A -F  are spliced between exons 
14 and 16, whilst exon G /G ’, when present, occurs between 
exo>ns 20 and 21. Exon numbers are indicated below.
are a common cause of Usher syndrome type 1 in 
the UK and whether mutations in this gene con­
tribute significantly to non-syndromic deafness in 
o u t  population.
M a te r ia ls  and m e th o d s
Pattients
Two cohorts of patients were studied. One con­
sisted of 14 British individuals of mixed ethnic 
origin who had been diagnosed with Usher 
syndrome type 1. The other group included 16 
Caiucasian sib pairs with non-syndromic deafness 
from the UK and two small consanguineous 
families that showed concordance for poly­
morphic markers flanking the DFNB18 locus. 
This group of patients, with congenital/childhood 
onset non-syndromic deafness, is part of a larger 
cohort of 133 Caucasian sib pairs and 55 sib pairs 
of Pakistani and Middle-Eastern origin, who 
have been systematically haplotyped using micro- 
sattellite markers flanking all of the known DFNB 
loci (6; Hutchin TP). The sibling pairs were diag­
nosed with non-syndromic deafness following 
evaluation by a clinical geneticist, experienced 
audiological physician or community paediatri­
cian in audiology, and most have had a detailed 
ophthalmological review. The age range of the 
patients varied from « 5 to  40 years, with the 
majority being in their teenage years. Their deaf­
ness was mainly severe to profound (although in
some cases a sibling had a moderate hearing loss) 
and was of congenital or early-childhood onset. 
Given the young age of some of the children, it is 
theoretically possible that the cohort may include 
some siblings with Usher in whom the condition 
is not yet apparent, although the chances of this 
are small given the relative proportion of Usher 
to non-syndromic deafness (7). The sib pairs had 
already been screened for mutations in GJB2 and 
32% had mutations confirmed by molecular 
analysis. These subjects were excluded from 
further investigation.
Screening USH1C exons
Denaturing high-performance liquid chroma­
tography (DHPLC) was used to screen all 28 
coding exons of the USH1C gene in these patients 
and any heteroduplexes observed were inves­
tigated by sequencing on an ABI 377 (Applied 
Biosystems) using the fluorescent dideoxy 
terminator method.
DNA from 96 controls of undetermined origin 
was also screened on the WAVE machine to 
confirm the identification of polymorphisms or 
disease-causing mutations found in the patients. 
Polymerase chain reaction (PCR) and WAVE 
machine conditions are available on request.
Haplotype analysis
The haplotype of the patient found to be 
homozygous for the 238-239insC mutation was 
determined by sequencing 16 intragenic single 
nucleotide polymorphisms (SNPs), reported 
previously (8).
R esu lts
Type 1 Usher patients
The 238-239insC mutation reported previously 
(2) was found in the homozygous state in a 
patient of Greek Cypriot origin and in the hetero­
zygous state in a Caucasian patient, in whom no 
other mutation was found. The haplotype of the 
Greek Cypriot patient was determined and com­
pared with the haplotypes of other patients with 
the 238-239insC mutation (Table 1).
A third patient was found to be heterozygous 
for a change at the first nucleotide of exon 5, a 
G—>A transition at nucleotide 388 (numbered 
according to ref. 9), resulting in a valine to iso­
leucine substitution at codon 130 (VI301) within 
the first PDZ domain of the protein. No sequence 
change on the other allele was identified.
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USH1C mutations: contribution to syndromic and non-syndromic deafness
Patients w ith non-syndrom ic deafness
In our cohort of patients who were concordant 
for markers flanking the non-syndromic deafness 
locus, DFNB18, there was no evidence of muta­
tions in the coding region of USH1C.
As a result of this work, six novel polymorph­
isms were found in the USH1C gene (Table 2).
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Discussion
Until recently, Usher syndrome type 1C was 
believed to be a disease exclusive to the Acadian 
population of Louisiana (10). In a large study of 
patients with type 1 Usher syndrome in the United 
States, only the two Acadian families purposefully 
included showed evidence of linkage to the 
USH1C region, whilst linkage to this region was 
excluded in all other families. However, since the 
USH1C gene has been identified, mutations have 
been reported in individuals of different ethnic 
origins, including Pakistani families (2), Lebanese 
families (3), Caucasian families from Germany, 
Switzerland and Denmark (8), an Indian family 
(5) and (in the present study) in a Greek Cypriot 
family and a Caucasian British individual. There­
fore, in Europe, mutations in the USH1C gene 
may account for a greater proportion of Usher 
type 1 than originally thought. In our cohort of 
patients with a confirmed diagnosis of Usher syn­
drome type 1, 14% (two of 14) were found to be 
caused by mutations in the USH1C gene. DHPLC 
has been shown to be a very sensitive method of 
mutation detection, with pick up rates of «95%  
reported in other genes (11-13).
It is not known whether or not the VI301 
change found in one other patient is disease causing. 
This change has not been found in 96 normal com 
trols (192 chromosomes) screened on the WAVE 
machine, and the Valine 130 residue, which occurs 
in the first PDZ domain, is conserved in the mouse 
homologue. However, a second disease-causing 
mutation has not been observed in this patient 
and, when compared with other PDZ domains, 
using the BLAST analysis program (http:// 
www.ncbi.nlm.nih.gov/BLAST/), an isoleucine resi­
due appears to be used in place of valine in some 
cases, including gamma-2 syntrophin in the mouse, 
syntrophin 4 in humans and also the second PDZ 
domain of the USH1C protein. It may therefore 
represent a rare polymorphism as it would not be 
predicted to alter splicing and results in a conserva­
tive amino acid substitution.
The 238-239insC mutation appears to be a 
common mutation in the USH1C gene. Haplo­
type analysis, using intragenic SNPs, showed that 
a Muslim family and individuals from Europe
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Table 2. Polymorphisms identified in USH1C
Nucleotide
change8 Location
Predicted
effect Novel?
IVS1-41insCC Intron 1 None No
IVS1-45C—>G Intron 1 None No
IVS1-47G—»T Intron 1 None No
IVS2-16C—»T Intron 2 None No
IVS6+2T—»G Intron 6 None Yes
IVS6+56A—>G Intron 6 None Yes
IVS7+61G—>A Intron 7 None No
IVS7-27G—»A Intron 7 None No
IVS8-53G->C Intron 8 None Yes
+1188A —>G Exon 14 P396P No
IV S A +83C -G Intron A None Yes
IVSA-34C—»T Intron A None No
IVSB+52T—>C Intron B None No
IVSB-34G—»A Intron B None No
Exon D nt 240 C->Tb Exon D A—*A No
IVSE-10delT Intron E None Yes
IVSF+43C—+T Intron F None Yes
IVS16+12C—>T Intron 16 None No
+1440C —»T Exon 18 V480V No
+1557G —>C Exon 19 E519D No
IVS19+12G->C Intron 19 None No
+1737T—*C Exon 21, 3'-UTR None No
+1877C —>T Exon 21, 3'-UTR None No
+1902A—»G Exon 21, 3'-UTR None No
The polymorphisms and their location in the USH1C gene are given along 
with any predicted effect. Novel polymorphisms are shown in bold. 
aNucleotide numbering is according to ref. 9. 
hThe numbering here refers to the nucleotide position within exon D.
had 238-239insC mutations occurring on the 
same haplotype and it was concluded that the 
prevalence of this mutation is probably the result 
of a founder effect (8). This would be similar to 
the 35delG mutation found in GJB2, the gene 
that encodes the protein connexin 26, which has 
recently been shown to be caused by an ancient 
founder effect (14). However, haplotype analysis 
carried out on our Greek Cypriot patient carrying 
the 238-239insC mutation (Table 1) reveals dif­
ferences compared with the previously reported 
haplotype (8). The mutation may therefore be 
recurrent, but it is also possible that a crossover 
event has occurred in our patient between the 
238-239insC mutation and the first change in 
the haplotype observed at IVS13+21C—>G. How­
ever, the haplotype found in the 7 kb of DNA 
associated with the mutation was found to be 
present in 19% of Pakistani and 40% of Greek 
Cypriot controls (data not shown). Hence, the 
genetic background reported to be associated 
with the 238-239insC mutation is not particularly 
rare in the general population and therefore the 
mutation is not necessarily the result of a founder 
effect.
Regardless of how the 238-239insC mutation 
has arisen, be it recurrent or caused by a founder 
effect, it does appear to be presenting as a com­
mon mutation in families from a range of ethnic 
backgrounds. Indeed, in the Usher type 1C 
families reported to date (2, 3, 8), excluding the 
Acadian population who have their own founder 
effect, 67% (10/15) have at least one 238-239insC 
allele of the USH1C gene. This has implications 
for the genetic testing of Usher type 1 patients in 
the UK. Usher type 1 syndrome is a genetically 
heterogeneous disease with seven loci identified. 
Although Usher type IB has been found to 
account for «75%  of all Usher type 1 cases in 
the USA (10), there are no known common muta­
tions in the M Y07A  gene, which consists of 48 
coding exons. Moreover, the CDH23 gene, which 
underlies Usher ID, is also a large gene, with at 
least 69 coding exons. This makes diagnostic 
mutation screening for type 1 Usher families 
both labour-intensive and expensive. As Usher 
type 1C seems to account for a higher percentage 
of Usher type 1 cases than originally thought, it 
may be reasonable to test for the 238-239insC 
mutation in USH1C first in families with type 1 
Usher, as it is the single most common type 1 
Usher mutation.
Regarding the cohort of sib pairs with non- 
syndromic deafness that was screened for muta­
tions, it is possible that the deafness in these 
families was not truly linked to the DFNB18
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locus, as there is a 25% chance that any sib pair 
will be concordant for markers at any given locus 
of the genome. Therefore, our sample of 16 sib 
pairs concordant for markers flanking DFNB18, 
derived from the original cohort of 133, is too 
small to have a >95% chance of having any 
truly linked families. However, in itself this 
suggests that the contribution of DFNB18 to 
non-syndromic deafness as a whole in the UK is 
very probably minor.
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